المؤلفون: E. Aseeva A., L. Vorobyeva D., S. Solovyev K., V. Amirdzhanova N., S. Glukhova I., G. Koilubaeva M., M. Letunovich V., Е. Асеева А., Л. Воробьева Д., С. Соловьев К., В. Амирджанова Н., С. Глухова И., Г. Койлубаева М., М. Летунович В.

المصدر: Rheumatology Science and Practice; Vol 56, No 2 (2018); 164-172 ; Научно-практическая ревматология; Vol 56, No 2 (2018); 164-172 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20182

مصطلحات موضوعية: systemic lupus erythematosus, health-related quality of life, LupusQol, SF-36, specific questionnaires, системная красная волчанка, качество жизни, связанное со здоровьем, специфические опросники

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2521/1676; Györi N, Giannakou I, Chatzidionysiou K, et al. Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. Lupus Sci Med. 2017 Feb 8;4(1):e000192. doi:10.1136/lupus-2016-000192.eCollection 2017.; Асеева ЕА, Амирджанова ВН, Лисицына ТА, Завальская МВ. Качество жизни у больных системной красной волчанкой. Научно-практическая ревматология. 2013;51(3):324-31. doi:10.14412/1995-4484-2013-1508; Воробьева ЛД, Асеева ЕА. Значение качества жизни, связанного со здоровьем, у больных системной красной волчанкой и современные инструменты его оценки. Современная ревматология. 2017;11(4):62-72. doi:10.14412/1996-7012-2017-4-62-72.; Urowitz MB, Gladman DD, Ibanez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res. 2012;64:132-7. doi:10.1002/acr.20648; Асеева ЕА, Соловьев СК, Клюквина НГ и др. Необратимые органные повреждения в когорте пациентов с системной красной волчанкой (РЕНЕССАНС). Научно-практическая ревматология. 2016;54(4):404-11 [Aseeva EA, Solovyev SK, Klyukvina NG, et al. Irreversible organ damages in a cohort of patients with systemic lupus erythematosus (RENAISSANCE). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):404-11 (In Russ.)]. doi:10.14412/1995-4484-2016-404-411; Shumaker S, Naughton M. The International Assessment of Health Related Quality of Life: A theoretical perspective. In: The International Assessment of Health Related Quality of Life: Theory, Translation, Measurement and Analysis. Oxford; 1995. P. 34-42.; Guidance for Industry, Systemic Lupus Erythematosus – Developing Medical Products for Treatment. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Center for Devices and Radiological Health (CDRH); 2010.; Strand V, Gladman D, Isenberg D, et al. Outcome Measures in Rheumatology. Endpoints: consensus recommendations from OMERACT IV. Lupus. 2000;9:322-7. doi:10.1191/096120300678828424; Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69:1269-74. doi:10.1136/ard.2009.117200; Соловьев СК, Асеева ЕА, Попкова ТВ и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9-16. doi:10.14412/1995-4484-2015-9-16; Schiffenbauer J, Simon LS. Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi:10.1191/0961203303lu1033oa; Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997;24:1608-14.; Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2007;26:24-9. doi:10.1007/s10067-006-0215-4; Leong KP, Kong KO, Thong BYH, et al. Development and preliminary validation of a Systemic Lupus Eerythematosus-specific Quality-Of-Life instrument (SLEQOL). Rheumatology. 2005;44:1267-76. doi:10.1093/rheumatology/keh605; McElhone K, Abbott J, Shelmardine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57:972-9. doi:10.1002/art.22881; Амирджанова ВН, Горячев ДВ, Коршунов НИ и др. Популяционные показатели качества жизни по опроснику SF-36 (результаты многоцентрового исследования качества жизни «МИРАЖ»). Научно-практическая ревматология. 2008;46(1):36-48. doi:10.14412/1995-4484-2008-852; Клинические рекомендации. Ревматология. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. С. 713-25.; Wild D, Grove A, Martin M. Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8:94-104. doi:10.1111/j.1524-4733.2005.04054.x; Новик АА, Ионова ТИ; Шевченко ЮЛ, редактор. Руководство по исследованию качества жизни в медицине. 2-е изд. Москва: ОЛМА Медиа Групп; 2007. С. 14-20.; Cella D, Tulsky D. Measuring quality of life today: methodological aspects. J Oncol. 1990;4;29-38.; Jolly M, Pickard A, Wilke R, et al. Lupus-specific health outcome measure for US patients: the LupusQoL – US version. Ann Rheum Dis. 2010 Jan;69(1):29-33. doi:10.1136/ard.2008.094763; Devilliers H, Amoura Z, Besancenot J, et al. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2012 Oct;51(10):1906-15. doi:10.1093/rheumatology/kes165. Epub 2012 Jul 22.; Wang S, Wu B, Leng L, et al. Validity of LupusQoL-China for the Assessment of Health Related Quality of Life in Chinese Patients with Systemic Lupus Erythematosus. PLoS One. 2013 May 23;8(5):e63795. doi:10.1371/journal.pone.0063795. Print 2013.; Conti F, Perricone C, Reboldi G, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus. 2014 Jul;23(8):74351. doi:10.1177/0961203314524466. Epub 2014 Feb 25.; Pamuk O, Onat A, Donmez S, et al. Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients. Lupus. 2015 Jul;24(8):816-21. doi:10.1177/0961203314565412. Epub 2014 Dec 26.; Machado Escobar M, Yacuzzi M, Martinez R, et al. Validation of an Argentine version of Lupus Quality of Life questionnaire. Lupus. 2016 Dec;25(14):1615-22. doi:10.1177/0961203316660202. Epub 2016 Jul 20.; Hosseini N, Bonakdar Z, Gholamrezaei A, Mirbagher L. Linguistic Validation of the LupusQoL for the Assessment of Quality of Life in Iranian Patients with Systemic Lupus Erythematosus. Int J Rheumatol. 2014;2014:151530. doi:10.1155/2014/151530. Epub 2014 Sep 9.; https://rsp.mediar-press.net/rsp/article/view/2521

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2521
https://doi.org/10.14412/1995-4484-2018-164-172

المؤلفون: V. Amirdzhanova N., A. Karateev E., E. Pogozheva Yu., В. Амирджанова Н., А. Каратеев Е., Е. Погожева Ю.

المصدر: Rheumatology Science and Practice; Vol 56, No 5 (2018); 549-555 ; Научно-практическая ревматология; Vol 56, No 5 (2018); 549-555 ; 1995-4492 ; 1995-4484 ; undefined

مصطلحات موضوعية: preoperative preparation, arthroplasty, rheumatic diseases, disease-modifying antiinflammatory drugs, biological agents, glucocorticoids, предоперационная подготовка, эндопротезирование суставов, ревматические заболевания, ба- зисные противовоспалительные препараты, генно-инженерные биологические препараты, глюкокортикоиды

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2616/1750; Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheum. 2017;69(8):1538-51. doi:10.1002/art.40149; Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidencefrom randomized controlled trials. Am J Manag Care. 2008;14:234-54.; Ravi B, Croxford R, Reichmann WM, et al. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. Best Pract Res Clin Rheumatol. 2012;26:637-47. doi:10.1016/j.berh.2012.07.014; Mertelsmann-Voss C, Lyman S, Pan TJ, et al. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991-2005. J Rheumatol. 2014;41:867-74. doi:10.3899/jrheum.130617; Mertelsmann-Voss C, Lyman S, Pan TJ, et al. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheum. 2014;66:1432-9. doi:10.1002/art.38384; Nikiphorou E, Carpenter L, Morris S, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheum. 2014;66:1081-9. doi:10.1002/art.38344; Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved longterm outcomes of rheumatoid arthritis. Ann Rheum Dis. 2007;66:341-4. doi:10.1136/ard.2006.057067; Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:254-63. doi:10.1002/art.38231; Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi:10.1136/annrheumdis-2012-202758; Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67:718-24. doi:10.1002/acr.22497; Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi:10.3899/jrheum.151373; Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-95 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94 (In Russ.)]. doi:10.14412/1995-4484-2014-477-494; Goodman SM, Ramsden-Stein DN, Huang WT, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol. 2014;41:1774-80. doi:10.3899/jrheum.140011; Goodman SM, Johnson B, Zhang M, et al. Patients with rheumatoid arthritis have similar excellent outcomes after total knee replacement compared with patients with osteoarthritis. J Rheumatol. 2016;43:46-53. doi:10.3899/jrheum.150525; LoVerde ZJ, Mandl LA, Johnson BK, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study. J Rheumatol. 2015;42:1123-30. doi:10.3899/jrheum.141251; Johnson BK, Goodman SM, Alexiades MM, et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013;40:617-23. doi:10.3899/jrheum.121171; Berbari EF, Osmon DR, Lahr B, et al. The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification. Infect Control Hosp Epidemiol. 2012;33:774-81. doi:10.1086/666641; Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1713-20. doi:10.1002/art.24060; Goodman SM, Menon I, Christos PJ, et al. Management of perioperative tumour necrosis factor a inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and metaanalysis. Rheumatology (Oxford). 2016;55:573-82.; Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-91.doi:10.1136/ard.2010.128637; Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300. doi:10.1002/art.10529; Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;Suppl 27:61-5. doi:10.1016/j.arth.2012.02.022; Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2011;60:22-3.; Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;Suppl 1:S3-8. doi:10.1016/j.amjmed.2008.06.010; Периоперационное ведение пациентов с ревматоидным артритом, нуждающихся в эндопротезировании крупных суставов нижних конечностей. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации «Ревматология». Москва: ГЭОТАР-Медиа; 2017. С. 360-70 [Perioperative management of patients with rheumatoid arthritis who need endoprosthetics of large joints of lower extremities. In: Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii «Revmatologiya» [Russian Clinical Recommendations «Rheumatology»]. Moscow: GEOTAR-Media; 2017. P. 360-70 (In Russ.)].; Амирджанова ВН, Макаров МА, Бялик ЕИ и др. Периоперационное ведение больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(4):366-76 [Amirdzhanova VN, Makarov MA, Byalik EI, et al. Perioperative; management of patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):366-75 (In Russ.)]. doi:10.14412/1995-4484-2014-366-375; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al.; ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009;54:e13-118. doi:10.1016/j.jacc.2009.07.010; Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120:e169-276. doi:10.1161/CIRCULATIONAHA.109.192690; Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 Suppl 2:e278S-325S.; Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94:746-7. doi:10.2106/JBJS.9408.EBO746; Савенкова НА. Амирджанова ВН, Макаров СА и др. Отменять ли базисную терапию больным ревматоидным артритом перед эндопротезированием суставов? Научно-практическая ревматология. 2011;49(5):46-50 [Savenkova NA; Amirdzhanova VN, Makarov SA, et al. Should disease-modifying therapy be stopped in patients with rheumatoid arthritis before endoprosthetic joint replacement? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(5):46-50 (In Russ.)]. doi:10.14412/1995-4484-2011-1460; Strand V, Ahadieh S, French J, et al. Systematic review and metaanalysis of serious infections with tofacitinib and biologic diseasemodifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362. doi:10.1186/s13075-015-0880-2; Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258-65. doi:10.1016/S0140-6736(14)61704-9; Maxwell LJ, Zochling J, Boonen A, et al. TNF-a inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.; Ito H, Kojima M, Nishida K, et al. Postoperative complications in patients with rheumatoid arthritis using a biological agent: a systematic review and meta-analysis. Mod Rheumatol. 2015;25:672-8. doi:10.3109/14397595.2015.1014302; Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356.; Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2014;9:CD007649.; Song GG, Bae SC, Lee YH. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a metaanalysis of randomized controlled trials. Korean J Intern Med. 2014;29:656-63. doi:10.3904/kjim.2014.29.5.656; Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and longterm extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:2924-37. doi:10.1002/art.38779; Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a metaanalysis update of 44 trials. Am J Med. 2014;127:1208-32. doi:10.1016/j.amjmed.2014.06.012; Borba HH, Wiens A, de Souza TT, et al. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs 2014;28:211-28. doi:10.1007/s40259-013-0074-x; He Y, Wong AY, Chan EW, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013;14:298. doi:10.1186/1471-2474-14-298; Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD004525.; Machado MA, Barbosa MM, Almeida AM, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33:2199-213. doi:10.1007/s00296-013-2772-6; Li ZH, Zhang Y, Wang J, Shi ZJ. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, doubleblind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013;23:497-506. doi:10.1007/s00590-012-1035-7; Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and metaanalysis informing a consensus statement. Ann Rheum Dis. 2013;72:583-9. doi:10.1136/annrheumdis-2012-202470; Lan L, Han F, Chen JH. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and metaanalysis. J Zhejiang Univ Sci B. 2012;13:731-44. doi:10.1631/jzus.B1200057; Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035- 50. doi:10.1016/j.jaad.2010.09.734; Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50:552-62. doi:10.1093/rheumatology/keq343; Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31:1493-9. doi:10.1007/s00296-010-1526-y; Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis. 2010;13:12-26. doi:10.1111/j.1756-185X.2009.01457.x; Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-53. doi:10.1592/phco.30.4.339; Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010;25:1-17. doi:10.3904/kjim.2010.25.1.1; An MM, Zou Z, Shen H, et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66:49-59. doi:10.1007/s00228-009-0754-0; Wiens A, Correr CJ, Pontarolo R, et al. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol. 2009;70:337-44. doi:10.1111/j.1365-3083.2009.02296.x; Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebocontrolled trials. Ann Rheum Dis. 2010;69:1756-61. doi:10.1136/ard.2008.098822; Leombruno JP, Einarson TR, Keystone EC. The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136-45. doi:10.1136/ard.2008.091025; Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor a drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi:10.1186/1471-2474-9-52; Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883-90.; Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398-408.; Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. doi:10.1001/jama.295.19.2275; Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379-84. doi:10.1136/ard.2005.035287; Capogrosso Sansone A, Mantarro S, Tuccori M, et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Safety. 2015;38:869-88. doi:10.1007/s40264-015-0336-2; Tarp S, Furst DE, Luta G, et al. Risk of serious adverse effects associated with different biological and targeted synthetic diseasemodifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:176-7.; De la Forest M, Brugneaux J, Utard G, Salliot C. Safety of anti-TNFs in RA patients in real life: results from a systematic literature review and meta-analyses from biologic registers [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:702. doi:10.1136/annrheumdis-2015-eular.2781; Hochberg M, Janssen K, Broglio K, et al. Comparison of abatacept and other biologic DMARDs for the treatment of rheumatoid arthritis patients: a systematic literature review and network metaanalysis [abstract]. Ann Rheum Dis. 2014;73 Suppl 2:676. doi:10.1136/annrheumdis-2014-eular.5331; Tarp S, Tarp U, Andersen LS, et al. Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel [abstract]. Arthritis Rheum. 2013;65 Suppl:S997-8.; He Y, Wong A, Chan E, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Drug Safety. 2013;36:852-3.; Singh JA, Wells G, Christensen R, et al. Risk of cancer, serious lung infections and death with biologics: a systematic review and network meta-analysis of randomized controlled trials (RCTs) [abstract]. Ann Rheum Dis. 2013;72:A74. doi:10.1136/annrheumdis-2013-eular.276; Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. J Pharmacokinetics Pharmacodynamics. 2013;40:S93-4.; Lin T, Shamliyan T, Choi H, et al. The safety of anti-TNF biologic agents in rheumatoid arthritis: a metaanalysis of 35 RCTs [abstract]. Arthritis Rheum. 2012;64 Suppl:S1854.; Venson R, Wiens A, Correr CJ, Pontarolo R. Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis. Brazil J Pharm Sci. 2012;48:781-91. doi:10.1590/S1984-82502012000400022; Cormier H, Barnetche T, Schaeverbeke T. The risk of serious infection with and without anti-TNF therapy in rheumatoid arthritis and ankylosing spondylitis: a metaanalysis [abstract]. Arthritis Rheum. 2011;63 Suppl:S878.; Dommasch E, Troxel A, Shin D, et al. The safety of tumor necrosis factor antagonists in patients with psoriatic disease: a systematic review and metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:AB8. doi:10.1016/j.jaad.2010.09.734; Rieder S, Thompson A, Pope J. Anti-TNF therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. J Rheumatol. 2010;37:1343.; Powers J, Martin R. Incidence of serious infectious events with methotrexate treatment: metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2010;62:AB4.; Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med. 2010;2:749-60.; Kaine JL. Abatacept for the treatment of rheumatoid arthritis: a review. Curr Ther Res. 2007;68:379-99. doi:10.1016/j.curtheres. 2007.12.001; Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34 Suppl 1:12-8. doi:10.1016/j.semarthrit.2005.01.004; Jinesh S. Pharmaceutical aspects of anti-inflammatory TNFblocking drugs. Inflammopharmacology. 2015;23:71-7. doi:10.1007/s10787-015-0229-0; Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human antitumor necrosis factor-a monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-21. doi:10.1016/S0149-2918(03)80164-9; Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47:1119-28. doi:10.1177/0091270007305297; Погожева ЕЮ, Амирджанова ВН, Макаров СА, Насонов ЕЛ. Осложнения после эндопротезирования суставов у пациентов, получающих генно-нженерные биологические препараты. Научно-практическая ревматология. 2012;50(3):43-8 [Pogozheva EYu, Amirdzhanova VN, Makarov SA, Nasonov EL. Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(3):43-8 (In Russ.)]. doi:10.14412/1995-4484-2012-708; Tarp S, Furst DE, Maarten B, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017;56:417-25.; Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767-76. doi:10.1177/0961203309106174; Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol. 2010;29:707-16. doi:10.1007/s10067-010-1387-5; Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30. doi:10.1002/art.30613; Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S726.; Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signaling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311-6. doi:10.1136/annrheumdis-2014-206028; Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143:1222-6. doi:10.1001/archsurg.143.12.1222; Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30.; Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119-24. doi:10.2174/1874312920131210005; https://rsp.mediar-press.net/rsp/article/view/2616

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2616
https://doi.org/10.14412/1995-4484-2018-549-555

المؤلفون: A. Khramov E., M. Makarov A., S. Makarov A., E. Byalik I., V. Amirdzhanova N., V. Pavlov P., A. Rybnikov V., А. Храмов Э., М. Макаров А., С. Макаров А., Е. Бялик И., В. Амирджанова Н., В. Павлов П., А. Рыбников В.

المصدر: Rheumatology Science and Practice; Vol 55, No 5 (2017); 549-554 ; Научно-практическая ревматология; Vol 55, No 5 (2017); 549-554 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20175

مصطلحات موضوعية: knee joint replacement, hip joint replacement, rheumatic diseases, complications, periprosthetic fractures, infection, neuropathy, instability, dislocation, эндопротезирование коленного сустава, эндопротезирование тазобедренного сустава, ревматические заболевания, осложнения, перипротезные переломы, инфекция, нейропатия, нестабильность, вывих

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2438/1623; NIH consensus conference: Total hip replacement. NIH Consensus Development Panel on Total Hip Replacement. [Consensus Development Conference Consensus Development Conference, NIH Review]. JAMA. 1995 Jun 28;273(24):1950-6.; Jones CA, Beaupre LA, Johnston DWC, Suarez-Almazor ME. Total joint arthroplasties: current concepts of patient outcomes after surgery. [Review]. Rheum Dis Clin N Am. 2007 Feb;33(1):71- 86. doi:10.1016/j.rdc.2006.12.008; Merx H, Dreinhofer K, Schrader P, et al. International variation in hip replacement rates. [Research Support, Non-U.S. Gov't Review]. Ann Rheum Dis. 2003 Mar;62(3):222-6. doi:10.1136/ard.62.3.222; Ravi B, Croxford R, Reichmann W, et al. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. Best Pract Res Clin Rheumatol. 2012;26(5):637-47. doi:10.1016/j.berh.2012.07.014; Santaguida PL, Hawker GA, Hudak PL, et al. Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: a systematic review. [Research Support, Non-U.S. Gov't Review]. Can J Surg. 2008 Dec;51(6):428-36.; Heck DA, Melfi CA, Mamlin LA, et al. Revision rates after knee replacement in the United States. [Research Support, U.S. Gov't, P.H.S.]. Med Care. 1998 May;36(5):661-9. doi:10.1097/00005650-199805000-00006; Papakostidou I, Dailiana ZH, Liaropoulos L, et al. Factors affecting the quality of life after total knee arthroplasties: a prospective study. BMC Musculoskelet Disord. 2012 Jun 29;13:116. doi:10.1186/1471-2474-13-116; Линник СА, Ромашов ПП, Новоселов КА и др. Раннее двухэтапное ревизионное эндопротезирование тазобедренного и коленного суставов после глубокого нагноения. Травматология и ортопедия. 2009;(3):151-5 [Linnik SA, Romashov PP, Novoselov KA, et al. Early two-stage revision of hip and knee joint endoprosthetics after deep suppuration. Travmatologiya i Ortopediya. 2009;(3):151-5 (In Russ.)].; Bauer T, Parvizi J, Kobayashi N, Krebs V. Diagnosis of Periprosthetic Infection. J Bone Jt. Surg. 2006;4:869-80.; Giulieri SG, Graber P, Ochsner PE, Zimmerli W. Management of infection associated with total hip arthroplasty according to a treatment algorithm. [Erratum appears in Infection. 2004 Oct;32(5):309]. Infection. 2004 Aug;32(4):222-8. doi:10.1007/s15010-004-4020-1; Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections.; [Comparative Study]. Infect Control Hosp Epidemiol. 1992 Oct;13(10):606-8. doi:10.1017/S0195941700015241; Moureau N. Vascular safety: it's all about PICCs. [Review]. Nurs Manag. 2006 May;37(5):22-7; quiz 50. doi:10.1097/00006247-200605000-00007; Toms AD, Davidson D, Masri BA, Duncan CP. The management of peri-prosthetic infection in total joint arthroplasty. [Research Support, Non-U.S. Gov't Review]. J Bone Joint Surg Br. 2006 Feb;88(2):149-55. doi:10.1302/0301-620X.88B2.17058; Clyburn TA, Cui Q. Antibiotic laden cement: Current state of the art. AAOS Now. 2013;7(6) (Available online: http://www.aaos.org/news/bulletin/may07/clinical7.asp).; De Palma L, Procaccini R, Soccetti A, Marinelli M. Hospital cost of treating early dislocation following hip arthroplasty. Hip International. 2012 Jan-Feb;22(1):62-7. doi:10.5301/HIP.2012.9059; Ключевский ВВ, Даниляк ВВ, Белов МВ и др. Вывихи после тотального замещения тазобедренного сустава: факторы риска, способы лечения. Травматология и ортопедия. 2009;(3):136-8 [Klyuchevskii VV, Danilyak VV, Belov MV, et al. Dislocation after total hip replacement: risk factors, treatment options. Travmatologiya i Ortopediya. 2009; (3):136-8 (In Russ.)].; Kwon MS, Kuskowski M, Mulhall KJ, et al. Does surgical approach affect total hip arthroplasty dislocation rates? [Comparative Study Meta-Analysis Research Support, Non- U.S. Gov't Review]. Clin Orthop. 2006 Jun;447:34-8. doi:10.1097/01.blo.0000218746.84494.df; Richards CJ, Garbuz DS, Masri BA, Duncan CP. Vancouver type B3 periprosthetic fractures: evaluation and treatment. Instruct Course Lect. 2009;58:177-81.; Волокитина ЕА, Зайцева ОП, Колотыгин ДА, Вишняков АА. Локальные интраоперационные и ранние послеоперационные осложнения эндопротезирования тазобедренного сустава. Гений ортопедии. 2009;(3):71-7 [Volokitina EA, Zaitseva OP, Kolotygin DA, Vishnyakov AA. Local intraoperative and early postoperative complications of hip arthroplasty. Genii Ortopedii. 2009;(3):71-7 (In Russ.)].; Mounasamy V. Acute sciatic neuritis following total hip arthroplasty: a case report. Arch Orthop Trauma Surg. 2008;128:25-8. doi:10.1007/s00402-006-0261-z; Руцкий АВ, Маслов АП. К проблеме эндопротезирования крупных суставов. Медицинские новости. 2005;(12):73-6 [Rutskii AV, Maslov AP. To the problem of arthroplasty of large joints. Meditsinskie Novosti. 2005;(12):73-6 (In Russ.)].; Pellicci PM, Wilson PD Jr, Sledge CB, et al. Long-term results of revision total hip replacement: a follow-up report. J Bone Joint Surg. 1985;67-A:513-6. doi:10.2106/00004623-198567040-00002; Raikin S.M. Total ankle arthroplasty. Orthopedics. 2010 Dec;33(12):890-1. doi:10.3928/01477447-20101021-18; Parker DA, Dunbar MJ, Rorabeck CH. Extensor mechanism failure associated with total knee arthroplasty: prevention and management. J Am Acad Orthop Surg. 2003;11(4):238-47. doi:10.5435/00124635-200307000-00003; Burns AWR, Bourne RB, Chesworth BM, et al. Cost effectiveness of revision total knee arthroplasty. [Comparative Study]. Clin Orthop. 2006 May;446:29-33. doi:10.1097/01.blo.0000214420.14088.76; Bozic KJ, Katz P, Cisternas M, et al. Hospital resource utilization for primary and revision total hip arthroplasty. [Comparative Study Research Support, Non-U.S. Gov't]. J Bone Joint Surg – Amer Vol. 2005 Mar;87(3):570-6. doi:10.2106/00004623-200503000-00014; Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non- U.S. Gov't]. Arthritis Rheum. 2008 Dec 15;59(12):1713-20. doi:10.1002/art.24060; Schrama JC, Espehaug B, Hallan G, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population- based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. [Comparative Study]. Arthritis Care Res (Hoboken). 2010 Apr;62(4):473-9. doi:10.1002/acr.20036; Boursinos LA, Karachalios T, Poultsides L, Malizos KN. Do steroids, conventional non- steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing? [Review]. J Musculoskelet Neur Interact. 2009 Jan-Mar;9(1):44-52.; Gravallese EM. Bone destruction in arthritis. [Review]. Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6. doi:10.1136/ard.61.suppl_2.ii84; Mikuls TR, Saag KG, Curtis J, et al. Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. [Multicenter Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. J Nat Med Assoc. 2005 Aug;97(8):1155-60.; Goldring SR. Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility. [Erratum appears in Ann Rheum Dis. 2009 Jun;68(6):1080]. [Comment Editorial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Ann Rheum Dis. 2009 Mar;68(3):297- 9. doi:10.1136/ard.2008.099408; Слободской АБ, Осинцев ЕЮ, Лежнев АГ. Осложнения эндопротезирования тазобедренного сустава. Вестник травматологии и ортопедии. 2011;(3):59-63 [Slobodskoi AB, Osintsev EYu, Lezhnev AG. Complications of hip arthroplasty. Vestnik Travmatologii i Ortopedii. 2011;(3):59-63 (In Russ.)].; Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. [Research Support, N.I.H., Extramural]. Clin Geriatr Med. 2011 Feb;27(1):79-87. doi:10.1016/j.cger.2010.08.002; Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. Medicial College of Virginia/Virginia Commonwealth University, Richmond 23298, USA. J Rheumatol. 1995;22(6):1055-9.; Khatod M, Barber T, Paxton E, et al. An analysis of the risk of hip dislocation with a contemporary total joint registry. [Comparative Study Research Support, Non-U.S. Gov't]. Clin Orthop. 2006 Jun;447:19-23. doi:10.1097/01.blo.0000218752.22613.78; Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al. Redefining overweight and obesity in rheumatoid arthritis patients. [Research Support, Non-U.S. Gov't]. Ann Rheum Dis. 2007 Oct;66(10):1316-21. doi:10.1136/ard.2006.060319; Conroy JL, Whitehouse SL, Graves SE, et al. Risk factors for revision for early dislocation in total hip arthroplasty. J Arthroplasty. 2008 Sep;23(6):867-72. doi:10.1016/j.arth.2007.07.009; Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. [Review]. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39.; https://rsp.mediar-press.net/rsp/article/view/2438

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2438
https://doi.org/10.14412/1995-4484-2017-549-554

المؤلفون: N. Savushkina M., V. Amirdzhanova N., S. Glukhova I., O. Egorova N., B. Belov S., Н. Савушкина М., В. Амирджанова Н., С. Глухова И., О. Егорова Н., Б. Белов С.

المصدر: Rheumatology Science and Practice; Vol 55, No 2 (2017); 177-181 ; Научно-практическая ревматология; Vol 55, No 2 (2017); 177-181 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20172

مصطلحات موضوعية: panniculitis, EQ-5D, RAPID-3, validation, quality of life, панникулит, EQ-5, валидация, качество жизни

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2360/1563; Staquet MJ, Berzon R, Osoba D, et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996 Oct;5(5):496-502. doi:10.1007/BF00540022; World Health Organization. Cancer pain relief. Geneva: WHO; 1986. P. 5-26.; Fries JF, Spitz PW, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45. doi:10.1002/art.1780230202; The EuroQol group. EuroQol – a new facility for the measurement of health related quality of life. Health Policy. 1990;16(3):199-208.; Амирджанова ВН, Эрдес ШФ. Валидация русской версии общего опросника EUROQOL – 5D (EQ-5D). Научно- практическая ревматология. 2007;45(3):69-76 [Amirdzhanova VN, Erdes ShF. Validation of general questionnaire EuroQol-5D (EQ-5D) Russian version. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2007;45(3):69- 76 (In Russ.)]. doi:10.14412/1995-4484-2007-691; Hurst NP, Kind P, Ruta D, et al. Measuring healthrelated quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36:551-9. doi:10.1093/rheumatology/36.5.551; Pincus T, Bergman MJ, Yazici Y. RAPID3 – An index of physical function, pain, and global status as «vital signs» to improve care for people with chronic rheumatic diseases. Bull NYU Hospital Joint Dis. 2009;67(2):211-25.; Старкова АС, Амирджанова ВН. Валидация русскоязычной версии опросника RAPID-3. Научно-практическая ревматология. 2011;49(4):36-40 [Starkova AS, Amirdzhanova VN. Validation of the russianlanguage version of the RAPID-3 questionnaire. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(4):36-40 (In Russ.)]. doi:10.14412/1995-4484-2011-59; Иванов ОЛ. Кожные и венерические болезни. Москва: Шико; 2006. С. 170-4 [Ivanov OL. Kozhnye i venericheskie bolezni [Skin and venereal disease]. Moscow: Shiko; 2006. P. 170-4].; Brooks R. EuroQol: The Current State of Play. Health Policy. 1996;37:53-72. doi:10.1016/0168-8510(96)00822-6; Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum. 1999;42:2220-30. doi:10.1002/1529- 0131(199910)42:103.0.CO;2-5; Meenan RF, Gertman PM, Mason JH. Measuring helth status in arthritis the Artrithis Impact Measurement Scales. Arthritis Rheum. 1980;23:146-52. doi:10.1002/art.1780230203; Pincus T, Amara I, Segurado O, et al. An index based on only patient reported outcome (PRO) measures, routine assessment of patient index data (RAPID3), distinguishes adalimumab from control at levels similar to disease activity score (DAS28) and clinical disease activity index (CDAI) [Abstract]. Ann Rheum Dis. 2007;184:66.; Williamson JW. Evaluating quality of patient care: a strategy relating outcome and process assessment. JAMA. 1971;218(4):564-9. doi:10.1001/jama.1971.03190170042009; Russac SM, Croft JD, Furst DE, et al. The use of Rheumatoid arthritis Health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Care Res. 2003;49(4):574-84. doi:10.1002/art.11208; Борисова ЕВ, Плеханов ИГ, Попов СВ. Качество жизни пациентов после создания полной артриовентрикулярной блокады и имплантации частотно-адаптивного электростимулятора. Сибирский медицинский журнал. 2013;28(2):74-8 [Borisova EV, Plekhanov IG, Popov SV. Quality of life in patients after the creation of artificiak complete atrioventrikuliar heart block and pacemaker implantation. Sibirskiy Meditsinskiy Zhurnal= Siberian Medical Journal. 2013;28(2):74-8 (In Russ.)].; Naik H, Howell D, Su S, et al. EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre. Patient. 2017 Feb;10(1):105-15. doi:10.1007/s40271-016-0190-z; Новик АА, Ионова ТИ. Руководство по исследованию качества жизни в медицине. Санкт-Петербург: Олма- Пресс; 2002. 300 с. [Novik AA, Ionova TI. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine [A guide to the study of quality of life in medicine]. St. Petersburg: OLMA-Press; 2002. 300 p.].; Насонова ВА. Медицинская и социальная значимость ревматических болезней в России и состояние специализированной помощи. Прогресс в лечении хронических воспалительных заболеваний суставов. Русский медицинский журнал. 2003;(2):4-5 [Nasonova VA. Medical and social significance of rheumatic diseases in Russia and the state of specialized care. Progress in the treatment of chronic inflammatory diseases of the joints. Russkiy Meditsinskiy Zhurnal= Russian Medical Journal. 2003;(2):4-5 (In Russ.)].; https://rsp.mediar-press.net/rsp/article/view/2360

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2360
https://doi.org/10.14412/1995-4484-2017-177-181

المؤلفون: V. Amirdzhanova N., В. Амирджанова Н.

المصدر: Rheumatology Science and Practice; Vol 55, No 5 (2017); 555-559 ; Научно-практическая ревматология; Vol 55, No 5 (2017); 555-559 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20175

مصطلحات موضوعية: nonsteroidal anti-inflammatory drugs, rheumatic diseases, perioperative analgesia, нестероидные противовоспалительные препараты, ревматические заболевания, периоперационное обезболивание

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2439/1624; Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с. [Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian Clinical Recommendations]. Moscow: GEOTAR-Media; 2017. 456 p.].; Каратеев АЕ, Алексеева ЛИ, Филатова ЕГ и др. Обезболивающие препараты в терапевтической практике. Москва: ИМА-ПРЕСС; 2013. 134 с. [Karateev AE, Alekseeva LI, Filatova EG, et al. Obezbolivayushchie preparaty v terapevticheskoi praktike [Anesthetics in therapeutic practice]. Moscow: IMAPRESS; 2013. 134 p.].; Яхно НН, Кукушкин МЛ, редакторы. Боль (практическое руководство для врачей). Москва: Издательство РАМН; 2012. 512 с. [Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for doctors)]. Moscow: Publishing house RAMS; 2012. 512 p.].; Allegri M, Clark M, De Andres J, Jensen T. Acute and chronic pain:where we are and where we have to go. Minerva Anest. 2012;78 (2):222-35.; De Buck F, Devroe S, Missant C, van de Velde M. Regional anesthesia outside the operating room:indications and techniques. Curr Opin Anaest. 2012;25 (4):501-7. doi:10.1097/ACO.0b013e3283556f58; Leversedge F, Srinivasan R. Management of soft-tissue injuries in distal radius fractures. Hand Clin. 2012;28(2):225-33. doi:10.1016/j.hcl.2012.03.005; Kurmis A, Kurmis T, O'Brien J, Dalen T. The effect of nonsteroidal anti-inflammatory drug administration on acute phase fracture-healing: a review. J Bone Joint Surg Am. 2012;94(9):815-23. doi:10.2106/JBJS.J.01743; Lierz P, Losch H, Felleiter P. Evaluation of single prepperative dose of etericoxib for postoperative pain relief in therapeutic knee arthroscopy: a randomized trial. Acta Orthop. 2012;83(6);642-7. doi:10.3109/17453674.2012.747053; Jones P, Lamdin R. Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury:systematic review and meta-analysis. Clin Drug Investig. 2010;30(7):419-37. doi:10.2165/11533350-000000000-00000; Осипова НА, Абузарова ГР, Петрова ВВ. Принципы клинического применения наркотических и ненаркотических анальгетических средств при острой и хронической боли. Методические указания для врачей. Москва; 2005. 78 с. [Osipova NA, Abuzarova GR, Petrova VV. Printsipy klinicheskogo primeneniya narkoticheskikh i nenarkoticheskikh anal'geticheskikh sredstv pri ostroi i khronicheskoi boli. Metodicheskie ukazaniya dlya vrachei [Principles of clinical use of narcotic and non-narcotic analgesics for acute and chronic pain. Methodical instructions for doctors]. Moscow; 2005. 78 p.].; Charlton JE, editor. Core curriculum for professional education in pain. 3rd ed. Seattle: IASP Press; 2005. P. 125-46.; Euroanaesthesia. Refresher course lectures. Vienna, Austria: Europian Society of Anaesthesiologists; 2005. P. 117-9.; Осипова НА, Петрова ВВ, Ермолаев ПМ, Береснев ВА. Нестероидные противовоспалительные препараты в лечении послеоперационной боли у онкологических больных. Фарматека. 2006;(6);74-8 [Osipova NA, Petrova VV, Ermolaev PM, Beresnev VA. Non-steroidal anti-inflammatory drugs in the treatment of postoperative pain in cancer patients. Farmateka. 2006;(6);74-8 (In Russ.)].; Осипова НА. Антиноцицептивные компоненты общей анестезии и послеоперационной аналгезии. Анестезиология и реаниматология. 1998;(5):11-5 [Osipova NA. Antinociceptive components of general anesthesia and postoperative analgesia. Anesteziologiya i Reanimatologiya. 1998;(5):11-5 (In Russ.)].; Осипова НА, Абузарова ГР. Проблема выбора нестероидного противовоспалительного препарата при хроническом болевом синдроме у онкологических больных. Вестник интенсивной терапии. 2003;(1):46-8 [Osipova NA, Abuzarova GR. The problem of choosing a non-steroidal anti-inflammatory drug in chronic pain syndrome in cancer patients. Vestnik Intensivnoi Terapii. 2003;(1):46-8 (In Russ.)].; Осипова НА, Береснев ВА, Ветшева МС и др. Кетопрофен как средство профилактики и лечения послеоперационной боли. Анестезиология и реаниматология. 1999;(6):71-4 [Osipova NA, Beresnev VA, Vetsheva MS, et al. Ketoprofen as a means of preventing and treating postoperative pain. Anesteziologiya i Reanimatologiya. 1999;(6):71-4 (In Russ.)].; Осипова НА, Петрова ВВ, Береснев ВА и др. Профилактическая аналгезия – новое направление в анестезиологии. Анестезиология и реаниматология. 1999;(6):13-8 [Osipova NA, Petrova VV, Beresnev VA, et al. Preventive analgesia – a new direction in anesthesiology. Anesteziologiya i Reanimatologiya. 1999;(6):13-8 (In Russ.)].; Hungund S, Thakkar R. Effect of pretreatment with ketorolac tromethamine on operative pain during periodontal surgery: A case-control study. J Indian Soc Periodontol. 2011;15(1):55-8. doi:10.4103/0972-124X.82274; Vadivelu N, Gowda AM, Urman RD, et al. Ketorolac tromethamine – routes and clinical implications. Pain Pract. 2015 Feb;15(2):175-93. doi:10.1111/papr.12198. Epub 2014 Apr 16.; Gobble RM, Hoang HL, Kachniarz B, Orgill DP. Ketorolac does not increase perioperative bleeding: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2014 Mar;133(3):741-55. doi:10.1097/01.prs.0000438459.60474.b5; Kimmel SE, Berlin JT, Kinman JL, et al. Parenteral ketorolac and risk of myocardial infarction. Pharm Drag Saf. 2002;11:113-9. doi:10.1002/pds.670; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-46. doi:10.1007/BF03261999; Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2013 Sep–Oct;31(5):731-8. Epub 2013 May 17.; Cerciello A, Auriemma G, Del Gaudio P, et al. Natural polysaccharides platforms for oral controlled release of ketoprofen lysine salt. Drug Dev Ind Pharm. 2016 Dec;42(12):2063-9. doi:10.1080/03639045.2016.1195401. Epub 2016 Jun 14.; Anacardio R, Bartolini S, Gentile MM, et al. HPLC investigated physicochemical compatibility between Artrosilene injectable solution and other pharmaceutical products frequently used for combined therapy into elastomeric Baxter LV5 infusion devices. Int J Immunopathol Pharmacol. 2005;18(4):791-8. doi:10.1177/039463200501800423; Anacardio R, Perillia O, Bartolinia S, et al. Physicochemical compatibility between ketoprofen lysine salt injections (Artrosilene) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal. 2003;32(6):1235-41. doi:10.1016/S0731-7085(03)00061-X; Ligniere G, Cherubino P. Patologie dolorosa muscolo-scheletriche Progr Med. 1996;87 Suppl 3;84.; https://rsp.mediar-press.net/rsp/article/view/2439

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2439
https://doi.org/10.14412/1995-4484-2017-555-559

المؤلفون: E. Nasonov L., A. Lila M., E. Galushko A., V. Amirdzhanova N., Е. Насонов Л., А. Лила М., Е. Галушко А., В. Амирджанова Н.

المصدر: Rheumatology Science and Practice; Vol 55, No 4 (2017); 339-343 ; Научно-практическая ревматология; Vol 55, No 4 (2017); 339-343 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20174

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2405/1593; Report of a WHO Scientific Group. The burden of musculoskeletal conditions at the start of the new millennium. Geneva: World Health Organization; 2003.; Perruccio AV, Power JD, Badley EM. The relative impact of 13 chronic conditions across three different outcomes. Epidemiol Community Health. 2007;611:1056-61. doi:10.1136/jech.2006.047308; Балабанова РМ, Эрдес ШФ. Ревматические заболевания у взрослого населения в федеральных округах России. Научно-практическая ревматология. 2014;52(1):5-7 [Balabanova RM, Erdes ShF. Rheumatic diseases in the adult population in federal districts of Russia. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):5-7 (In Russ.)]. doi:10.14412/1995-4484-2014-5-7; Фоломеева OM, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008;46(4):4-13 [Folomeeva OM, Galushko EA, Erdes SF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(4):4-13 (In Russ.)]. doi:10.14412/1995-4484-2008-529; Насонов ЕЛ. Проблемы ревматоидного артрита в XXI столетии. Вестник Российской академии наук. 2015;85:744-54 [Nasonov EL. Problems of rheumatoid arthritis in the 21st century. Vestnik Rossiyskoy Akademii Nauk. 2015;85:744-54 (In Russ.)].; Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;70(2):169-82 [Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personified therapy. Vestnik RAMN. 2015;70(2):169-82 (In Russ.)].; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 552 с. [Nasonov EL, editor. Genno- inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA- PRESS; 2013. 552 p.].; Насонов ЕЛ, Каратеев ДЕ, Сатыбалдыев АМ и др. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая ревматология. 2015;53(5):472-84 [Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.)]. doi:10.14412/1995-4484-2016-50-62; Асеева ЕА, Дубиков АИ, Левашева ЛА и др. Регистр пациентов с системной красной волчанкой, Евразийская когорта (РЕНЕССАНС). Научно-практическая ревматология. 2016;54(5):520-6 [Aseeva EA, Dubikov AI, Levasheva LA, et al. The registry of systemic lupus erythematosus patients, a Eurasian cohort (RENAISSANCE). Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):520-6 (In Russ.)]. doi:10.14412/1995-4484-2016-520-526; Бекетова ТВ. Значение Национального регистра больных АНЦА-ассоциированными системными васкулитами как инновационного инструмента персонифицированной индукционной и поддерживающей терапии. Научно-практическая ревматология. 2016;54(5):499-507 [Beketova TV. The value of the Russian National Registry of patients with ANCA-associated systemic vasculitis as an innovative tool of personalized induction and maintenance therapy. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):499-507 (In Russ.)]. doi:10.14412/1995-4484-2016-499-507; Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научно- практическая ревматология. 2014;52(4):362-5 [Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):362-5 (In Russ.)]. doi:10.14412/1995-4484-2014-362-365; Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с. [Nasonov EL, editor. Revmatologiya. Rossiyskie klinicheskie rekomendatsii [Rheumatology. Russian Clinical Recommendations]. Moscow: GEOTAR-Media; 2017. 456 p.].; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: Российские и международные рекомендации. Научно- практическая ревматология. 2016;54(5):557- 71 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: Russian and International guidelines. A pilot study. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):557-71 (In Russ.)]. doi:10.14412/1995-4484-2016-557-571; Насонов ЕЛ, Галушко ЕА, Амирджанова ВН. Непрерывное профессиональное образование врачей-ревматологов как условие модернизации ревматологической службы страны. Научно-практическая ревматология. 2012;50(2):12-3 [Nasonov EL, Galushko EA, Amirdzhanova VN. Continuous professional education of rheumatologists as a condition for modernization of rheumatology service of the country. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(2):12-3 (In Russ.)]. doi:10.14412/1995-4484-2012-1266; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.)]. doi:10.14412/1995-4484-2017-409-419; Насонов ЕЛ, Зонова ЕВ, Иванова ОН и др. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия® и Мабтера®) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016;54(5):510-9 [Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and MabThera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):510-9 (In Russ.)]. doi:10.14412/1995-4484-2016-510-519; Насонов ЕЛ. Биоаналоги в ревматологии. Научно-практическая ревматология. 2016;54(6):628-40 [Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):628-40 (In Russ.)]. doi:10.14412/1995-4484-2016-628-640; Насонов ЕЛ, Мазуров ВИ, Усачева ЮВ и др. Разработки отечественных оригинальных генно- инженерных биологических препаратов для лечения иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2017;55(2):201-10 [Nasonov EL, Mazurov VI, Usacheva YuV, et al. Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):201-10 (In Russ.)]. doi:10.14412/1995-4484- 2017-201-210; https://rsp.mediar-press.net/rsp/article/view/2405

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2405
https://doi.org/10.14412/1995-4484-2017-339-343

المؤلفون: E. Nasonov L., V. Mazurov I., D. Karateev E., G. Lukina V., E. Zhilyaev V., V. Amirdzhanova N., Yu. Muraviyo V., N. Tchichasova V., Е. Насонов Л., В. Мазуров И., Д. Каратеев Е., Г. Лукина В., Е. Жиляев В., А. Амирджанова Н., Ю. Муравьев В., Н. Чичасова В.

المصدر: Rheumatology Science and Practice; Vol 54 (2016): ; 1-17 ; Научно-практическая ревматология; Vol 54 (2016): ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20160

مصطلحات موضوعية: rheumatoid arthritis, «Treat to Target», disease modifying anti-rheumatic drugs, biologics, methotrexate, ревматоидный артрит, стратегия «Лечение до достижения цели», базисные противовоспа- лительные препараты, генно-инженерные биологические препараты, метотрексат

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2291/1495; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ.Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL,Nasonova VA, editors. Moscow: GEOTAR-media; 2008.P. 290–331.]; McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2012;365:2205–19. DOI: http://dx.doi.org/10.1056/NEJMra1004965.; Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–71. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-201036.; Furst DE, Keystone EC, Braun J, et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann Rheum Dis. 2012;71 (Suppl II):i2–i45. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-201036.; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013.]; Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009;374:430–2. DOI: http://dx.doi.org/10.1016/S0140-6736(09)61432-X.; Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7. DOI:http://dx.doi.org/10.1136/ard.2009.126532.; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2010;69:964–75. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204573.; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with systemic and biological disease-modifying anti-rheumatic drugs: 2013. Ann Rheum Dis. 2014;73:492–509. DOI:10.1136/annrheumdis-2013-204573.; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно- практическая ревматология. 2013;51(6):609–22. [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and disputable problems. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):609–22. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-609-22.; Aletaha D, Neogri T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81. DOI: http://dx.doi.org/10.1002/art.27584.; Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204317.; Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2014;73:3–5. DOI:10.1136/annrheumdis-2013-204317.; Национальные рекомендации по лечению ревматоидного артрита, 2013 (проект). Доступ по ссылке: http://www.rheumatolog.ru/experts/national-guidelines [Natsional'nye rekomendatsii po lecheniyu revmatoidnogo artrita, 2013 (proekt) [National recommendations about treatment of rheumatoid arthritis, 2013 (project)]. Available from: http://www.rheumatolog.ru/experts/national-guidelines]; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical recommendations.]. Moscow: GEOTAR-Media; 2010. 752 p.]; Насонов ЕЛ, редактор. Лечение ревматоидного артрита. Клинические рекомендации. Москва: Алмаз; 2006. 118 с. [Nasonov EL, editor. Lechenie revmatoidnogo artrita. Klinicheskie rekomendatsii [Treatment of rheumatoid arthritis. Clinical recommendations]. Moscow: Almaz; 2006. 118 p.]; Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34–45. DOI: http://dx.doi.org/10.1136/ard.2005.044354.; Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45:1167–9. DOI: http://dx.doi.org/10.1093/rheumatology/kel215a.; Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology (Oxford), British Health Professionals in Rheumatology (Oxford) Standards, Guidelines and Audit Working Group. British Society for Rheumatology (Oxford) and British Health Professionals in Rheumatology (Oxford) Guideline for the Management of Rheumatoid Arthritis (after the first two years). Rheumatology (Oxford). 2009;48:436–9. DOI:10.1093/Rheumatology (Oxford)/key450a.; Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying ant rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84. DOI: http://dx.doi.org/10.1002/art.23721.; Singh JA, Furst D, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–39. DOI: http://dx.doi.org/10.1002/acr.21641.; Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology (Oxford) Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. J Rheumatol. 2012;39:1559–82. DOI:10.3899/jrheum.110207.; National Institute for Clinical Excellence (NICE). Rheumatoid arthritis: The management of rheumatoid arthritis in adults. NICE guidelines [CG79]. 2009. [Internet. Accessed July 14, 2011.] Available from: http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf; The Royal Australian College of General Practitioners. Clinical guidelines for diagnosis and management of early rheumatoid arthritis; 2008. [Internet. Accessed July 14, 2011.] Available from: www.healthnetworks.health.wa.gov.au/docs/Clinical_guidelines_Rheumatoid_Arthritis.pdf;http://www.racgp.org.au/guidelines/ musculoskeletaldiseases; Baecklund E, Forsblad d’Elia H, Turesson K. Guidelines for the pharmaceutical management of rheumatoid arthritis Swedish Society of Rheumatology. 2011. April 14. Available from: http://www.svenskreumatologi.se/index2.htm; Scottish Intercollegiate Guidelines Network (SIGN). Management of early rheumatoid arthritis: SIGN Publication No. 48 2000; [Internet. Accessed July 14, 2011.] Available from: http: //www. sign.ac.uk/guidelines/fulltext/48/index.html; GUIPCAR group. Update of cliniсal practice guidline for the management of rheumatoid arthritis in Spain. Madrid (Spain):Spanish Scociety of Rheumatology; 2011. 367 p.; Da Mota LMH, Cruz BA, Brenol CV, et al. 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol. 2012;52:135–74.; Ataman S, Borman P, Evcik D, et al. Management of rheumatoid arthritis: consensus recommendations from the Turkish League Against Rheumatism. Turk J Rheumatol. 2011;26:273–94. DOI: http://dx.doi.org/10.5606/tjr.2011.046.; Mok CC, Tam LS, Chan TH, et al. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol. 2011;30:303–12. DOI: http://dx.doi.org/10.1007/s10067-010-1596-y.; El Zorkany B, Alwahshi HA, Hammoudeh M, et al. Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution? Clin Rheumatol. 2013;32:151–9. DOI: http://dx.doi.org/10.1007/s10067-012-2153-7.; Fonseca JE, Bernardes M, Canhao H, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis – October 2011 update. Acta Reumatol Port. 2011;36:385–8.; Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spain. 2014;81(4):287–97. DOI:10.1016/j.jbspin.2014.05002.; Cardiel MH, Diaz-Borjon A, Vazquez del Mercado Espinosa M, et al. Update of the Mexican College of Rheumatology (Oxford) Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis. Reumatologia Clinica. 2014;19:227–40.; Wollenhaupt J, Albrecht K, Kruger K, Muller-Ladner U. The new 2012 German recommendations for treating rheumatoid arthritis. Z Rheumatol. 2013;72:6–9. DOI: http://dx.doi.org/10.1007/s00393-012-1093-6.; Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoidarthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64–71. DOI:http://dx.doi.org/10.1136/annrheumdis-2011-201247.; Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46:975–9. DOI: http://dx.doi.org/10.1093/rheumatology/kem007.; Smolen JS, Han C, van der Heijde D, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNFblockade. Ann Rheum Dis. 2009;68:823–37. DOI:http://dx.doi.org/10.1136/ard.2008.090019.; Koevoets R, van der Heijde D. Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Arthritis Rheum. 2009;60(Suppl):957.; Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63:3702–11. DOI: http://dx.doi.org/10.1002/art.30634.; Sakellariou G, Scire CA, Verstappen SM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 2013;72:245–9. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201817.; Gartner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid arthritis: Associations with clinical joint assessment in remission. Arthritis Rheum. 2013;65:2005–14. DOI:10.1002/art38016.; Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360–4. DOI: http://dx.doi.org/10.1136/ard.2008.091454.; Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1815–21. DOI: http://dx.doi.org/10.1136/ard.2010.149260.; Scire CA, Lunt M, Marshall T, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2014;73:1677–82. DOI:10.1136/annrheumdis- 2013-203339.; Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol. 1997;24:2290.; Yelin EH, Such CL, Criswell LA, Epstein WV. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Med Care. 1998;36:513–22. DOI: http://dx.doi.org/10.1097/00005650-199804000-00007.; Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with Rheumatology subspecialty care. Arch Intern Med. 1993;153:2229–37. DOI: http://dx.doi.org/10.1001/archinte. 1993.00410190069009.; Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodological standards. Ann Intern Med. 1997;127:52–60. DOI: http://dx.doi.org/10.7326/0003-4819-127-1-199707010-00009.; Widdifield J, Bernatsky S, Paterson JM, et al. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken). 2011;63:53–7. DOI: http://dx.doi.org/10.1002/acr.20304.; Bonafede MM, Fox KM, Johnson BH, et al. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther. 2012;34:457–67. DOI: http://dx.doi.org/10.1016/j.clinthera.2011.12.016.; Lahiri M, Morgan C, Symmons DPM, Bruce IN. Modifiable risk factors for RA: prevention, better than cure. Rheumatology (Oxford). 2012;51:499–512. DOI: http://dx.doi.org/10.1093/rheumatology/ker299.; Sanberg ME, Bengtsson C, Kallberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-205094.; Ellerby N, Mattey D, Packham J, et al. Obesity and comorbidity are independently associated with failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2014-206254.; De Pablo P, Chapple ILC, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic disease. Nat Rev Rheumatol. 2009;68(5):218–24. DOI:10.1038/nrrheum.2009.28.; Iversen MD, Brawerman M, Iversen CN. Recommendations and the state of the evidence for physicial activity interventions for adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumatol. 2012;7(5):489–503. DOI:10.2217/ijr.12.53.; Whittle S, Colebatch A, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford). 2012;51:1416–25. DOI: http://dx.doi.org/10.1093/rheumatology/kes032.; Каратеев АЕ, Яхно НН, Лазебник ЛБ и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва: ИМА-ПРЕСС; 2009. 167 с. [Karateev AE, Yakhno NN, Lazebnik LB, et al. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii [Application of nonsteroid antiinflammatory preparations. Clinical recommendations]. Moscow: IMA-PRESS; 2009. 167 p.]; Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinion of multidisciplinar European expert panel. Ann Rheum Dis. 2010;70(5):818–22. DOI:10.1136/ard.2010.128660.; Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for management of rheumatoid arthritis with glucocorticoids: systemic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1010–4. DOI: http://dx.doi.org/10.1136/ard.2009.127332.; Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560–7. DOI:10.1136/ard.2007072157.; Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. A review on safety: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93. DOI: http://dx.doi.org/10.1136/ard.2005.038638.; Donahue KE, Gartlehner G, Jonas DE, et al. Systemic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124–34. DOI: http://dx.doi.org/10.7326/0003-4819-148-2-200801150-00192.; Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systemic literature review informing EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1004–9. DOI: http://dx.doi.org/10.1136/ard.2009.127225.; Gaujoux-Viala C, Nam JL, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib – a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:510–5. DOI:10.1136/annrheumdis-2013-204588.; Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976–86. DOI: http://dx.doi.org/10.1136/ard.2009.126573.; Nam JL, Ramiros S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–28. DOI:10.1136/annrheumdis-2013-204577.; Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs – a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529–35. DOI:10.1136/annrheumdis-2013-204575.; Vliet Vlielan TPM. Non-drug care for RA – is the era of evidence-based practice approaching? Rheumatology (Oxford). 2007;46:1397–1404. DOI:10.1093/Rheumatology/key149.; Oldfield V, Felson DT. Exercise therapy and orthotic devices in rheumatoid arthritis: evidence-based review. Curr Opin Rheumatol. 2008;20:353–9. DOI: http://dx.doi.org/10.1097/BOR.0b013e3282fd17df.; Finckh A, Liang MH, Mugica C, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Care Res. 2006;15:864–72. DOI: http://dx.doi.org/10.1002/art.22353.; Nies JAB, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73:861–70. DOI:10.1136/annrheumdis-2012-203130.; Van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2019;62:3537–46. DOI: http://dx.doi.org/10.1002/art.27692.; Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum.2007;56:3226–35. DOI: http://dx.doi.org/10.1002/art.22943.; Radner H, Neogi T, Smolen J, Aletaha D. Perfomance of the 2010 ACR/EULAR classifications criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73:114–23. DOI: 101136/annrheumdis-2013-20328.; Sakellariou G, Scire CA, Zambon A, Caporali R. Perfomance of the 2010 classification criteria for rheumatoid arthritis: a systemic literature review and meta-analysis. PLOS ONE. 2013;8e56528.; Knevel R, Schoels M, Huizinga TWJ, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987–94. DOI: http://dx.doi.org/10.1136/ard.2009.126748.; Schipper LG, van Hulst LTC, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010;49:2154–64. DOI:10.1093/Rheumatology/keq195.; Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with biological agent in early rheumatoid arthritis: a metaanalysis of clinical and radiographic remission. Ann Rheum Dis. 2010;69:1298–304. DOI:10.1136/ard 2009.118307.; Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105–12. DOI: http://dx.doi.org/10.1136/ard.2008.099861.; Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systemic literature research. Ann Rheum Dis. 2009;68:1100–4. DOI: http://dx.doi.org/10.1136/ard.2008.093690.; Visser K, Katchhamart W, Losa E, et al. Multinational evidence- based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiatiive. Ann Rheum Dis. 2009;68:1086–93. DOI: http://dx.doi.org/10.1136/ard.2008.094474.; Todoerti M, Maglione W, Bernero E, et al. Systemic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic disease, with focus one rheumatoid arthritis. Rheumatismo. 2013;65:207–18.; Van Dongen H, vam Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424–32. DOI: http://dx.doi.org/10.1002/art.22525.; Kudo-Tanaka E, Matsushita M, Tsuji S, et al. Prevention of development of rheumatoid arthritis (RA) in patients with undifferentiated arthritis (UA) by very early therapeutic interventioin of methotrexate (MTX). Ann Rheum Dis. 2013;72(Suppl 3):244. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.763.; Heimans L, Wevers-de Boer K, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed achieving remission: the IMPROVED study. Ann Rheum Dis. 2013;73(7):1356–61. DOI:10.1136/annrheumdos-2013-203243.; Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69:510–6. DOI: http://dx.doi.org/10.1136/ard.2009.119016.; De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72(1):72–8. DOI:10.1136/annrheumdis-2011-201162.; De Jong PHPD, Hazes JM, Luime JJ, et al. Randomized comparison of triple DMARD therapy with methotrexate monotherapy. Ann Rheum Dis. 2013;72(Suppl 3):113. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.382.; Villeneuve E, Nam JL, Hensor E, et al. Preliminary results of a multicenter randomized controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis Rheum. 2011;63 (Suppl 10):2465.; Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a Threat-to-Target Strategy in very early rheumatoid arthritis. Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Study. Arthritis Rheum. 2011;63:2865–72. DOI: http://dx.doi.org/10.1002/art.30494.; Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Sustained beneficial effects of a protocolized Treat-to-Target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort. Arthritis Care Res. 2013;65:1219–26. DOI:10.1992/acr.21984.; Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70:1292–5. DOI: http://dx.doi.org/10.1136/ard.2010.142729.; Baker M, Jacobs JWG, Welsing PMJ, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med. 2012;156;329–39. DOI: http://dx.doi.org/10.7326/0003-4819- 156-5-201203060-00004.; Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisolone improves clinical and ultrasonography remission rates in early rheumatoid arthritis: results of a 12- month open-label randomized study. Arthritis Res Ther. 2012;14:R112. DOI: http://dx.doi.org/10.1186/ar3838.; St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43. DOI: http://dx.doi.org/10.1002/art.20568.; Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study – a multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37. DOI: http://dx.doi.org/10.1002/art.21519.; Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for prevention of joint damage in Japanese patients with early rheumatoid arthritis; the HOPEFUL 1 study. Ann Rheum Dis. 2013;73(3):536–43. DOI:10.1136/annrheumdis-2012-202433.; Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in the patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467–74. DOI: http://dx.doi.org/10.1002/art.24106.; Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT-HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844–50. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201612.; Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate- naive patients with active rheumatoid arthritis: twentyfour- week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83. DOI: http://dx.doi.org/10.1002/art.24638.; Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008;372:375–82. DOI: http://dx.doi.org/10.1016/S0140-6736(08)61000-4.; Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanerceptmethotrexate therapy versus monotherapy in early rheumatoid arthritis. A two-year, double-blind, randomized study. Arthritis Rheum. 2010;62:674–82. DOI:10.1002/art.272668.; Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870–7. DOI: http://dx.doi.org/10.1136/ard.2008.101121.; Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39–46. DOI: http://dx.doi.org/10.1136/ard.2010.137703.; Burmester GR, Rigby W, van Vollenhoven R, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis. 2013;72(Suppl):OP041. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.246.; Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early arthritis: a randomized trial. Lancet. 1999;353:1568–73. DOI: http://dx.doi.org/10.1016/S0140-6736(98)08513-4.; Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum. 2004;50:2072–81. DOI: http://dx.doi.org/10.1002/art.20351.; Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time. The eleven-year results of the Finish rheumatoid arthritis combination therapy trial. Arthritis Rheum. 2009;60:1222–31. DOI: http://dx.doi.org/10.1002/art.24447.; Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modygying antirheumatic drug therapy anf tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12:R122. DOI: http://dx.doi.org/10.1186/ar3060.; Hertland ML, Stengaard-Petersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethason in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, doubleblind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006;54:1401–9. DOI: http://dx.doi.org/10.1002/art.21796.; Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum. 2005;52:3381–90. DOI: http://dx.doi.org/10.1002/art.21405.; Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis. Ann Intern Med. 2007;146:406–15. DOI: http://dx.doi.org/10.7326/0003-4819-146-6-200703200- 00005.; Markusse IM, Akdemir G, van den Broek M, et al. 10 year of treat-to-target therapy in rheumatoid arthritis patients (the BeST study): clinical and radiological outcome. Arthritis Rheum. 2013;65 (Suppl):S62.; Leirisalo-Repo M, Kautinen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2 year results from an investigator-initiated, randomized, double-blind, placebo-controlled study (the NEORACo Study). Ann Rheum Did. 2013;72:851–7. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201365.; Rantalaiho V, Kautianen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-tear follow-up results of a randomized clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-203497.; Horslev-Petersen K, Hertland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA study; an investigator-initiated, randomized, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014;73:654–61. DOI:10.1136/annrheumdis-2012-202735.; Nam JR, Villeneuve E, Hensor EME, et al. Remission induction comparing infliximab and high-dose intravenous steroids, followed by treat-to target: a double-blind, randomized, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75–85. DOI:10.1136/annrheumdis-2013-2034440.; Den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy («COBRA-light») compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. 2014;73(6):1071–8. DOI:10.1136/annrheumdis-2012-202818.; Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009;48:1429–34. DOI: http://dx.doi.org/10.1093/rheumatology/kep261.; Yamanaka H, Ishigurp N, Takeuchi T, et al. Recovery of clinical but not radiographic outcome by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014. DOI:101093/Rheumatology (Oxford)/key465.; Moreland LW, O’Dell JR, Paulus H, et al. TEAR: treatment of early aggressive RA; A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum. 2012;64:2824–35. DOI: http://dx.doi.org/10.1002/art.34498.; O’Dell JR, Curtis JR, Mikuls TR, et al.; TEAR trial investigators. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis. Results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013;65:1985–94. DOI:10.1002/art.38012.; O’Dell, JR, Mikuls TR, Taylor TH, et al.; CSP 551 RACAT investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307–18. DOI:10.1056/NEJMoa1303006.; Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomized, non-blinded, parallelgroup Swefot trial. Lancet. 2012;379:1712–20. DOI: http://dx.doi.org/10.1016/S0140-6736(12)60027-0.; De Cock D, Meyfroidt S, Joly J, et al. For remission induction with glucocorticoid bridging, methotrexate monotherapy is as effective as combination with other DMARDs, with fewer reported side effects: 4-month primary outcome of CareRa, a randomized induction strategy and treated-to-target trial in early RA. Arthritis Rheum. 2013;14 (abstract 14).; Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388–95.; Katchamart W, Bourre-Tessier J, Donka T, et al. Canadian recommendation for use methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1422–30. DOI:10.3894/jrheum/090978.; Tornero Molina J, Garcia FJB, Alen JC, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration route. Reumatologia Clinica. 2014;pii:S1699–258X(14)00059–X. DOI:10.1016/j.reuma.2014.02.012.; Насонов ЕЛ. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012;51(приложение 3):1–24. [Nasonov EL. Treatment of rheumatoid arthritis 2012: methotrexate place. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Suppl 3):1–24. (In Russ.)]; Visser K, van der Heijde D. Optimal dosage and rout of administration of methotrexate in rheumatoid arthritis: a systemic review of the literature. Ann Rheum Dis. 2009;68:1094–9. DOI: http://dx.doi.org/10.1136/ard.2008.092668.; Mouterde G, Baillet A, Gaujoux-Viala C, et al. Optimizing methotexate therapy in rheumatoid arthritis: a systemic literature review. Joint Bone Spine. 2011;78:587–92. DOI:10.1016/jjbspin.2011.01.010.; Shea B, Swinden MV, Tanjong Ghogomi E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;5:CD000951. DOI: 1002/14651858.CD000951.pub2.; Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double- blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81. DOI: http://dx.doi.org/10.1002/art.23144.; Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheumatol. 1997;36:86–90. DOI: http://dx.doi.org/10.1093/rheumatology/36.1.86.; Rozin A, Scharpira D, Balbir-Gurman A, et al. Relapse of rheumatoid arthritis after substitution of oral for parental administration of methotrexate. Ann Rheum Dis. 2002;61:756–7. DOI: http://dx.doi.org/10.1136/ard.61.8.756.; Bingman SJ, Buch MH, Lindsay S, et al. Parental methotrexate should be given before biological therapy. Rheumatology (Oxford). 2003;42:1009–10. DOI: http://dx.doi.org/10.1093/rheumatology/keg246.; Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232–4. DOI: http://dx.doi.org/10.1136/ard.2003.011593.; Moitra RK, Ledingham JM, Hull RG, et al. Caveats to the use of parental methotrexate in the treatment of rheumatic disease. Rheumatology (Oxford). 2005;44:256–7. DOI: http://dx.doi.org/10.1093/rheumatology/keh471.; Osman A, Mulherin D. Is parental methotrexate worth trying. Ann Rheum Dis. 2001;60:432. DOI: http://dx.doi.org/10.1136/ard.60.4.432.; Burbage G, Gupta R, Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann Rheum Dis. 2001;60:1156. DOI: http://dx.doi.org/10.1136/ard.60.12.1156.; Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheumatol. 2006;35:102–6. DOI: http://dx.doi.org/10.1080/03009740500343294.; Bakker MF, Jacobs JWG, Welsing PMJ, et al. Are switching from oral to subcutaneous methotrexate or additional of cyclosporine to methotrexate useful steps in tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69:1849–52. DOI: http://dx.doi.org/10.1136/ard.2009.124065.; Mainman H, McClaren E, Heycock C, et al. When should we use parental methotrexate? Clin Rheumatol. 2010;29:1093–8. DOI:10.1007/s10067-010-1500-09.; Scott D, Claydon P, Ellis C, Buchan S. A retrospective study of the effect of switching from oral to subcutaneous (SC) methotrexate (MTX): the Methotrexate Evaluation of Norwich Treatment Outcomes in RA (MENTOR) study. Glasgow, UK: British Soc Rheumatology (Oxford); 2012. P. 221.; Hazlewood G. Sucutaneous delivery of methotrexate is associated with improved treatment survival compared to oral administration of the initial treatment of patients with early rheumatoid arthritis. Arthritis Rheum. 2013;65(Suppl 10):627.; Liakos A, Batley M, Hammond T, et al. Subcutaneous methotrexate is more efficacious and better tolerated than oral methotrexate: the experience of a large group of patients in the Rheumatology department of a district general hospital. Ann Rheum Dis. 2012;71(Suppl 3):672. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-eular.593.; Mueller R, Schiff MH, Haile SR, von Kempis J. Effectiveness, tolerability, and safety of subcutaneous methotexate in early rheumatoid arthritis: clinical data from Dt. Gallen cohort. Ann Rheum Dis. 2014;73(Suppl 2). DOI:10.1136/annrheumdis- 2014-eular.2031.; Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at dose ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51. DOI:10.1136/annrheumdis-2014-205228.; Fitzpatric R, Scott DG, Keary I. Cost-minimization analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who had have an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32:1605–12. DOI: http://dx.doi.org/10.1007/s10067-013-2318-z.; Van der Heijde DM, van Riel PL, Gribnau FW, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;333:1036–8. DOI: http://dx.doi.org/10.1016/S0140-6736(89)92442-2.; Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet. 1999;353:259–66. DOI: http://dx.doi.org/10.1016/S0140-6736(98)09403-3.; Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 2000;43:495–505. DOI: http://dx.doi.org/10.1002/1529- 0131(200003)43:3%3C495::AID-ANR4%3E3.0.CO;2-U.; Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med. 1999;159:2542–50. DOI: http://dx.doi.org/10.1001/archinte.159.21.2542.; Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomized, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–5. DOI: http://dx.doi.org/10.1136/ard.58.4.220.; Kavanaugh A, Wells AF. Benefits and risk of low-dose glucocorticoid treatment in the patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology/keu135.; Caporali R, Scire CA, Todoerti M, Montecucco C. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol. 2013;31(Suppl 78):S9–13.; Roubille C, Richer V, Starnino T. The effects of the TNF inhibitors, methotrexate, NSAIDS and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2014;73 (Suppl 2) [P0169].; Dernis E, Ruyssen-Wtrand A, Mouterde C, et al. Use of glucocorticoids in rheumatoid arthritis – practical modalities based on data from literature and expert opinion. Join Bone Spain. 2010;77:451–7. DOI:10.1016/j.jbspin.2009.12.010.; Ma MHY, Kingsley GH, Scott DL. A systemic comparison of combination DMARD therapy and tumor necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2010;49:91–8. DOI:10.1093/Rheumatology (Oxford)/kep331.; Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and meta-analysis of efficacy and safety. BMC Musculoskeletal Dis. 2008;9:52. DOI: http://dx.doi.org/10.1186/1471-2474-9-52.; Aaltonen KJ, Vikki LM, Malmiaara A, et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in the treatment of rheumatoid arthritis. PLoS ONE. 2012;7:e30275. DOI: http://dx.doi.org/10.1371/journal. pone.0030275.; Nixon RM, Bansback N, Brennan A. Using mixed treatment comparison and meta-regression to perform indirect comparisons to estimate efficacy of biologic treatment in rheumatoid arthritis. Stat Med. 2007;26:1237–54. DOI: http://dx.doi.org/10.1002/sim.2624.; Schmitz S, Adams R, Walsh CD, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrated differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225–30. DOI:10.1136/ard.2011.200228.; Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta-analysis. J Rheumatol. 2006;33(12):2398–407.; Kristensen LE, Christensen R, Biddal H, et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systemic literature review. Scand J Rheumatol. 2007;36:411–7. DOI: http://dx.doi.org/10.1080/03009740701607067.; Wiens A, Venson R, Pharm D, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339–53. DOI: http://dx.doi.org/10.1592/phco.30.4.339.; Schmitz S, Adams R, Walsh C, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225–30. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-200228.; Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. DOI:10.1002/14651858.CD007848.pub2; Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological anti-rheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta-analysis. Ann Rheum Dis. 2011;70:266–71. DOI: http://dx.doi.org/10.1136/ard.2010.132134.; Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010;39:425–41. DOI: http://dx.doi.org/10.1016/j.semarthrit.2009.12.002.; Kristensen LE, Jakobsen AK, Bartels EM, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011;40:1–7. DOI:10.3109/03009742.2010.491834.; Devine EB, Alfonso-Cristanchp R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy. 2011;31:39–51. DOI: http://dx.doi.org/10.1592/phco.31.1.39.; Roy S, Cifaldi MA. Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate: a mixed treatment comparison meta-analysis. Ann Rheum Dis. 2011;70(Suppl 3):432.; Gallego-Galisteo M, Villa-Rubio A, Alergre-del Rau E, et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012;37:301–7. DOI:10.1111/j.1365-2710.2011.01292.x.; Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther. 2011;13:R204. DOI: http://dx.doi.org/10.1186/ar3537.; Turksta E, Ng S-K, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011;27:1885–97. DOI: http://dx.doi.org/10.1185/03007995.2011.608655.; Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011;90:828–35. DOI: http://dx.doi.org/10.1038/clpt.2011.256.; Favalli EG, Pregnolato F, Biggioggero M, Meroni PL. The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskeletal Dis. 2012;4:213–23. DOI:10.1177/1759720X12449082.; Pierreisnard A, Issa N, Barnetche T, et al. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Join Bone Spain. 2013;80:386–93. DOI:10.1016/j.jbspin.2012.09.03.; Jones G, Darian-Smith E, Kwok M, Winzenberg T. Effect of biologic therapy on radiologic progression in rheumatoid arthritis: what does it add to methotrexate? Biologics. 2012;6:155–61.; Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65:28–38. DOI: http://dx.doi.org/10.1002/art.37711.; Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;17:2275–85. DOI:http://dx.doi.org/10.1001/jama.295.19.2275.; Leombruno JP, Einarson TR, Keystone EC. The safety of antitumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analysis of serious adverse events. Ann Rheum Dis. 2009;68:1136–45. DOI:10.1136/ard.2008.091025.; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. DOI:10.1002/14651858.CD008794.pub2.; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2012;3.; Fautrel B, Pham T, Mouterde G, et al. Recommendations of the French Society for Rheumatology (Oxford) regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine. 2007;74:627–37. DOI: http://dx.doi.org/10.1016/j.jbspin.2007.10.001.; Caporali R, Conti F, Aliverini S, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology (Oxford). I Efficacy. Clin Exp Rheumatol. 2011;29(Suppl 66):S7–14.; Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010;49:1197–9. DOI: http://dx.doi.org/10.1093/rheumatology/ keq006a.; Goeb V, Ardizzone M, Arnaud L, et al.; Club Rhumatismes at Inflammations (CRI). Recommendations for using TNFα antagonists and French clinical practice guidelines endorsed by French National Authority for health. Join Bone Spain. 2013;80:574–81. DOI:10.1016/j.jspin.2013.09.001.; Smolen JS, Schoels MM, Nishimoto N, et al. Consensus state on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72:482–92. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-202469.; Malavia AP, Ledingham J, Bloxham J, et al.; BSR Clinical Affairs Committee and Standards, audit and Guidelines Working Group, the BHPR. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology/ker168.; Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of Rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–20. DOI:10.1136/annrheumdis.-2010-144998.; Bukhari M, Abernethy R, Deighton C, et al. BSR and BHPR guidelines on the use of Rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:2311–3. DOI:10.1093/Rheumatology/ker106a.; Bathon JM, Martin RW, Fleischmann RM, et al. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93. DOI: http://dx.doi.org/10.1056/NEJM200011303432201.; Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcome. Arthritis Rheum. 2002;46:1443–50. DOI: http://dx.doi.org/10.1002/art.10308.; Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomized CONCERTO trial. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-204769.; Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914–5. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201544.; Pope JE, Haraoui B, Thorne JT, et al. The Canadian Methotrexate and Etanercept Outcome Study: a randomized trial of discontinuation methotrexate after 6 months or etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-203684.; Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from JESMR study. J Rheumatol. 2011;38:1585–92. DOI:10.3899/jrheum.110014.; Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or anather diseasemodifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatolofy Biologics Register. Arthritis Rheum. 2006;54:1786–95. DOI: http://dx.doi.org/10.1002/art.21830.; Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to AR and EULAR criteria in patients with established RA: results from South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495–99. DOI:10.1093/Rheumatology (Oxford)/ken002.; Kristensen LE, Saxne T, Nilsson JA, Geborec P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from six-year observational study in South Sweden. Artritis Res Ther. 2006;8(6):R174; Hertland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveilance of clinical practice in the natiowide Danish DANBIO registry. Arthritis Rheum. 2010;62:22–32. DOI:10.1002/art.27227.; Iannone F, Gremese E, Atzeni F, et al. Long-term retention of tumor necrosis factor-alpha inhibitor therapy in large Italian cohort of patients with rheumatoid arthritis from GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179–84. DOI:10.3899/jrheum.111125.; Aga A-B, Lie E, Uhling T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-204020.; Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology (Oxford) Biologics Register. Ann Rheum Dis. 2011;70:583–9. DOI:10.1136/ard.2010.139774.; Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with adherence to biologics for rheumatoid arthritis: a systemic review. Clin Ther. 2011;33:901–3. DOI:10/1016/j.clinthera.2011.06.001.; Takeuchi T, Kaneko Y, Atsumi T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study). Ann Rheum Dis. 2013;72(Suppl 3):62.; Kojima T, Yabe Y, Kaneko A, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology (Oxford)/key/302.; Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010;69:88–96. DOI: http://dx.doi.org/10.1136/ard.2008.105197.; Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet. 2013;381:1541–50. DOI: http://dx.doi.org/10.1016/S0140-6736(13)60250-0.; Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial inrheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43–50. DOI:10.1136/annrheumdis-2011-201282.; Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenetic effects after 1 year of tocilisumab- based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803–9. DOI:10.1136/annrheumdis-2013-204761.; Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systemic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72:583–9. DOI:10.1136/annrheumdis-2012- 202470.; Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patients reported outcome (PROs) in rheumatoid arthritis patients with an inadequate to conventional DMARDs – a systemic review and network meta-analysis. Health Quality Life Outcome. 2014;12:102. DOI: http://dx.doi.org/10.1186/1477-7525-12-102.; Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806. DOI: http://dx.doi.org/10.1002/art.22025.; Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23. DOI: http://dx.doi.org/10.1136/ard.2007.074773.; Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Ann Rheum Dis. 2008;67:547–54. DOI: http://dx.doi.org/10.1136/ard.2007.074773.; Emery P, Keystone E, Tony H-P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23. DOI: http://dx.doi.org/10.1136/ard.2008.092932.; Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors (GO-AFTER study): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210–21. DOI: http://dx.doi.org/10.1016/S0140-6736(09)60506-7.; Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum. 2007;57:448–53. DOI: http://dx.doi.org/10.1002/art.22617.; Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29. DOI: http://dx.doi.org/10.1186/ar1881.; Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34:353–8. DOI: http://dx.doi.org/10.1080/03009740510026887.; Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumor necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71:1861–4. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201324.; Burmester GR, Kary S, Unnebrink K, et al. Treatment of rheumatoid arthritis with adalimumab is effective for patients with and without history of other anti-TNF therapies. Rheumatology (Oxford). 2010;49(Suppl 1):i89–111.; Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis – a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30:1447–54. DOI: http://dx.doi.org/10.1007/s10067-011-1779-1.; Chatzidionysiou K, Askling J, Eriksson J, et al.; ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-204714.; Lloyd S, Bujkiewicz S, Wailoo AJ, et al. The effectiveness of anti-TNF-α therapies when used sequential in rheumatoid arthritis patients: a systemic review and meta-analysis. Rheumatology (Oxford). 2010;49:2313–21. DOI:10.1093/Rheumatology (Oxford) keq169.; Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis with inadequate response to tumor necrosis factoralpha inhibitors. Arthritis Res Ther. 2011;13:R25. DOI: http://dx.doi.org/10.1186/ar3249.; Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumor necrosis factor inhibitor failure in rheumatoid arthritis: systemic review and indirect pair wise meta-analysis. Ann Rheum Dis. 2012;71:1303–8. DOI:10.1136/annrheumdis-2011-200490.; Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96–103.; NICE. Rheumatoid arthritis – drugs for treatment after failure of a TNF inhibitor: final appraisal determination. Available from: http://guidance.nice.org.uk/TA/WaveR/61/FAD/FinalApprais alDetermination/pdf/; Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after failure of a tumor necrosis factor inhibitor: a systemic review and economic evaluation. Health Technol Assess. 2011;15(4):1–278.; Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: a systemic review. Rheumatology (Oxford). 2012;51:2252–61. DOI:10.1093/Rheumatology (Oxford)/kes217.; Finckh A, Ciurea A, Brulhart L, et al.; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417–23. DOI: http://dx.doi.org/10.1002/art.22520.; Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumor necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387–93. DOI: http://dx.doi.org/10.1136/ard.2008.105064.; Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology (Oxford) Biologics Register. Arthritis Care Res (Hoboken). 2012;64:1108–15.; Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine. 2012;79:281–4. DOI: http://dx.doi.org/10.1016/j.jbspin.2011.05.002.; Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-203993.; Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. В кн: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2011. C. 55–93. [Nasonov EL. Application rituksimab at rheumatoid arthritis. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Nasonov EL, editor. Moscow: IMA-PRESS; 2011. P. 55–93.]; Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19. DOI: http://dx.doi.org/10.1056/NEJMoa1112072.; Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507. DOI: http://dx.doi.org/10.1056/NEJMoa1109071.; Van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-month data from a 24-month phase 3 randomized radiographic study. Arthritis Rheum. 2013;65:559–70. DOI: http://dx.doi.org/10.1002/art.37816.; Lee EB, Fleischmann RM, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New Engl J Med. 2014;370:2377–86. DOI: http://dx.doi.org/10.1056/NEJMoa1310476.; Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomized phase 3 trial. Lancet. 2013;381:451–60. DOI:10.1016/S0140-6736(12)61424-X.; Kawalec P, Mikrut A, Wisniewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor. In the treatment of rheumatoid arthritis: a systemic review and meta-analysis. Clin Rheumatol. 2013;32:1414–24. DOI:10.1007/s10067-013- 2329-9.; Berhan A. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying antirheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC Musculoskeletal Disorders. 2103;14:332. DOI: http://dx.doi.org/10.1186/1471-2474-14-332.; Vieira MC, Wallenstein G, Bradley J, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors – a network meta-analysis. Ann Rheum Dis. 2014;72(Suppl 3):619. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.1841.; Bredermeier M, de Oliveira FK, Rocha CM. Low-versus highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228–35. DOI:10.1002/acr.22116.; Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: expletory analysis from the BeST study. Ann Rheum Dis. 2011;70:315–9. DOI: http://dx.doi.org/10.1136/ard.2010.136556.; Van der Maas A, Kievit W, van der Bemt BJF, et al. Downtitration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012:71:1849–54. DOI:10.1136/annrheumdis-2011-200945.; Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-3013- 204016.; Chatzidionysiou K, Turesson C, Teleman A, et al. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Arthritis Rheum. 2012;64(Suppl):S336.; Hariga M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 2012;22(6):814–22. DOI: http://dx.doi.org/10.3109/s10165- 011-0586-5.; Kavanaugh A, Emery P, Felischmann RM, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2012;51(Suppl 3):iii27.; Fautrel B, Gandjbakhch F, Foltz V, et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial). Ann Rheum Dis. 2013;2(Suppl 3):72. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.271.; Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet. 2013;381:918–29. DOI: 10/1016/S0140-6736(12)61811-X.; Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet. 2014;383:321–32. DOI:10.1016/S010- 673(13)61751-1.; Horslev-Petersen K, Hertland ML, Junker P, et al. Very high rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab; year 2 clinical results of an investigator-initiated randomized, controlled clinical trial of early, rheumatoid arthritis (OPERA). Arthritis Rheum. 2013;65 (Suppl):S1148.; Emery P, Hamouden M, FitzGerald M, et al. Induction of remission in patients with up to 12 months of moderate-tosevere rheumatoid arthritis symptoms treated with etanercept plus methotrexate over 52 weeks. Arthritis Rheum. 2012;64 (Suppl):S1077.; Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study. Ann Rheum Dis. 2013;72(Suppl 3):399.; Nampei A, Nagayama Y. Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 3):877. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.2618.; Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1069–73. DOI:10.3899/jrheum.121427.; Durez P, Depresseux G, Nzeusseu Toukar A, et al. Rate or remission by tocilizumab or methotrexate induction therapy in early active rheumatoid arthritis: results of the TOMERS trial. Ann Rheum Dis. 2013;72(Suppl 3):623. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.1852.; Takeuchi T, Matsubara T, Ohta S, et al. Abatacept biologicfree remission study in established rheumatoid arthritis – ORION study. Ann Rheum Dis. 2013;72(Suppl 3):613. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.1826.; Batticciotto A, Varisco V, Antivalle M, et al. Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis. 2013;72(Suppl l):877. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.2619.; O’Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2010;69:1823–6. DOI: http://dx.doi.org/10.1136/ard.2008.105577.; Ten Wolde S, Breedveld FC, Hermans J, et al. Randomized placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347–52. DOI: http://dx.doi.org/10.1016/S0140-6736(96)90535-8.; Ten Wolde S, Hermans J, Breedvald FC, Dijkmans BA. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis. 1997;56:235–9. DOI:http://dx.doi.org/10.1136/ard.56.4.235.; Van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012;51:1120–8. DOI: http://dx.doi.org/10.1093/rheumatology/ker516.; Gonzalez A, Maradit KH, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64–9. DOI: http://dx.doi.org/10.1136/ard.2006.059980.; Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701. DOI: http://dx.doi.org/10.1002/art.21675.; Попкова ТВ, Герасимова ЕВ, Новикова ДС, Насонов ЕЛ. Метотрексат и риск сердечно-сосудистых осложнений при ревматоидном артрите. Научно-практическая ревматология. 2012;50(6):70–9. [Popkova TV, Gerasimova EV, Novikova DS, Nasonov EL. Methotrexate and cardiovascular risk in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):70–9. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1297.; Wasco MCM, Dasgupta A, Hubert H, et al. Propensity-adjusted assoсiation of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334–42. DOI: http://dx.doi.org/10.1002/art.37723.; Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatologic register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from British Society for Rheumatology (Oxford) Biologics Register. Arthritis Rheum. 2007;56:2905–91. DOI: http://dx.doi.org/10.1002/art.22809.; Westlake SL, Colebatch AN, Baird J, et al. Tumоr necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518–31. DOI: http://dx.doi.org/10.1093/rheumatology/keq316.; Del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose trashholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2013. DOI 10.1002/art.38210.; Pereira IA, da Mota LMH, Cruz BA, et al. 2012 Brazilian Society of Rheumatology (Oxford) Consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol. 2012;52:474–95.; Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31. DOI: http://dx.doi.org/10.1136/ard.2009.113696.; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26. [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-8-26.; Pincus T, Kathryn A, Gibson MD, Castrejon I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Joint Dis. 2013;71 (Suppl 1):S9–19.; McLean-Tooke A, Aldridge C, Waugh A, et al. Methotrexate, rheumatoid arthritis and infection risk – what is the evidence? Rheumatology (Oxford). 2009;48:867–71. DOI: http://dx.doi.org/10.1093/rheumatology/kep101.; Bourre-Tessier J, Haraou B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systemic review. J Rheumatology (Oxford). 2010;37:1416–21. DOI:10.3899/jrheum.090153.; Dougados MR, van der Heijde DM, Brault Y, et al. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: finding from a randomized study (COMET). J Rheumatol. 2014. DOI:10.3899/jrheum.131238.; Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. 2014. DOI:10.1002/acr.22383.; Alsaeedi S, Keystone EC. Oral or subcutaneous methotrexate for rheumatoid arthritis. Nat Rev Rheumatol. 2014. DOI:10.1038/nrreum.2014.129.; Strand V, Williams S, Miller PSJ, et al. Discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the Consortium of Rheumatology (Oxford) Researchers of North America (CORRONA) database. Ann Rheum Dis. 2013;72(Suppl 3):71.; Asai S, Kojima T, Oguchi T, et al. OP0069 Concomitant methotrexate affect the incidence of large joint replacement surgery in the rheumatoid arthritis patients treated with etanercept. Ann Rheum Dis. 2014;73:86–87. DOI:10.1136/annrheumdis-2014-eular.1502.; Rezaei H, Saevarsdottir S, Forslind K, et al. The early rheumatoid arthritis patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responder’s population in the SWEFOT trial. Ann Rheum Dis. 2012;71:186–91. DOI:10.1136/annrheumdis-2011-200038.; Gaujoux-Viala C, Mitrovic S, Barnetche T, et al. THU0116 Efficacy of glucocorticoids for early rheumatoid arthritis (RA): a meta-analysis of randomized controlled trials. Ann Rheum Dis. 2014;73:218. DOI:10.1136/annrheumdis-2014- eular.5840.; Verschueren P, de Cock D, Corluy L, et al. THU0137 Associated with a glucocorticoid bridging scheme, methotrexate is as effective alone as in combination with other DMARDs for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the CARERA trial. Ann Rheum Dis. 2014;73:226. DOI:10.1136/annrheumdis-2014-eular.2137.; Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно- практическая ревматология. 2014;52(2):209–21. [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):209–21. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-209-221.; European Medical Agency. Xeljanz. 2013; accessed 25 May, 2014) Available from: http://www.ema.europa.eu/ema/indexjsp?curl=pages/medicines/ human/medicines/002542/smops/Negative/human_smo p_000501jsp&mid=WC0b01ac058001d127; Committee for Medicinal Products for Human Use (CHMP). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). 22–25 July 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_a nd_events/news/2013/07/news_detail_001851.jsp&mid=WC0 b01ac058004d5c1.; Pfizer. Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ (tofacitinib citrate). 2013; accessed 25 May 2013. Available from: http://press.pfizer.com/pressrelease/ pfizer-receives-chmp-negative-opinion-regardingmarketing- authorization-europe-rheumat; Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systemic review and meta-analysis. Ann Rheum Dis. 2013, April 18. DOI:10.1136/annrheumdis-2012-203116.; Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–95. DOI: http://dx.doi.org/10.1001/jama.2013.1099.; https://rsp.mediar-press.net/rsp/article/view/2291; undefined

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2291

المؤلفون: E. Nasonov L., V. Mazurov I., D. Karateev E., G. Lukina V., E. Zhilyaev V., V. Amirdzhanova N., Yu. Muraviyov V., N. Tchichasova V., Е. Насонов Л., В. Мазуров И., Д. Каратеев Е., Г. Лукина В., Е. Жиляев В., В. Амирджанова Н., Ю. Муравьев В., Н. Чичасова В.

المصدر: Rheumatology Science and Practice; Vol 53, No 5s (2015); 1-17 ; Научно-практическая ревматология; Vol 53, No 5s (2015); 1-17 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20155s

مصطلحات موضوعية: rheumatoid arthritis, «Treat to Target», disease modifying anti-rheumatic drugs, biologics, methotrexate, ревматоидный артрит, стратегия «Лечение до достижения цели», базисные противовоспалительные препараты, генно-инженерные биологические препараты, метотрексат

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2136/1362; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290-331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. atsional’noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: PEOTAR-media; 2008. P. 290-331.]; McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2012;365:2205-19. DOI:10.1056/NEJMra1004965.; Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861-71. DOI:10.1136/annrheumdis-2011-201036.; Furst DE, Keystone EC, Braun J, et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann Rheum Dis. 2012;71 (Suppl II):i2-i45. DOI:10.1136/annrheumdis-2011-201036.; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013.]; Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009;374:430-2. DOI:10.1016/S0140-6736(09)61432-X.; Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. DOI:10.1136/ard.2009.126532.; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2010;69:964-75. DOI:10.1136/annrheumdis-2013-204573.; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with systemic and biological disease-modifying anti-rheumatic drugs: 2013. Ann Rheum Dis. 2014;73:492-509. DOI:10.1136/annrheumdis-2013-204573.; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита - 2013: общая характеристика и дискуссионные проблемы. Научно- практическая ревматология. 2013;51(6):609-22. [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis - 2013: general characteristics and disputable problems. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):609-22. (In Russ.)]. DOI:10.14412/1995-4484-2013-609-22.; Aletaha D, Neogri T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81. DOI:10.1002/art.27584.; Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86. DOI:10.1136/annrheumdis-2013-204317.; Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2014;73:3-5. DOI:10.1136/annrheumdis-2013-204317.; Национальные рекомендации по лечению ревматоидного артрита, 2013 (проект). Доступ по ссылке: http://www.rheumatolog.ru/experts/national-guidelines [Natsional'nye rekomendatsii po lecheniyu revmatoidnogo artrita, 2013 (proekt) [National recommendations about treatment of rheumatoid arthritis, 2013 (project)]. Available from: http://www.rheumatolog.ru/experts/national-guidelines]; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical recommendations.]. Moscow: GEOTAR-Media; 2010. 752 p.]; Насонов ЕЛ, редактор. Лечение ревматоидного артрита. Клинические рекомендации. Москва: Алмаз; 2006. 118 с. [Nasonov EL, editor. Lechenie revmatoidnogo artrita. Klinicheskie rekomendatsii [Treatment of rheumatoid arthritis. Clinical recommendations]. Moscow: Almaz; 2006. 118 p.]; Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45. DOI:10.1136/ard.2005.044354.; Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45:1167-9. DOI:10.1093/rheumatology/kel215a.; Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology (Oxford), British Health Professionals in Rheumatology (Oxford) Standards, Guidelines and Audit Working Group. British Society for Rheumatology (Oxford) and British Health Professionals in Rheumatology (Oxford) Guideline for the Management of Rheumatoid Arthritis (after the first two years). Rheumatology (Oxford). 2009;48:436-9. DOI:10.1093/Rheumatology(Oxford)/key450a.; Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying ant rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84. DOI:10.1002/art.23721.; Singh JA, Furst D, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625-39. DOI:10.1002/acr.21641.; Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology (Oxford) Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. J Rheumatol. 2012;39:1559-82. DOI:10.3899/jrheum.110207.; National Institute for Clinical Excellence (NICE). Rheumatoid arthritis: The management of rheumatoid arthritis in adults. NICE guidelines [CG79]. 2009. [Internet. Accessed July 14, 2011.] Available from: http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf; The Royal Australian College of General Practitioners. Clinical guidelines for diagnosis and management of early rheumatoid arthritis; 2008. [Internet. Accessed July 14, 2011.] Available from: http://www.healthnetworks.health.wa.gov.au/docs/Clinical_guidelines_Rheumatoid_Arthritis.pdf; http://www.racgp.org.au/guidelines musculoskeletaldiseases; Baecklund E, Forsblad d’Elia H, Turesson K. Guidelines for the pharmaceutical management of rheumatoid arthritis Swedish Society of Rheumatology. 2011. April 14. Available from: http://www.svenskreumatologi.se/index2.htm; Scottish Intercollegiate Guidelines Network (SIGN). Management of early rheumatoid arthritis: SIGN Publication No. 48 2000; [Internet. Accessed July 14, 2011.] Available from: http: //www. http://sign.ac.uk/guidelines/fulltext/48/index.html; GUIPCAR group. Update of cliniсal practice guidline for the management of rheumatoid arthritis in Spain. Madrid (Spain): Spanish Scociety of Rheumatology; 2011. 367 p.; Da Mota LMH, Cruz BA, Brenol CV, et al. 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol. 2012;52:135-74.; Ataman S, Borman P, Evcik D, et al. Management of rheumatoid arthritis: consensus recommendations from the Turkish League Against Rheumatism. Turk J Rheumatol. 2011;26:273-94. DOI:10.5606/tjr.2011.046.; Mok CC, Tam LS, Chan TH, et al. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol. 2011;30:303-12. DOI:10.1007/s10067-010-1596-y.; El Zorkany B, Alwahshi HA, Hammoudeh M, et al. Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution? Clin Rheumatol. 2013;32:151-9. DOI:10.1007/s10067-012-2153-7.; Fonseca JE, Bernardes M, Canhao H, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. Acta Reumatol Port. 2011;36:385-8.; Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spain. 2014;81(4):287-97. DOI:10.1016/j.jbspin.2014.05002.; Cardiel MH, Diaz-Borjon A, Vazquez del Mercado Espinosa M, et al. Update of the Mexican College of Rheumatology (Oxford) Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis. Reumatologia Clinica. 2014;19:227-40.; Wollenhaupt J, Albrecht K, Kruger K, Muller-Ladner U. The new 2012 German recommendations for treating rheumatoid arthritis. Z Rheumatol. 2013;72:6-9. DOI:10.1007/s00393-012-1093-6.; Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid rthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64-71. DOI:10.1136/annrheumdis-2011-201247.; Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46:975-9. DOI:10.1093/rheumatology/kem007.; Smolen JS, Han C, van der Heijde D, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNFblockade. Ann Rheum Dis. 2009;68:823-37. DOI:10.1136/ard.2008.090019.; Koevoets R, van der Heijde D. Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Arthritis Rheum. 2009;60(Suppl):957.; Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63:3702-11. DOI:10.1002/art.30634.; Sakellariou G, Scire CA, Verstappen SM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 2013;72:245-9. DOI:10.1136/annrheumdis-2012-201817.; Gartner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid arthritis: Associations with clinical joint assessment in remission. Arthritis Rheum. 2013;65:2005-14. DOI:10.1002/art38016.; Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360-4. DOI:10.1136/ard.2008.091454.; Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1815-21. DOI:10.1136/ard.2010.149260.; Scire CA, Lunt M, Marshall T, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2014;73:1677-82. DOI:10.1136/annrheumdis-2013-203339.; Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol. 1997;24:2290.; Yelin EH, Such CL, Criswell LA, Epstein WV. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Med Care. 1998;36:513-22. DOI:10.1097/00005650-199804000-00007.; Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with Rheumatology subspecialty care. Arch Intern Med. 1993;153:2229-37. DOI:10.1001/archinte.1993.00410190069009.; Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodological standards. Ann Intern Med. 1997;127:52-60. DOI:10.7326/0003-4819-127-1-199707010-00009.; Widdifield J, Bernatsky S, Paterson JM, et al. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken). 2011;63:53-7. DOI:10.1002/acr.20304.; Bonafede MM, Fox KM, Johnson BH, et al. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther. 2012;34:457-67. DOI:10.1016/j.clinthera.2011.12.016.; Lahiri M, Morgan C, Symmons DPM, Bruce IN. Modifiable risk factors for RA: prevention, better than cure. Rheumatology (Oxford). 2012;51:499-512. DOI:10.1093/rheumatology/ker299.; Sanberg ME, Bengtsson C, Kallberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-205094.; Ellerby N, Mattey D, Packham J, et al. Obesity and comorbidity are independently associated with failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2014-206254.; De Pablo P, Chapple ILC, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic disease. Nat Rev Rheumatol. 2009;68(5):218-24. DOI:10.1038/nrrheum.2009.28.; Iversen MD, Brawerman M, Iversen CN. Recommendations and the state of the evidence for physicial activity interventions for adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumatol. 2012;7(5):489-503. DOI:10.2217/ijr.12.53.; Whittle S, Colebatch A, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford). 2012;51:1416-25. DOI:10.1093/rheumatology/es032.; Каратеев АЕ, Яхно НН, Лазебник ЛБ и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва: ИМА-ПРЕСС; 2009. 167 с. [Karateev AE, Yakhno NN, Lazebnik LB, et al. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii [Application of nonsteroid antiinflammatory preparations. Clinical recommendations]. Moscow: IMA-PRESS; 2009. 167 p.]; Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinion of multidisciplinar European expert panel. Ann Rheum Dis. 2010;70(5):818-22. DOI:10.1136/ard.2010.128660.; Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for management of rheumatoid arthritis with glucocorticoids: systemic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1010-4. DOI:10.1136/ard.2009.127332.; Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-7. DOI:10.1136/ard.2007072157.; Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. A review on safety: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-93. DOI:10.1136/ard.2005.038638.; Donahue KE, Gartlehner G, Jonas DE, et al. Systemic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124-34. DOI:10.7326/0003-4819-148-2-200801150-00192.; Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systemic literature review informing EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1004-9. DOI:10.1136/ard.2009.127225.; Gaujoux-Viala C, Nam JL, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib - a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:510-5. DOI:10.1136/annrheumdis-2013-204588.; Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976-86. DOI:10.1136/ard.2009.126573.; Nam JL, Ramiros S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516-28. DOI:10.1136/annrheumdis-2013-204577.; Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs - a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529-35. DOI:10.1136/annrheumdis-2013-204575.; Vliet Vlielan TPM. Non-drug care for RA - is the era of evidence-based practice approaching? Rheumatology (Oxford). 2007;46:1397-1404. DOI:10.1093/Rheumatology/key149.; Oldfield V, Felson DT. Exercise therapy and orthotic devices in rheumatoid arthritis: evidence-based review. Curr Opin Rheumatol. 2008;20:353-9. DOI:10.1097/BOR.0b013e3282fd17df.; Finckh A, Liang MH, Mugica C, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Care Res. 2006;15:864-72. DOI:10.1002/art.22353.; Nies JAB, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73:861-70. DOI:10.1136/annrheumdis-2012-203130.; Van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2019;62:3537-46. DOI:10.1002/art.27692.; Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226-35. DOI:10.1002/art.22943.; Radner H, Neogi T, Smolen J, Aletaha D. Perfomance of the 2010 ACR/EULAR classifications criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73:114-23. DOI: 101136/annrheumdis-2013-20328.; Sakellariou G, Scire CA, Zambon A, Caporali R. Perfomance of the 2010 classification criteria for rheumatoid arthritis: a systemic literature review and meta-analysis. PLOS ONE. 2013;8e56528.; Knevel R, Schoels M, Huizinga TWJ, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987-94. DOI:10.1136/ard.2009.126748.; Schipper LG, van Hulst LTC, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010;49:2154-64. DOI:10.1093/Rheumatology/keq195.; Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with biological agent in early rheumatoid arthritis: a metaanalysis of clinical and radiographic remission. Ann Rheum Dis. 2010;69:1298-304. DOI:10.1136/ard2009.118307.; Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105-12. DOI:10.1136/ard.2008.099861.; Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systemic literature research. Ann Rheum Dis. 2009;68:1100-4. DOI:10.1136/ard.2008.093690.; Visser K, Katchhamart W, Losa E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiatiive. Ann Rheum Dis. 2009;68:1086-93. DOI:10.1136/ard.2008.094474.; Todoerti M, Maglione W, Bernero E, et al. Systemic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic disease, with focus one rheumatoid arthritis. Rheumatismo. 2013;65:207-18.; Van Dongen H, vam Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424-32. DOI:10.1002/art.22525.; Kudo-Tanaka E, Matsushita M, Tsuji S, et al. Prevention of development of rheumatoid arthritis (RA) in patients with undifferentiated arthritis (UA) by very early therapeutic interventioin of methotrexate (MTX). Ann Rheum Dis. 2013;72(Suppl 3):244. DOI:10.1136/annrheumdis-2013-eular.763.; Heimans L, Wevers-de Boer K, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed achieving remission: the IMPROVED study. Ann Rheum Dis. 2013;73(7):1356-61. DOI:10.1136/annrheumdos-2013-203243.; Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69:510-6. DOI:10.1136/ard.2009.119016.; De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72(1):72-8. DOI:10.1136/annrheumdis-2011-201162.; De Jong PHPD, Hazes JM, Luime JJ, et al. Randomized comparison of triple DMARD therapy with methotrexate monotherapy. Ann Rheum Dis. 2013;72(Suppl 3):113. DOI:10.1136/annrheumdis-2013-eular.382.; Villeneuve E, Nam JL, Hensor E, et al. Preliminary results of a multicenter randomized controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis Rheum. 2011;63 (Suppl 10):2465.; Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a Threat-to-Target Strategy in very early rheumatoid arthritis. Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Study. Arthritis Rheum. 2011;63:2865-72. DOI:10.1002/art.30494.; Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Sustained beneficial effects of a protocolized Treat-to-Target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort. Arthritis Care Res. 2013;65:1219-26. DOI:10.1992/acr.21984.; Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70:1292-5. DOI:10.1136/ard.2010.142729.; Baker M, Jacobs JWG, Welsing PMJ, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med. 2012;156;329-39. DOI:10.7326/0003-4819-156-5-201203060-00004.; Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisolone improves clinical and ultrasonography remission rates in early rheumatoid arthritis: results of a 12- month open-label randomized study. Arthritis Res Ther. 2012;14:R112. DOI:10.1186/ar3838.; St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43. DOI:10.1002/art.20568.; Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study - a multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. DOI:10.1002/art.21519.; Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for prevention of joint damage in Japanese patients with early rheumatoid arthritis; the HOPEFUL 1 study. Ann Rheum Dis. 2013;73(3):536-43. DOI:10.1136/annrheumdis-2012-202433.; Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in the patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467-74. DOI:10.1002/art.24106.; Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT-HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844-50. DOI:10.1136/annrheumdis-2012-201612.; Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate- naive patients with active rheumatoid arthritis: twentyfour- week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272-83. DOI:10.1002/art.24638.; Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008;372:375-82. DOI:10.1016/S0140-6736(08)61000-4.; Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanerceptmethotrexate therapy versus monotherapy in early rheumatoid arthritis. A two-year, double-blind, randomized study. Arthritis Rheum. 2010;62:674-82. DOI:10.1002/art.272668.; Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870-7. DOI:10.1136/ard.2008.101121.; Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. DOI:10.1136/ard.2010.137703.; Burmester GR, Rigby W, van Vollenhoven R, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis. 2013;72(Suppl):OP041. DOI:10.1136/annrheumdis-2013-eular.246.; Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early arthritis: a randomized trial. Lancet. 1999;353:1568-73. DOI:10.1016/S0140-6736(98)08513-4.; Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum. 2004;50:2072-81. DOI:10.1002/art.20351.; Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time. The eleven-year results of the Finish rheumatoid arthritis combination therapy trial. Arthritis Rheum. 2009;60:1222-31. DOI:10.1002/art.24447.; Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modygying antirheumatic drug therapy anf tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12:R122. DOI:10.1186/ar3060.; Hertland ML, Stengaard-Petersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethason in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, doubleblind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006;54:1401-9. DOI:10.1002/art.21796.; Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum. 2005;52:3381-90. DOI:10.1002/art.21405.; Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis. Ann Intern Med. 2007;146:406-15. DOI:10.7326/0003-4819-146-6-200703200-00005.; Markusse IM, Akdemir G, van den Broek M, et al. 10 year of treat-to-target therapy in rheumatoid arthritis patients (the BeST study): clinical and radiological outcome. Arthritis Rheum. 2013;65 (Suppl):S62.; Leirisalo-Repo M, Kautinen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2 year results from an investigator-initiated, randomized, double-blind, placebo-controlled study (the NEORACo Study). Ann Rheum Did. 2013;72:851-7. DOI:10.1136/annrheumdis-2012-201365.; Rantalaiho V, Kautianen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-tear follow-up results of a randomized clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-203497.; Horslev-Petersen K, Hertland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA study; an investigator-initiated, randomized, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014;73:654-61. DOI:10.1136/annrheumdis-2012-202735.; Nam JR, Villeneuve E, Hensor EME, et al. Remission induction comparing infliximab and high-dose intravenous steroids, followed by treat-to target: a double-blind, randomized, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75-85. DOI:10.1136/annrheumdis-2013-2034440.; Den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy («COBRA-light») compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. 2014;73(6):1071-8. DOI:10.1136/annrheumdis-2012-202818.; Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009;48:1429-34. DOI:10.1093/rheumatology/kep261.; Yamanaka H, Ishigurp N, Takeuchi T, et al. Recovery of clinical but not radiographic outcome by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014. DOI: 101093/Rheumatology(Oxford)/key465.; Moreland LW, O’Dell JR, Paulus H, et al. TEAR: treatment of early aggressive RA; A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum. 2012;64:2824-35. DOI:10.1002/art.34498.; O’Dell JR, Curtis JR, Mikuls TR, et al.; TEAR trial investigators. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis. Results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013;65:1985-94. DOI:10.1002/art.38012.; O’Dell, JR, Mikuls TR, Taylor TH, et al.; CSP 551 RACAT investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307-18. DOI:10.1056/NEJMoa1303006.; Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomized, non-blinded, parallelgroup Swefot trial. Lancet. 2012;379:1712-20. DOI:10.1016/S0140-6736(12)60027-0.; De Cock D, Meyfroidt S, Joly J, et al. For remission induction with glucocorticoid bridging, methotrexate monotherapy is as effective as combination with other DMARDs, with fewer reported side effects: 4-month primary outcome of CareRa, a randomized induction strategy and treated-to-target trial n early RA. Arthritis Rheum. 2013;14 (abstract 14).; Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388-95.; Katchamart W, Bourre-Tessier J, Donka T, et al. Canadian recommendation for use methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1422-30. DOI:10.3894/jrheum/090978.; Tornero Molina J, Garcia FJB, Alen JC, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration route. Reumatologia Clinica. ;pii:S1699-258X(14)00059-X. DOI:10.1016/j.reuma.2014.02.012.; Насонов ЕЛ. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012;51(приложение 3):1-24. [Nasonov EL. Treatment of rheumatoid arthritis 2012: methotrexate place. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Suppl 3):1-24. (In Russ.)]; Visser K, van der Heijde D. Optimal dosage and rout of administration of methotrexate in rheumatoid arthritis: a systemic review of the literature. Ann Rheum Dis. 2009;68:1094-9. DOI:10.1136/ard.2008.092668.; Mouterde G, Baillet A, Gaujoux-Viala C, et al. Optimizing methotexate therapy in rheumatoid arthritis: a systemic literature review. Joint Bone Spine. 2011;78:587-92. DOI:10.1016/jjbspin.2011.01.010.; Shea B, Swinden MV, Tanjong Ghogomi E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;5:CD000951. DOI: 1002/14651858.CD000951.pub2.; Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73-81. DOI:10.1002/art.23144.; Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheumatol. 1997;36:86-90. DOI:10.1093/rheumatology/36.1.86.; Rozin A, Scharpira D, Balbir-Gurman A, et al. Relapse of rheumatoid arthritis after substitution of oral for parental administration of methotrexate. Ann Rheum Dis. 2002;61:756-7. DOI:10.1136/ard.61.8.756.; Bingman SJ, Buch MH, Lindsay S, et al. Parental methotrexate should be given before biological therapy. Rheumatology (Oxford). 2003;42:1009-10. DOI:10.1093/rheumatology/keg246.; Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232-4. DOI:10.1136/ard.2003.011593.; Moitra RK, Ledingham JM, Hull RG, et al. Caveats to the use of parental methotrexate in the treatment of rheumatic disease. Rheumatology (Oxford). 2005;44:256-7. DOI: ttp://dx.doi.org/10.1093/rheumatology/keh471.; Osman A, Mulherin D. Is parental methotrexate worth trying. Ann Rheum Dis. 2001;60:432. DOI:10.1136/ard.60.4.432.; Burbage G, Gupta R, Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann Rheum Dis. 2001;60:1156. DOI:10.1136/ard.60.12.1156.; Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheumatol. 2006;35:102-6. DOI:10.1080/03009740500343294.; Bakker MF, Jacobs JWG, Welsing PMJ, et al. Are switching from oral to subcutaneous methotrexate or additional of cyclosporine to methotrexate useful steps in tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69:1849-52. DOI:10.1136/ard.2009.124065.; Mainman H, McClaren E, Heycock C, et al. When should we use parental methotrexate? Clin Rheumatol. 2010;29:1093-8. DOI:10.1007/s10067-010-1500-09.; Scott D, Claydon P, Ellis C, Buchan S. A retrospective study of the effect of switching from oral to subcutaneous (SC) methotrexate (MTX): the Methotrexate Evaluation of Norwich Treatment Outcomes in RA (MENTOR) study. Glasgow, UK: British Soc Rheumatology (Oxford); 2012. P. 221.; Hazlewood G. Sucutaneous delivery of methotrexate is associated with improved treatment survival compared to oral administration of the initial treatment of patients with early rheumatoid arthritis. Arthritis Rheum. 2013;65(Suppl 10):627.; Liakos A, Batley M, Hammond T, et al. Subcutaneous methotrexate is more efficacious and better tolerated than oral methotrexate: the experience of a large group of patients in the Rheumatology department of a district general hospital. Ann Rheum Dis. 2012;71(Suppl 3):672. DOI:10.1136/annrheumdis-2012-eular.593.; Mueller R, Schiff MH, Haile SR, von Kempis J. Effectiveness, tolerability, and safety of subcutaneous methotexate in early rheumatoid arthritis: clinical data from Dt. Gallen cohort. Ann Rheum Dis. 2014;73(Suppl 2). DOI:10.1136/annrheumdis-2014-eular.2031.; Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at dose ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549-51. DOI:10.1136/annrheumdis-2014-205228.; Fitzpatric R, Scott DG, Keary I. Cost-minimization analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who had have an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32:1605-12. DOI:10.1007/s10067-013-2318-z.; Van der Heijde DM, van Riel PL, Gribnau FW, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;333:1036-8. DOI:10.1016/S0140-6736(89)92442-2.; Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet. 1999;353:259-66. DOI:10.1016/S0140-6736(98)09403-3.; Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 2000;43:495-505. DOI:10.1002/1529-0131(200003)43:3%3C495::AID-ANR4%http://3E3.0.CO;2-U.; Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med. 1999;159:2542-50. DOI:10.1001/archinte.159.21.2542.; Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomized, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220-5. DOI:10.1136/ard.58.4.220.; Kavanaugh A, Wells AF. Benefits and risk of low-dose glucocorticoid treatment in the patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology/keu135.; Caporali R, Scire CA, Todoerti M, Montecucco C. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol. 2013;31(Suppl 78):S9-13.; Roubille C, Richer V, Starnino T. The effects of the TNF inhibitors, methotrexate, NSAIDS and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2014;73 (Suppl 2) [P0169].; Dernis E, Ruyssen-Wtrand A, Mouterde C, et al. Use of glucocorticoids in rheumatoid arthritis - practical modalities based on data from literature and expert opinion. Join Bone Spain. 2010;77:451-7. DOI:10.1016/j.jbspin.2009.12.010.; Ma MHY, Kingsley GH, Scott DL. A systemic comparison of combination DMARD therapy and tumor necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2010;49:91-8. DOI:10.1093/Rheumatology(Oxford)/kep331.; Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and meta-analysis of efficacy and safety. BMC Musculoskeletal Dis. 2008;9:52. DOI:10.1186/1471-2474-9-52.; Aaltonen KJ, Vikki LM, Malmiaara A, et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in the treatment of rheumatoid arthritis. PLoS ONE. 2012;7:e30275. DOI:10.1371/journal.pone.0030275.; Nixon RM, Bansback N, Brennan A. Using mixed treatment comparison and meta-regression to perform indirect comparisons to estimate efficacy of biologic treatment in rheumatoid arthritis. Stat Med. 2007;26:1237-54. DOI:10.1002/sim.2624.; Schmitz S, Adams R, Walsh CD, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrated differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225-30. DOI:10.1136/ard.2011.200228.; Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta-analysis. J Rheumatol. 2006;33(12):2398-407.; Kristensen LE, Christensen R, Biddal H, et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systemic literature review. Scand J Rheumatol. 2007;36:411-7. DOI:10.1080/03009740701607067.; Wiens A, Venson R, Pharm D, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-53. DOI:10.1592/phco.30.4.339.; Schmitz S, Adams R, Walsh C, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225-30. DOI: DOI:10.1136/annrheumdis-2011-200228.; Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. DOI:10.1002/14651858.CD007848.pub2; Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological anti-rheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta-analysis. Ann Rheum Dis. 2011;70:266-71. DOI:10.1136/ard.2010.132134.; Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010;39:425-41. DOI:10.1016/j.semarthrit.2009.12.002.; Kristensen LE, Jakobsen AK, Bartels EM, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011;40:1-7. DOI:10.3109/03009742.2010.491834.; Devine EB, Alfonso-Cristanchp R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy. 2011;31:39-51. DOI:10.1592/phco.31.1.39.; Roy S, Cifaldi MA. Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate: a mixed treatment comparison meta-analysis. Ann Rheum Dis. 2011;70(Suppl 3):432.; Gallego-Galisteo M, Villa-Rubio A, Alergre-del Rau E, et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012;37:301-7. DOI:10.1111/j.1365-2710.2011.01292.x.; Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther. 2011;13:R204. DOI:10.1186/ar3537.; Turksta E, Ng S-K, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011;27:1885-97. DOI:10.1185/03007995.2011.608655.; Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011;90:828-35. DOI:10.1038/clpt.2011.256.; Favalli EG, Pregnolato F, Biggioggero M, Meroni PL. The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskeletal Dis. 2012;4:213-23. DOI:10.1177/1759720X12449082.; Pierreisnard A, Issa N, Barnetche T, et al. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Join Bone Spain. 2013;80:386-93. DOI:10.1016/j.jbspin.2012.09.03.; Jones G, Darian-Smith E, Kwok M, Winzenberg T. Effect of biologic therapy on radiologic progression in rheumatoid arthritis: what does it add to methotrexate? Biologics. 2012;6:155-61.; Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65:28-38. DOI:10.1002/art.37711.; Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;17:2275-85. DOI:10.1001/jama.295.19.2275.; Leombruno JP, Einarson TR, Keystone EC. The safety of antitumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analysis of serious adverse events. Ann Rheum Dis. 2009;68:1136-45. DOI:10.1136/ard.2008.091025.; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. DOI:10.1002/14651858.CD008794.pub2.; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2012;3.; Fautrel B, Pham T, Mouterde G, et al. Recommendations of the French Society for Rheumatology (Oxford) regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine. 2007;74:627-37. DOI: DOI:10.1016/j.jbspin.2007.10.001.; Caporali R, Conti F, Aliverini S, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology (Oxford). I Efficacy. Clin Exp Rheumatol. 2011;29(Suppl 66):S7-14.; Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010;49:1197-9. DOI:10.1093/rheumatology/keq006a.; Goeb V, Ardizzone M, Arnaud L, et al.; Club Rhumatismes at Inflammations (CRI). Recommendations for using TNFα antagonists and French clinical practice guidelines endorsed by French National Authority for health. Join Bone Spain. 2013;80:574-81. DOI:10.1016/j.jspin.2013.09.001.; Smolen JS, Schoels MM, Nishimoto N, et al. Consensus state on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72:482-92. DOI:10.1136/annrheumdis-2012-202469.; Malavia AP, Ledingham J, Bloxham J, et al.; BSR Clinical Affairs Committee and Standards, audit and Guidelines Working Group, the BHPR. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology/ker168.; Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of Rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909-20. DOI:10.1136/annrheumdis.-2010-144998.; Bukhari M, Abernethy R, Deighton C, et al. BSR and BHPR guidelines on the use of Rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:2311-3. DOI:10.1093/Rheumatology/ker106a.; Bathon JM, Martin RW, Fleischmann RM, et al. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93. DOI:10.1056/NEJM200011303432201.; Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcome. Arthritis Rheum. 2002;46:1443-50. DOI:10.1002/art.10308.; Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomized CONCERTO trial. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-204769.; Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914-5. DOI:10.1136/annrheumdis-2012-201544.; Pope JE, Haraoui B, Thorne JT, et al. The Canadian Methotrexate and Etanercept Outcome Study: a randomized trial of discontinuation methotrexate after 6 months or etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-203684.; Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from JESMR study. J Rheumatol. 2011;38:1585-92. DOI:10.3899/jrheum.110014.; Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or anather diseasemodifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatolofy Biologics Register. Arthritis Rheum. 2006;54:1786-95. DOI:10.1002/art.21830.; Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to AR and EULAR criteria in patients with established RA: results from South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495-99. DOI:10.1093/Rheumatology(Oxford)/ken002.; Kristensen LE, Saxne T, Nilsson JA, Geborec P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from six-year observational study in South Sweden. Artritis Res Ther. 2006;8(6):R174; Hertland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveilance of clinical practice in the natiowide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32. DOI:10.1002/art.27227.; Iannone F, Gremese E, Atzeni F, et al. Long-term retention of tumor necrosis factor-alpha inhibitor therapy in large Italian cohort of patients with rheumatoid arthritis from GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179-84. DOI:10.3899/jrheum.111125.; Aga A-B, Lie E, Uhling T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-204020.; Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the ersistence with anti- TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology (Oxford) Biologics Register. Ann Rheum Dis. 2011;70:583-9. DOI:10.1136/ard.2010.139774.; Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with adherence to biologics for rheumatoid arthritis: a systemic review. Clin Ther. 2011;33:901-3. DOI: 10/1016/j.clinthera.2011.06.001.; Takeuchi T, Kaneko Y, Atsumi T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study). Ann Rheum Dis. 2013;72(Suppl 3):62.; Kojima T, Yabe Y, Kaneko A, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology(Oxford)/key/302.; Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010;69:88-96. DOI:10.1136/ard.2008.105197.; Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet. 2013;381:1541-50. DOI:10.1016/S0140-6736(13)60250-0.; Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43-50. DOI:10.1136/annrheumdis-2011-201282.; Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenetic effects after 1 year of tocilisumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803-9. DOI:10.1136/annrheumdis-2013-204761.; Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systemic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72:583-9. DOI:10.1136/annrheumdis-012-202470.; Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patients reported outcome (PROs) in rheumatoid arthritis patients with an inadequate to conventional DMARDs - a systemic review and network meta-analysis. Health Quality Life Outcome. 2014;12:102. DOI:10.1186/1477-7525-12-102.; Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. DOI:10.1002/art.22025.; Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-23. DOI:10.1136/ard.2007.074773.; Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Ann Rheum Dis. 2008;67:547-54. DOI:10.1136/ard.2007.074773.; Emery P, Keystone E, Tony H-P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-23. DOI:10.1136/ard.2008.092932.; Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors (GO-AFTER study): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210-21. DOI:10.1016/S0140-6736(09)60506-7.; Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum. 2007;57:448-53. DOI:10.1002/art.22617.; Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29. DOI:10.1186/ar1881.; Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34:353-8. DOI:10.1080/03009740510026887.; Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumor necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71:1861-4. DOI:10.1136/annrheumdis-2012-201324.; Burmester GR, Kary S, Unnebrink K, et al. Treatment of rheumatoid arthritis with adalimumab is effective for patients ith and without history of other anti-TNF therapies.Rheumatology (Oxford). 2010;49(Suppl 1):i89-111.; Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis - a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30:1447-54. DOI:10.1007/s10067-011-1779-1.; Chatzidionysiou K, Askling J, Eriksson J, et al.; ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-204714.; Lloyd S, Bujkiewicz S, Wailoo AJ, et al. The effectiveness of anti-TNF-α therapies when used sequential in rheumatoid arthritis patients: a systemic review and meta-analysis. Rheumatology (Oxford). 2010;49:2313-21. DOI:10.1093/Rheumatology(Oxford) keq169.; Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis with inadequate response to tumor necrosis factoralpha inhibitors. Arthritis Res Ther. 2011;13:R25. DOI:10.1186/ar3249.; Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumor necrosis factor inhibitor failure in rheumatoid arthritis: systemic review and indirect pair wise meta-analysis. Ann Rheum Dis. 2012;71:1303-8. DOI:10.1136/annrheumdis-2011-200490.; Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96-103. 233. NICE. Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: final appraisal determination. Available from: http://guidance.nice.org.uk/TA/WaveR/61/FAD/FinalAppraisalDetermination/pdf; Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after failure of a tumor necrosis factor inhibitor: a syreview and economic evaluation. Health Technol Assess. 2011;15(4):1-278.; Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: a systemic review. Rheumatology (Oxford). 2012;51:2252-61. DOI:10.1093/Rheumatology(Oxford)/kes217.; Finckh A, Ciurea A, Brulhart L, et al.; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417-23. DOI:10.1002/art.22520.; Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumor necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387-93. DOI:10.1136/ard.2008.105064.; Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology (Oxford) Biologics Register. Arthritis Care Res (Hoboken). 2012;64:1108-15.; Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine. 2012;79:281-4. DOI; Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-203993.; Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. В кн: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2011. C. 55-93. [Nasonov EL. Application rituksimab at rheumatoid arthritis. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Nasonov EL, editor. Moscow: IMA-PRESS; 2011. P. 55-93.]; Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-19. DOI:10.1056/NEJMoa1112072.; Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507. DOI:10.1056/NEJMoa1109071.; Van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-month data from a 24-month phase 3 randomized radiographic study. Arthritis Rheum. 2013;65:559-70. DOI:10.1002/art.37816.; Lee EB, Fleischmann RM, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New Engl J Med. 2014;370:2377-86. DOI:10.1056/NEJMoa1310476.; Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomized phase 3 trial. Lancet. 2013;381:451-60. DOI:10.1016/S0140-6736(12)61424-X.; Kawalec P, Mikrut A, Wisniewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor. In the treatment of rheumatoid arthritis: a systemic review and meta-analysis. Clin Rheumatol. 2013;32:1414-24. DOI:10.1007/s10067-013-2329-9.; Berhan A. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying antirheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC Musculoskeletal Disorders. 2103;14:332. DOI:10.1186/1471-2474-14-332.; Vieira MC, Wallenstein G, Bradley J, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors - a network meta-analysis. Ann Rheum Dis. 2014;72(Suppl 3):619. DOI:10.1136/annrheumdis-2013-eular.1841.; Bredermeier M, de Oliveira FK, Rocha CM. Low-versus highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-35. DOI:10.1002/acr.22116.; Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: expletory analysis from the BeST study. Ann Rheum Dis. 2011;70:315-9. DOI:10.1136/ard.2010.136556.; Van der Maas A, Kievit W, van der Bemt BJF, et al. Downtitration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012:71:1849-54. DOI:10.1136/annrheumdis-2011-200945.; Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-3013-204016.; Chatzidionysiou K, Turesson C, Teleman A, et al. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Arthritis Rheum. 2012;64(Suppl):S336.; Hariga M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 2012;22(6):814-22. DOI:10.3109/s10165-011-0586-5.; Kavanaugh A, Emery P, Felischmann RM, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2012;51(Suppl 3):iii27.; Fautrel B, Gandjbakhch F, Foltz V, et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial). Ann Rheum Dis. 2013;2(Suppl 3):72. DOI:10.1136/annrheumdis-2013-eular.271.; Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet. 2013;381:918-29. DOI: 10/1016/S0140-6736(12)61811-X.; Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet. 2014;383:321-32. DOI:10.1016/S010-673(13)61751-1.; Horslev-Petersen K, Hertland ML, Junker P, et al. Very high rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab; year 2 clinical results of an investigator-initiated randomized, controlled clinical trial of early, rheumatoid arthritis (OPERA). Arthritis Rheum. 2013;65 (Suppl):S1148.; Emery P, Hamouden M, FitzGerald M, et al. Induction of remission in patients with up to 12 months of moderate-tosevere rheumatoid arthritis symptoms treated with etanercept plus methotrexate over 52 weeks. Arthritis Rheum. 2012;64 (Suppl):S1077.; Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study. Ann Rheum Dis. 2013;72(Suppl 3):399.; Nampei A, Nagayama Y. Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 3):877. DOI:10.1136/annrheumdis-2013-eular.2618.; Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1069-73. DOI:10.3899/jrheum.121427.; Durez P, Depresseux G, Nzeusseu Toukar A, et al. Rate or remission by tocilizumab or methotrexate induction therapy in early active rheumatoid arthritis: results of the TOMERS trial. Ann Rheum Dis. 2013;72(Suppl 3):623. DOI:10.1136/annrheumdis-2013-eular.1852.; Takeuchi T, Matsubara T, Ohta S, et al. Abatacept biologicfree remission study in established rheumatoid arthritis - ORION study. Ann Rheum Dis. 2013;72(Suppl 3):613. DOI:10.1136/annrheumdis-2013-eular.1826.; Batticciotto A, Varisco V, Antivalle M, et al. Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis. 2013;72(Suppl l):877. DOI:10.1136/annrheumdis-2013-eular.2619.; O’Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2010;69:1823-6. DOI:10.1136/ard.2008.105577.; Ten Wolde S, Breedveld FC, Hermans J, et al. Randomized placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347-52. DOI:10.1016/S0140-6736(96)90535-8.; Ten Wolde S, Hermans J, Breedvald FC, Dijkmans BA. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis. 1997;56:235-9. DOI:10.1136/ard.56.4.235.; Van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012;51:1120-8. DOI:10.1093/rheumatology/ker516.; Gonzalez A, Maradit KH, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64-9. DOI:10.1136/ard.2006.059980.; Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701. DOI:10.1002/art.21675.; Попкова ТВ, Герасимова ЕВ, Новикова ДС, Насонов ЕЛ. Метотрексат и риск сердечно-сосудистых осложнений при ревматоидном артрите. Научно-практическая ревматология. 2012;50(6):70-9. [Popkova TV, Gerasimova EV, Novikova DS, Nasonov EL. Methotrexate and cardiovascular risk in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):70-9. (In Russ.)]. DOI:10.14412/1995-4484-2012-1297.; Wasco MCM, Dasgupta A, Hubert H, et al. Propensity-adjusted assoсiation of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334-42. DOI:10.1002/art.37723.; Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatologic register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from British Society for Rheumatology (Oxford) Biologics Register. Arthritis Rheum. 2007;56:2905-91. DOI:10.1002/art.22809.; Westlake SL, Colebatch AN, Baird J, et al. Tumоr necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518-31. DOI:10.1093/rheumatology/keq316.; Del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose trashholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2013. DOI 10.1002/art.38210.; Pereira IA, da Mota LMH, Cruz BA, et al. 2012 Brazilian Society of Rheumatology (Oxford) Consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol. 2012;52:474-95.; Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31. DOI:10.1136/ard.2009.113696.; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26. [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8-26. (In Russ.)]. DOI:10.14412/1995-4484-2014-8-26.; Pincus T, Kathryn A, Gibson MD, Castrejon I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Joint Dis. 2013;71 (Suppl 1):S9-19.; McLean-Tooke A, Aldridge C, Waugh A, et al. Methotrexate, rheumatoid arthritis and infection risk - what is the evidence? Rheumatology (Oxford). 2009;48:867-71. DOI:10.1093/rheumatology/kep101.; Bourre-Tessier J, Haraou B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systemic review. J Rheumatology (Oxford). 2010;37:1416-21. DOI:10.3899/jrheum.090153.; Dougados MR, van der Heijde DM, Brault Y, et al. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: finding from a randomized study (COMET). J Rheumatol. 2014. DOI:10.3899/jrheum.131238.; Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. 2014. DOI:10.1002/acr.22383.; Alsaeedi S, Keystone EC. Oral or subcutaneous methotrexate for rheumatoid arthritis. Nat Rev Rheumatol. 2014. DOI:10.1038/nrreum.2014.129.; Strand V, Williams S, Miller PSJ, et al. Discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the Consortium of Rheumatology (Oxford) Researchers of North America (CORRONA) database. Ann Rheum Dis. 2013;72(Suppl 3):71.; Asai S, Kojima T, Oguchi T, et al. OP0069 Concomitant methotrexate affect the incidence of large joint replacement surgery in the rheumatoid arthritis patients treated with etanercept. Ann Rheum Dis. 2014;73:86-87. DOI:10.1136/annrheumdis-2014-eular.1502.; Rezaei H, Saevarsdottir S, Forslind K, et al. The early rheumatoid arthritis patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responder’s population in the SWEFOT trial. Ann Rheum Dis. 2012;71:186-91. DOI:10.1136/annrheumdis-2011-200038.; Gaujoux-Viala C, Mitrovic S, Barnetche T, et al. THU0116 Efficacy of glucocorticoids for early rheumatoid arthritis (RA): a meta-analysis of randomized controlled trials. Ann Rheum Dis. 2014;73:218. DOI:10.1136/annrheumdis-2014-eular.5840.; Verschueren P, de Cock D, Corluy L, et al. THU0137 Associated with a glucocorticoid bridging scheme, methotrexate is as effective alone as in combination with other DMARDs for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the CARERA trial. Ann Rheum Dis. 2014;73:226. DOI:10.1136/annrheumdis-2014-eular.2137.; Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно- практическая ревматология. 2014;52(2):209-21. [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21. (In Russ.)]. DOI:10.14412/1995-4484-2014-209-221.; European Medical Agency. Xeljanz. 2013; accessed 25 May, 2014) Available from: http://www.ema.europa.eu/ema/indexjsp?curl=pages/medicines/human/medicines/002542/smops/Negative/human_smop_000501jsp&mid=WC0b01ac058001d127; Committee for Medicinal Products for Human Use (CHMP). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). 22-25 July 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_a nd_events/news/2013/07/news_detail_001851.jsp&mid=WC0 b01ac058004d5c1.; Pfizer. Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ (tofacitinib citrate). 2013; accessed 25 May 2013. Available from: http://press.pfizer.com/pressrelease pfizer-receives-chmp-negative-opinion-regardingmarketing-authorization-europe-rheumat; Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systemic review and meta-analysis. Ann Rheum Dis. 2013, April 18. DOI:10.1136/annrheumdis-2012-203116.; Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887-95. DOI:10.1001/jama.2013.1099.; https://rsp.mediar-press.net/rsp/article/view/2136

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2136
https://doi.org/10.14412/1995-4484-2015-1-17

المؤلفون: D. Ivanov V., S. Makarov A., D. Karateev E., V. Pavlov P., M. Makarov A., A. Logunov L., I. Nikishina P., T. Shelepina A., V. Amirdzhanova N., Д. Иванов В., С. Макаров А., Д. Каратеев Е., В. Павлов П., М. Макаров А., А. Логунов Л., И. Никишина П., Т. Шелепина А., В. Амирджанова Н.

المصدر: Rheumatology Science and Practice; Vol 53, No 3 (2015); 323-328 ; Научно-практическая ревматология; Vol 53, No 3 (2015); 323-328 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20153

مصطلحات موضوعية: juvenile rheumatoid arthritis, total hip arthroplasty, ювенильный ревматоидный артрит, тотальное эндопротезирование тазобедренного сустава

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2097/1322; Kitsoulis PB, Stafilas KS, Siamopoulou A, et al. Total hip arthroplasty in children with juvenile chronic arthritis: long-term results. J Pediatr Orthop. 2006;26:8–12. doi:10.1097/01.bpo.0000187997.84213.d9; Odent T, Journeau P, Prieur A, et al. Cementless hip arthroplasty in juvenile idiopathic arthritis. J Pediatr Orthop. 2005;25:465–70. doi:10.1097/01.bpo.0000161096.53963.0e; Sherry DD. What is new in the diagnosis and treatment of juvenile rheumatoid arthritis. J Pediatr Orthop. 2000;20:419–20. doi:10.1097/01241398-200007000-00001; Diamantberger MS. Du Rhumatisme noueux (polyarthrite deformante) chez les enfants. These pour le doctoral en medicine. Paris: Lecrosnier et Babe; 1891.; Oen K, Malleson PN, Cabral DA, et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29(9):1989–99.; Haber D, Goodman SB. Total hip arthroplasty in juvenile chronic arthritis: a consecutive series. J Arthroplasty. 1998;13:259–65. doi:10.1016/S0883-5403(98)90170-X; Carl HD, Schraml A, Swoboda B, Hohenberger G. Synovectomy of the hip in patients with juvenile rheumatoid arthritis. J Bone Joint Surg Am. 2007;89:1986–92. doi:10.2106/JBJS.F.00657; Chmell MJ, Scott RD, Thomas WH, Sledge CB. Total hip arthroplasty with cement for juvenile rheumatoid arthritis: results at a minimum of ten years in patients less than thirty years old. J Bone Joint Surg Am. 1997;79:44–52.; Clohisy JC, Oryhon JM, Seyler TM, et al. Function and fixation of total hip arthroplasty in patients 25 years of age or younger. Clin Orthop Relat Res. 2010;468:3207–13. doi:10.1007/s11999-010-1468-4; Goodman SB, Oh K, Imrie S, et al. Revision total hip arthroplasty in juvenile chronic arthritis. Acta Orthop Scand. 2006;77:242–50. doi:10.1080/17453670610045975; Slooff TJ, Huiskes R, van Horn J, Lemmens AJ. Bone grafting in total hip replacement for acetabular protrusion. Acta Orthop Scand. 1984;55:593–6. doi:10.3109/17453678408992402; Still GF. On a form of chronic joint disease in children. Reprinted in: Clin Orthop. 1990;259:4–10. doi:10.1097/00003086-199010000-00002; Kruscic A, Zgajnar B. Fracture of the acetabulum with femoral head protrusion treated with an external fixation apparatus using the AO method. Acta Chir Iugosl. 1985;32(1):57–63.; Кавалерский ГМ, Мурылев ВЮ, Рукин ЯА, Терентьев ДИ. Тотальное эндопротезирование тазобедренного сустава при протрузионных дефектах дна вертлужной впадины. Хирургия. Журнал им. Н.И. Пирогова. 2009;(1):38–43. [Kavalerskii GM, Murylev VYu, Rukin YaA, Terentiev DI. Total hip arthroplasty at the bottom of the protrusion defects of acetabulum. Khirurgiya. Zhurnal im. N.I. Pirogova. 2009;(1):38–43 (In Russ.).]; Hastings DE, Parker SM. Protrusio acetabuli in rheumatoid arthritis. Clin Orthop. 1975;108:76–83. doi:10.1097/00003086-197505000-00012; Ranawat CS, Zahn MG. Role of bone grafting in correction of protrusio acetabuli by total hip arthroplasty. J Arthroplasty. 1986;1:131–7. doi:10.1016/S0883-5403(86)80051-1; Bayley JC, Christie MJ, Ewald FC, Kelley K. Long-term results of total hip arthroplasty in protrusio acetabuli. J Arthroplasty. 1987;2:275–9. doi:10.1016/S0883-5403(87)80059-1; Heywood AWB. Arthroplasty with a solid bone graft for protrusio acetabuli. J Bone Joint Surg. 1980;62:332–6.; Ansell BM, Bywaters EGL. Growth in Still's disease. Ann Rheum Dis. 1956;15:295–319. doi:10.1136/ard.15.4.295; Ansell BM, Bywaters EGL. Rheumatoid arthritis (Still's disease). Pediat Clin North Am. 1963;10: 921–39.; Насонова ВА. Справочник по ревматологии. Москва; 2012 [Nasonova VA. Spravochnik po revmatologii [Handbook of Rheumatology]. Moscow; 2012].; Павлов ВП, Насонова ВА. Ревмоортопедия. Москва; 2011. С. 281–2, 294–5 [Pavlov VP, Nasonova VA. Revmoortopediya [Rheumoorthopedics]. Moscow; 2011. P. 281–2, 294–5].; Banta JV, Scrutton D. Hip disorders in childhood. Mac Keith Press; 2003.; Prevoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eigth-joint counts. Arthritis Rheum. 1995;38:44–8. doi:10.1002/art.1780380107; Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 292–3 [Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National guidelines]. Moscow: GEOTAR-Media; 2008. P. 292–3].; Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: Treatment by mold arthroplasty. An end result study using a new method of resalt evalution. J Bone Joint Surg Am. 1969;51:737–55.; Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnare, Disability Pain Scale. J Rheumatol. 1982;9:789–93.; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010. С. 90–725 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical Recommendations]. 2nd ed. Moscow: GEOTAR-Media; 2010. P. 90–725].; Andersson Gare B, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. J Rheumatol. 1995;22:308–19.; Ruperto N, Levinson JE, Ravelli A, et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol. 1997;24(5):945–51.; Bilsel N, Gö kce A, Kesmezacar H, et al. Long term results of tatal hip arthroplasty in patients with juvenile rheumatoid arthritis. Acta Orthop Traumatol Turc. 2008;42(2):119–24.; Kumar MH, Swann M. Uncemented total hip arthroplasty in young patients with juvenile chronic arthritis. Department of Orthopaedics, Wexham Park Hospital, Slough. Ann R Coll Surg Engl. 1998;80:203.; Mogensen B, Brattströ m H, Ekelund L, Lidgren L. Total hip replacement in juvenile chronic arthritis. Acta Orthop Scand. 1983 Jun;54(3):422–30. doi:10.3109/17453678308996595; Severt R, Wood R, Cracchiolo A 3rd, Amstutz HC. Long-term follow-up of cemented total hip arthroplasty in rheumatoid arthritis. Clin Orthop Relat Res. 1991 Apr;265:137–45. doi:10.1097/00003086-199104000-00016; Kitsoulis PB, Stafilas KS, Siamopoulou A, et al. Total hip arthroplasty in children with juvenile chronic arthritis: long-term results. J Pediatr Orthop. 2006 Jan-Feb;26(1):8–12. doi:10.1097/01.bpo.0000187997.84213.d9; https://rsp.mediar-press.net/rsp/article/view/2097

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2097
https://doi.org/10.14412/1995-4484-2015-323-328

المؤلفون: I. Zinchuk Yu., V. Amirdzhanova N., И. Зинчук Ю., В. Амирджанова Н.

المصدر: Rheumatology Science and Practice; Vol 52, No 3 (2014); 331-335 ; Научно-практическая ревматология; Vol 52, No 3 (2014); 331-335 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20143

مصطلحات موضوعية: rheumatoid arthritis, relevance, epidemiology, social burden, disability, quality of life, ревматоидный артрит, актуальность, эпидемиология, социальное бремя, инвалидизация, потеря трудоспособности, качество жизни

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1948/1220; World Health Organization, The Global Burden of Disease, 2004 Update. Accessed 13 March 2012. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_rep ort_2004update_full.pdf; Балабанова РМ, Эрдес ШФ. Динамика распространенности ревматических заболеваний, входящих в ХIII класс МКБ-10; в популяции взрослого населения Российской Федерации за 2000–2010 гг. Научно-практическая ревматология. 2012;52(3):10–2. [Balabanova RM, Erdes ShF. Trends in the preva- lence of rheumatic diseases in ICD-10 in the adult population of the Russian Federation over 2000-2010. Nauchno-prakticheskaya revma- tologiya = Rheumatology Science and Practice. 2012;52(3):10–2. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-702.; Мясоедова СЕ, Лесняк ОМ, Меньшикова ЛВ. Распространенность ревматоидного артрита в России (по данным эпидемиологических исследований). Терапевтический архив. 2010;82(5):9–14. [Myasoedova SE, Lesnyak OM, Men'shikova LV. Prevalence of rheumatoid arthritis in Russia (according to epidemiological researches). Terapevticheskii arkhiv. 2010;82(5):9–14. (In Russ.)]; Verstappen SM, Bijlsma JW, Verkleij H, et al.; Utrecht Rheumatoid Arthritis Cohort Study Group. Overview of work dis- ability in rheumatoid Arthritis patients as observed in cross-sec- tional and longitudinal surveys. Arthritis Rheum. 2004 Jun. 15;51(3):488–97. DOI: http://dx.doi.org/10.1002/art.20419.; Da Silva E, Doran MF, Crowson CS, et al. Declining use of orthopedic surgery in patients with RA? Results of a long-term, population-based assessment). Arthritis Rheum. 2003;49(2):216–20. DOI: http://dx.doi.org/10.1002/art.10998.; Girard F, Guillemin F, Novella JL, et al. Health-care use by rheumatoid arthritis compared with non-arthritic subjects. Rheumatogoly (Oxford). 2002;41(2):167–75. DOI: http://dx.doi.org/10.1093/rheumatology/41.2.167.; Вакуленко ОЮ, Кричевская ОА, Горячев ДВ, Эрдес ШФ.; Взаимосвязь клинических характеристик ревматоидного артрита с трудоспособностью и производительностью труда. Научно-практическая ревматология. 2012;52(3):60–7. [Vakulenko OYu, Krichevskaya OA, Goryachev DV, Erdes ShF. Relationship of the clinical characteristics of rheumatoid arthritis to work capacity and efficiency. Nauchno-prakticheskaya revma- tologiya = Rheumatology Science and Practice. 2012;52(3):60–7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-711.; Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006 Sep.;65(9):1175–83. DOI: http://dx.doi.org/10.1136/ard.2005.046367.; Kobelt G, Thoughts on health economics in rheumatoid arthritis). Ann Rheum Dis. 2007 Nov;6(3):iii35–9.; Bone and Joint Decade. European Action towards Better Musculoskeletal Health: A public health strategy to reduce the burden of musculoskeletal conditions. Lund: The Bone and Joint Decade, Department of Orthopedics, University Hospital; 2005; Young A, Dixey J, Kulinskaya E, et al. Which patients stop work- ing because of RA. Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002;61(4):335–40. DOI: http://dx.doi.org/10.1136/ard.61.4.335.; Mau W, Bornmann M, Weber H, et al. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: results of a tree structured analysis using RECPAM. Br J Rheumatol. 1996 Jul;35(7):652–9. DOI: http://dx.doi.org/10.1093/rheumatology/35.7.652.; Kobelt G, Eberhardt K, Jonsson L, Jö nsson B. Economic conse- quences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999;4(2):347–56. DOI: http://dx.doi.org/10.1002/1529-0131(199902)42:2%3C347::AID- ANR18%3E3.0.CO;2-P.; Fex E, Larsson BM, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol. 1998 Jan; 25(1):44–50.; Borg G, Allander E, Berg E, et al. Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial. J Rheumatol. 1991;18(17):1015–20.; Doeglas D, Krol B, Guillemin F, et al. The assessment of func- tional status in rheumatoid arthritis: a cross-cultural, longitudinal comparison of the Health Assessment Questionnaire and the Groningen Activity Restriction Scale. J Rheumatol. 1995 Oct; 22(10):1834–43.; Albers JM, Kuper HH, van Riel PL, et al. Socio-economic conse- quences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford). 1999 May;38(5):423–30. DOI: http://dx.doi.org/10.1093/rheumatology/38.5.423.; Chorus AM, Miedema HS, Wevers CW, van der Linden S. Work factors and behavioural coping in relation to withdrawal from the labour force in patients with rheumatoid arthritis. Ann Rheum Dis. 2001 Nov;60(11):1025–32. DOI: http://dx.doi.org/10.1136/ard.60.11.1025.; Фоломеева OM, Насонов ЕЛ, Андрианова ИА и др. Ревматоидный артрит в ревматологической практике России: тяжесть заболевания в российской популяции больных. Одномоментное (поперечное) эпидемиологическое исследование (RAISER). Научно-практическая ревматология. 2010;(1):50–60. [Folomeeva OM, Nasonov EL, Andrianova IA, et al. Rheumatoid arthritis in rheumatological care of russia: the severity of the disease in a russian patient population: a cross-sectional epidemiological study (RAISER). Nauchno-prak- ticheskaya revmatologiya = Rheumatology Science and Practice. 2010;(1):50–60. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2010-1406.; Эрдес ШФ, Фоломеева ОМ. Проблема ревматических заболеваний в России. Русский медицинский журнал. 2004;12(20):1121–2. [Erdes ShF, Folomeeva OM. Problem of rheumatic diseases in Russia. Russkii meditsinskii zhurnal. 2004;12(20):1121–2. (In Russ.)]; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. DOI:10.1136/annrheumdis-2013-204573.; Ермакова ЮА. Влияние уровня активности на функциональный статус у пациентов с ранним ревматоидным артритом: результаты 5-летнего наблюдения; в рамках российской программы «РАДИКАЛ». Научно- практическая ревматология. Тезисы. 2013;51(Прил.):55–6. [Ermakova YuA. Influence of level of activity on the functional status at patients with early rheumatoid arthritis: results of 5 years' supervision within the Russian RADICAL program. Nauchno- prakticheskaya revmatologiya = Rheumatology Science and Practice. Theses. 2013;51(Suppl.):55–6. (In Russ.)]; Коршунов НИ, Речкина ЕВ. Ревматоидный артрит: болезнь и семья. Научно-практическая ревматология. Тезисы. 2013;51(Прил.)80–1. [Korshunov NI, Rechkina EV. Rheumatoid arthritis: illness and family. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. Theses. 2013;51(Suppl.):80–1. (In Russ.)]; Балабанова РМ, Амирджанова ВН, Насонов ЕЛ. Применение генно-инженерных биологических препаратов при ревматоидном артрите в Российской Федерации. Научно-практическая ревматология. 2012;50(6):10–4. [Balabanova RM, Amirdzhanova VN, Nasonov EL. Use of geneti- cally engineered biological drugs for rheumatoid arthritis in the Russian Federation. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):10–4. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1286. Фармацевтический рынок России. Итоги 2012 года: Аналитический обзор DSM Group. Доступ по ссылке: http://www.dsm.ru/marketnews/1170_22.05.2013 [Farmatsevticheskii rynok Rossii. Itogi 2012 goda: Analiticheskii obzor DSM Group [Pharmaceutical market of Russia. Results of 2012: State-of-the-art review of DSM Group]. Available from: http://www.dsm.ru/marketnews/1170_22.05.2013]; IMS Health Россия. Аналитический обзор потребления лекарственных средств на территории Российской Федерации. Доступно по ссылке: http://www.imshealth.com/portal/site/imshealth [IMS Health Russia. Analiticheskii obzor potrebleniya lekarstvennykh sredstv na territorii Rossiiskoi Federatsii [The state-of-the-art review of con- sumption of medicines in the territory of the Russian Federation. Available from: http://www.imshealth.com/portal/site/imshealth] Cursor: аналитический обзор тендерных закупок лекарственных средств на территории России по итогам 2012 года. Доступ по ссылке: http://www.cursor- is.ru/ru/reports/Remedium.2012.pdf [Cursor: analiticheskii obzor tendernykh zakupok lekarstvennykh sredstv na territorii Rossii po itogam 2012 goda [Cursor: the state-of-the-art review of tender purchases of medicines in the territory of Russia following the results of 2012]. Available from: http://www.cursor- is.ru/ru/reports/Remedium.2012.pdf]; Приказ Минздрава России от 13.02.2013 No 66 «Об утверждении Стратегии лекарственного обеспечения населения Российской Федерации на период до 2025 года; и плана ее реализации». Доступно по ссылке: http://www.con- sultant.ru/law/hotdocs/24202.html [Prikaz Minzdrava Rossii ot 13.02.2013 No 66 «Ob utverzhdenii Strategii lekarstvennogo obe- specheniya naseleniya Rossiiskoi Federatsii na period do 2025 goda i plana ee realizatsii» [The order of Ministry of Health of Russia of 13.02.2013 No 66 «About the adoption of Strategy of provision of medicines of the population of the Russian Federation for the period till 2025 and the plan of its realization». Available from: http://www.consultant.ru/law/hotdocs/24202.html]; https://rsp.mediar-press.net/rsp/article/view/1948

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1948
https://doi.org/10.14412/1995-4484-2014-331-335

المؤلفون: E. Nasonov L., V. Amirdzhanova N., R. Balabanova M., L. Alekseeva I., L. Denisov N., Е. Насонов Л., В. Амирджанова Н., Р. Балабанова М., Л. Алексеева И., Л. Денисов Н.

المصدر: Rheumatology Science and Practice; Vol 52, No 6 (2014); 586-588 ; Научно-практическая ревматология; Vol 52, No 6 (2014); 586-588 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20146

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2002/1261; https://rsp.mediar-press.net/rsp/article/view/2002

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2002
https://doi.org/10.14412/1995-4484-2014-586-588

المؤلفون: E. Nasonov L., V. Mazurov I., D. Karateev E., G. Lukina V., E. Zhilyaev V., V. Amirdzhanova N., Yu. Muraviyov V., N. Tchichasova V., Е. Насонов Л., В. Мазуров И., Д. Каратеев Е., Г. Лукина В., Е. Жиляев В., В. Амирджанова Н., Ю. Муравьев В., Н. Чичасова В.

المصدر: Rheumatology Science and Practice; Vol 52, No 5 (2014); 477-494 ; Научно-практическая ревматология; Vol 52, No 5 (2014); 477-494 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20145

مصطلحات موضوعية: rheumatoid arthritis, «Treat to Target», disease modifying anti-rheumatic drugs, biologics, methotrexate, ревматоидный артрит, стратегия «Лечение до достижения цели», базисные противовоспа- лительные препараты, генно-инженерные биологические препараты, метотрексат

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1981/1245; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. atsional’noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: PEOTAR-media; 2008. P. 290–331.]; McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2012;365:2205–19. DOI: http://dx.doi.org/10.1056/NEJMra1004965.; Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–71. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-201036.; Furst DE, Keystone EC, Braun J, et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann Rheum Dis. 2012;71 (Suppl II):i2–i45. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-201036.; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013.]; Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009;374:430–2. DOI: http://dx.doi.org/10.1016/S0140-6736(09)61432-X.; Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7. DOI: http://dx.doi.org/10.1136/ard.2009.126532.; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2010;69:964–75. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204573.; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with systemic and biological disease-modifying anti-rheumatic drugs: 2013. Ann Rheum Dis. 2014;73:492–509. DOI:10.1136/annrheumdis-2013-204573.; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно- практическая ревматология. 2013;51(6):609–22. [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and disputable problems. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):609–22. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-609-22.; Aletaha D, Neogri T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81. DOI: http://dx.doi.org/10.1002/art.27584.; Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204317.; Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2014;73:3–5. DOI:10.1136/annrheumdis-2013-204317.; Национальные рекомендации по лечению ревматоидного артрита, 2013 (проект). Доступ по ссылке: http://www.rheumatolog.ru/experts/national-guidelines [Natsional'nye rekomendatsii po lecheniyu revmatoidnogo artrita, 2013 (proekt) [National recommendations about treatment of rheumatoid arthritis, 2013 (project)]. Available from: http://www.rheumatolog.ru/experts/national-guidelines]; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical recommendations.]. Moscow: GEOTAR-Media; 2010. 752 p.]; Насонов ЕЛ, редактор. Лечение ревматоидного артрита. Клинические рекомендации. Москва: Алмаз; 2006. 118 с. [Nasonov EL, editor. Lechenie revmatoidnogo artrita. Klinicheskie rekomendatsii [Treatment of rheumatoid arthritis. Clinical recommendations]. Moscow: Almaz; 2006. 118 p.]; Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34–45. DOI: http://dx.doi.org/10.1136/ard.2005.044354.; Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45:1167–9. DOI: http://dx.doi.org/10.1093/rheumatology/ kel215a.; Luqmani R, Hennel S, Estrach C, et al.; British Society for Rheumatology (Oxford), British Health Professionals in Rheumatology (Oxford) Standards, Guidelines and Audit Working Group. British Society for Rheumatology (Oxford) and British Health Professionals in Rheumatology (Oxford) Guideline for the Management of Rheumatoid Arthritis (after the first two years). Rheumatology (Oxford). 2009;48:436–9. DOI:10.1093/Rheumatology (Oxford)/key450a.; Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying ant rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84. DOI: http://dx.doi.org/10.1002/art.23721.; Singh JA, Furst D, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–39. DOI: http://dx.doi.org/10.1002/acr.21641.; Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology (Oxford) Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. J Rheumatol. 2012;39:1559–82. DOI:10.3899/jrheum.110207.; National Institute for Clinical Excellence (NICE). Rheumatoid arthritis: The management of rheumatoid arthritis in adults. NICE guidelines [CG79]. 2009. [Internet. Accessed July 14, 2011.] Available from: http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf; The Royal Australian College of General Practitioners. Clinical guidelines for diagnosis and management of early rheumatoid arthritis; 2008. [Internet. Accessed July 14, 2011.] Available from: www.healthnetworks.health.wa.gov.au/docs/Clinical_guidelines_Rheumatoid_Arthritis.pdf; http://www.racgp.org.au/guidelines/ musculoskeletaldiseases; Baecklund E, Forsblad d’Elia H, Turesson K. Guidelines for the pharmaceutical management of rheumatoid arthritis Swedish Society of Rheumatology. 2011. April 14. Available from: http://www.svenskreumatologi.se/index2.htm; Scottish Intercollegiate Guidelines Network (SIGN). Management of early rheumatoid arthritis: SIGN Publication No. 48 2000; [Internet. Accessed July 14, 2011.] Available from: http: //www. sign.ac.uk/guidelines/fulltext/48/index.html; GUIPCAR group. Update of cliniсal practice guidline for the management of rheumatoid arthritis in Spain. Madrid (Spain): Spanish Scociety of Rheumatology; 2011. 367 p.; Da Mota LMH, Cruz BA, Brenol CV, et al. 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol. 2012;52:135–74.; Ataman S, Borman P, Evcik D, et al. Management of rheumatoid arthritis: consensus recommendations from the Turkish League Against Rheumatism. Turk J Rheumatol. 2011;26:273–94. DOI: http://dx.doi.org/10.5606/tjr.2011.046.; Mok CC, Tam LS, Chan TH, et al. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol. 2011;30:303–12. DOI: http://dx.doi.org/10.1007/s10067-010-1596-y.; El Zorkany B, Alwahshi HA, Hammoudeh M, et al. Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution? Clin Rheumatol. 2013;32:151–9. DOI: http://dx.doi.org/10.1007/s10067-012-2153-7.; Fonseca JE, Bernardes M, Canhao H, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis – October 2011 update. Acta Reumatol Port. 2011;36:385–8.; Gaujoux-Viala C, Gossec L, Cantagrel A, et al. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spain. 2014;81(4):287–97. DOI:10.1016/j.jbspin.2014.05002.; Cardiel MH, Diaz-Borjon A, Vazquez del Mercado Espinosa M, et al. Update of the Mexican College of Rheumatology (Oxford) Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis. Reumatologia Clinica. 2014;19:227–40.; Wollenhaupt J, Albrecht K, Kruger K, Muller-Ladner U. The new 2012 German recommendations for treating rheumatoid arthritis. Z Rheumatol. 2013;72:6–9. DOI: http://dx.doi.org/10.1007/s00393-012-1093-6.; Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid rthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64–71. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-201247.; Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46:975–9. DOI: http://dx.doi.org/10.1093/rheumatology/kem007.; Smolen JS, Han C, van der Heijde D, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNFblockade. Ann Rheum Dis. 2009;68:823–37. DOI: http://dx.doi.org/10.1136/ard.2008.090019.; Koevoets R, van der Heijde D. Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Arthritis Rheum. 2009;60(Suppl):957.; Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63:3702–11. DOI: http://dx.doi.org/10.1002/art.30634.; Sakellariou G, Scire CA, Verstappen SM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 2013;72:245–9. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201817.; Gartner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid arthritis: Associations with clinical joint assessment in remission. Arthritis Rheum. 2013;65:2005–14. DOI:10.1002/art38016.; Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360–4. DOI: http://dx.doi.org/10.1136/ard.2008.091454.; Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1815–21. DOI: http://dx.doi.org/10.1136/ard.2010.149260.; Scire CA, Lunt M, Marshall T, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis. 2014;73:1677–82. DOI:10.1136/annrheumdis-2013-203339.; Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol. 1997;24:2290.; Yelin EH, Such CL, Criswell LA, Epstein WV. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Med Care. 1998;36:513–22. DOI: http://dx.doi.org/10.1097/00005650-199804000-00007.; Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with Rheumatology subspecialty care. Arch Intern Med. 1993;153:2229–37. DOI: http://dx.doi.org/10.1001/archinte. 1993.00410190069009.; Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodological standards. Ann Intern Med. 1997;127:52–60. DOI: http://dx.doi.org/10.7326/0003-4819-127-1-199707010- 00009.; Widdifield J, Bernatsky S, Paterson JM, et al. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken). 2011;63:53–7. DOI: http://dx.doi.org/10.1002/acr.20304.; Bonafede MM, Fox KM, Johnson BH, et al. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther. 2012;34:457–67. DOI: http://dx.doi.org/10.1016/j.clinthera.2011.12.016.; Lahiri M, Morgan C, Symmons DPM, Bruce IN. Modifiable risk factors for RA: prevention, better than cure. Rheumatology (Oxford). 2012;51:499–512. DOI: http://dx.doi.org/10.1093/rheumatology/ker299.; Sanberg ME, Bengtsson C, Kallberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-205094.; Ellerby N, Mattey D, Packham J, et al. Obesity and comorbidity are independently associated with failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2014-206254.; De Pablo P, Chapple ILC, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic disease. Nat Rev Rheumatol. 2009;68(5):218–24. DOI:10.1038/nrrheum.2009.28.; Iversen MD, Brawerman M, Iversen CN. Recommendations and the state of the evidence for physicial activity interventions for adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumatol. 2012;7(5):489–503. DOI:10.2217/ijr.12.53.; Whittle S, Colebatch A, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford). 2012;51:1416–25. DOI: http://dx.doi.org/10.1093/rheumatology/ es032.; Каратеев АЕ, Яхно НН, Лазебник ЛБ и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва: ИМА-ПРЕСС; 2009. 167 с. [Karateev AE, Yakhno NN, Lazebnik LB, et al. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii [Application of nonsteroid antiinflammatory preparations. Clinical recommendations]. Moscow: IMA-PRESS; 2009. 167 p.]; Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinion of multidisciplinar European expert panel. Ann Rheum Dis. 2010;70(5):818–22. DOI:10.1136/ard.2010.128660.; Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for management of rheumatoid arthritis with glucocorticoids: systemic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1010–4. DOI: http://dx.doi.org/10.1136/ard.2009.127332.; Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560–7. DOI:10.1136/ard.2007072157.; Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. A review on safety: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93. DOI: http://dx.doi.org/10.1136/ard.2005.038638.; Donahue KE, Gartlehner G, Jonas DE, et al. Systemic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124–34. DOI: http://dx.doi.org/10.7326/0003-4819-148-2-200801150-00192.; Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systemic literature review informing EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1004–9. DOI: http://dx.doi.org/10.1136/ard.2009.127225.; Gaujoux-Viala C, Nam JL, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib – a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:510–5. DOI:10.1136/annrheumdis-2013-204588.; Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976–86. DOI: http://dx.doi.org/10.1136/ard.2009.126573.; Nam JL, Ramiros S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–28. DOI:10.1136/annrheumdis- 2013-204577.; Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs – a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529–35. DOI:10.1136/annrheumdis-2013-204575.; Vliet Vlielan TPM. Non-drug care for RA – is the era of evidence-based practice approaching? Rheumatology (Oxford). 2007;46:1397–1404. DOI:10.1093/Rheumatology/key149.; Oldfield V, Felson DT. Exercise therapy and orthotic devices in rheumatoid arthritis: evidence-based review. Curr Opin Rheumatol. 2008;20:353–9. DOI: http://dx.doi.org/10.1097/BOR.0b013e3282fd17df.; Finckh A, Liang MH, Mugica C, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Care Res. 2006;15:864–72. DOI: http://dx.doi.org/10.1002/art.22353.; Nies JAB, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73:861–70. DOI:10.1136/annrheumdis-2012-203130.; Van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2019;62:3537–46. DOI: http://dx.doi.org/10.1002/art.27692.; Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226–35. DOI: http://dx.doi.org/10.1002/art.22943.; Radner H, Neogi T, Smolen J, Aletaha D. Perfomance of the 2010 ACR/EULAR classifications criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73:114–23. DOI: 101136/annrheumdis-2013-20328.; Sakellariou G, Scire CA, Zambon A, Caporali R. Perfomance of the 2010 classification criteria for rheumatoid arthritis: a systemic literature review and meta-analysis. PLOS ONE. 2013;8e56528.; Knevel R, Schoels M, Huizinga TWJ, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987–94. DOI: http://dx.doi.org/10.1136/ard.2009.126748.; Schipper LG, van Hulst LTC, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010;49:2154–64. DOI:10.1093/Rheumatology/keq195.; Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with biological agent in early rheumatoid arthritis: a metaanalysis of clinical and radiographic remission. Ann Rheum Dis. 2010;69:1298–304. DOI:10.1136/ard 2009.118307.; Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105–12. DOI: http://dx.doi.org/10.1136/ard.2008.099861.; Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systemic literature research. Ann Rheum Dis. 2009;68:1100–4. DOI: http://dx.doi.org/10.1136/ard.2008.093690.; Visser K, Katchhamart W, Losa E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiatiive. Ann Rheum Dis. 2009;68:1086–93. DOI: http://dx.doi.org/10.1136/ard.2008.094474.; Todoerti M, Maglione W, Bernero E, et al. Systemic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic disease, with focus one rheumatoid arthritis. Rheumatismo. 2013;65:207–18.; Van Dongen H, vam Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424–32. DOI: http://dx.doi.org/10.1002/art.22525.; Kudo-Tanaka E, Matsushita M, Tsuji S, et al. Prevention of development of rheumatoid arthritis (RA) in patients with undifferentiated arthritis (UA) by very early therapeutic interventioin of methotrexate (MTX). Ann Rheum Dis. 2013;72(Suppl 3):244. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.763.; Heimans L, Wevers-de Boer K, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed achieving remission: the IMPROVED study. Ann Rheum Dis. 2013;73(7):1356–61. DOI:10.1136/annrheumdos-2013-203243.; Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69:510–6. DOI: http://dx.doi.org/10.1136/ard.2009.119016.; De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72(1):72–8. DOI:10.1136/annrheumdis-2011- 201162.; De Jong PHPD, Hazes JM, Luime JJ, et al. Randomized comparison of triple DMARD therapy with methotrexate monotherapy. Ann Rheum Dis. 2013;72(Suppl 3):113. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.382.; Villeneuve E, Nam JL, Hensor E, et al. Preliminary results of a multicenter randomized controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis Rheum. 2011;63 (Suppl 10):2465.; Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a Threat-to-Target Strategy in very early rheumatoid arthritis. Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Study. Arthritis Rheum. 2011;63:2865–72. DOI: http://dx.doi.org/10.1002/art.30494.; Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Sustained beneficial effects of a protocolized Treat-to-Target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort. Arthritis Care Res. 2013;65:1219–26. DOI:10.1992/acr.21984.; Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70:1292–5. DOI: http://dx.doi.org/10.1136/ard.2010.142729.; Baker M, Jacobs JWG, Welsing PMJ, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med. 2012;156;329–39. DOI: http://dx.doi.org/10.7326/0003-4819- 156-5-201203060-00004.; Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisolone improves clinical and ultrasonography remission rates in early rheumatoid arthritis: results of a 12- month open-label randomized study. Arthritis Res Ther. 2012;14:R112. DOI: http://dx.doi.org/10.1186/ar3838.; St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43. DOI: http://dx.doi.org/10.1002/art.20568.; Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study – a multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37. DOI: http://dx.doi.org/10.1002/art.21519.; Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for prevention of joint damage in Japanese patients with early rheumatoid arthritis; the HOPEFUL 1 study. Ann Rheum Dis. 2013;73(3):536–43. DOI:10.1136/annrheumdis-2012-202433.; Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in the patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467–74. DOI: http://dx.doi.org/10.1002/art.24106.; Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT-HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844–50. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201612.; Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate- naive patients with active rheumatoid arthritis: twentyfour- week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83. DOI: http://dx.doi.org/10.1002/art.24638.; Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008;372:375–82. DOI: http://dx.doi.org/10.1016/S0140-6736(08)61000-4.; Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanerceptmethotrexate therapy versus monotherapy in early rheumatoid arthritis. A two-year, double-blind, randomized study. Arthritis Rheum. 2010;62:674–82. DOI:10.1002/art.272668.; Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870–7. DOI: http://dx.doi.org/10.1136/ard.2008.101121.; Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39–46. DOI: http://dx.doi.org/10.1136/ard.2010.137703.; Burmester GR, Rigby W, van Vollenhoven R, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis. 2013;72(Suppl):OP041. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.246.; Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early arthritis: a randomized trial. Lancet. 1999;353:1568–73. DOI: http://dx.doi.org/10.1016/S0140-6736(98)08513-4.; Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum. 2004;50:2072–81. DOI: http://dx.doi.org/10.1002/art.20351.; Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time. The eleven-year results of the Finish rheumatoid arthritis combination therapy trial. Arthritis Rheum. 2009;60:1222–31. DOI: http://dx.doi.org/10.1002/art.24447.; Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modygying antirheumatic drug therapy anf tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12:R122. DOI: http://dx.doi.org/10.1186/ar3060.; Hertland ML, Stengaard-Petersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethason in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, doubleblind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006;54:1401–9. DOI: http://dx.doi.org/10.1002/art.21796.; Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum. 2005;52:3381–90. DOI: http://dx.doi.org/10.1002/art.21405.; Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis. Ann Intern Med. 2007;146:406–15. DOI: http://dx.doi.org/10.7326/0003-4819-146-6-200703200-00005.; Markusse IM, Akdemir G, van den Broek M, et al. 10 year of treat-to-target therapy in rheumatoid arthritis patients (the BeST study): clinical and radiological outcome. Arthritis Rheum. 2013;65 (Suppl):S62.; Leirisalo-Repo M, Kautinen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2 year results from an investigator-initiated, randomized, double-blind, placebo-controlled study (the NEORACo Study). Ann Rheum Did. 2013;72:851–7. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201365.; Rantalaiho V, Kautianen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-tear follow-up results of a randomized clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-203497.; Horslev-Petersen K, Hertland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA study; an investigator-initiated, randomized, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2014;73:654–61. DOI:10.1136/annrheumdis-2012-202735.; Nam JR, Villeneuve E, Hensor EME, et al. Remission induction comparing infliximab and high-dose intravenous steroids, followed by treat-to target: a double-blind, randomized, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75–85. DOI:10.1136/annrheumdis-2013-2034440.; Den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy («COBRA-light») compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. 2014;73(6):1071–8. DOI:10.1136/annrheumdis-2012-202818.; Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009;48:1429–34. DOI: http://dx.doi.org/10.1093/rheumatology/kep261.; Yamanaka H, Ishigurp N, Takeuchi T, et al. Recovery of clinical but not radiographic outcome by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014. DOI: 101093/Rheumatology (Oxford)/key465.; Moreland LW, O’Dell JR, Paulus H, et al. TEAR: treatment of early aggressive RA; A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum. 2012;64:2824–35. DOI: http://dx.doi.org/10.1002/art.34498.; O’Dell JR, Curtis JR, Mikuls TR, et al.; TEAR trial investigators. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis. Results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013;65:1985–94. DOI:10.1002/art.38012.; O’Dell, JR, Mikuls TR, Taylor TH, et al.; CSP 551 RACAT investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307–18. DOI:10.1056/NEJMoa1303006.; Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomized, non-blinded, parallelgroup Swefot trial. Lancet. 2012;379:1712–20. DOI: http://dx.doi.org/10.1016/S0140-6736(12)60027-0.; De Cock D, Meyfroidt S, Joly J, et al. For remission induction with glucocorticoid bridging, methotrexate monotherapy is as effective as combination with other DMARDs, with fewer reported side effects: 4-month primary outcome of CareRa, a randomized induction strategy and treated-to-target trial n early RA. Arthritis Rheum. 2013;14 (abstract 14).; Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388–95.; Katchamart W, Bourre-Tessier J, Donka T, et al. Canadian recommendation for use methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1422–30. DOI:10.3894/jrheum/090978.; Tornero Molina J, Garcia FJB, Alen JC, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration route. Reumatologia Clinica. ;pii:S1699–258X(14)00059–X. DOI:10.1016/j.reuma.2014.02.012.; Насонов ЕЛ. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012;51(приложение 3):1–24. [Nasonov EL. Treatment of rheumatoid arthritis 2012: methotrexate place. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Suppl 3):1–24. (In Russ.)]; Visser K, van der Heijde D. Optimal dosage and rout of administration of methotrexate in rheumatoid arthritis: a systemic review of the literature. Ann Rheum Dis. 2009;68:1094–9. DOI: http://dx.doi.org/10.1136/ard.2008.092668.; Mouterde G, Baillet A, Gaujoux-Viala C, et al. Optimizing methotexate therapy in rheumatoid arthritis: a systemic literature review. Joint Bone Spine. 2011;78:587–92. DOI:10.1016/jjbspin.2011.01.010.; Shea B, Swinden MV, Tanjong Ghogomi E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;5:CD000951. DOI: 1002/14651858.CD000951.pub2.; Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81. DOI: http://dx.doi.org/10.1002/art.23144.; Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheumatol. 1997;36:86–90. DOI: http://dx.doi.org/10.1093/rheumatology/36.1.86.; Rozin A, Scharpira D, Balbir-Gurman A, et al. Relapse of rheumatoid arthritis after substitution of oral for parental administration of methotrexate. Ann Rheum Dis. 2002;61:756–7. DOI: http://dx.doi.org/10.1136/ard.61.8.756.; Bingman SJ, Buch MH, Lindsay S, et al. Parental methotrexate should be given before biological therapy. Rheumatology (Oxford). 2003;42:1009–10. DOI: http://dx.doi.org/10.1093/rheumatology/keg246.; Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232–4. DOI: http://dx.doi.org/10.1136/ard.2003.011593.; Moitra RK, Ledingham JM, Hull RG, et al. Caveats to the use of parental methotrexate in the treatment of rheumatic disease. Rheumatology (Oxford). 2005;44:256–7. DOI: ttp://dx.doi.org/10.1093/rheumatology/keh471.; Osman A, Mulherin D. Is parental methotrexate worth trying. Ann Rheum Dis. 2001;60:432. DOI: http://dx.doi.org/10.1136/ard.60.4.432.; Burbage G, Gupta R, Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann Rheum Dis. 2001;60:1156. DOI: http://dx.doi.org/10.1136/ard.60.12.1156.; Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheumatol. 2006;35:102–6. DOI: http://dx.doi.org/10.1080/03009740500343294.; Bakker MF, Jacobs JWG, Welsing PMJ, et al. Are switching from oral to subcutaneous methotrexate or additional of cyclosporine to methotrexate useful steps in tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69:1849–52. DOI: http://dx.doi.org/10.1136/ard.2009.124065.; Mainman H, McClaren E, Heycock C, et al. When should we use parental methotrexate? Clin Rheumatol. 2010;29:1093–8. DOI:10.1007/s10067-010-1500-09.; Scott D, Claydon P, Ellis C, Buchan S. A retrospective study of the effect of switching from oral to subcutaneous (SC) methotrexate (MTX): the Methotrexate Evaluation of Norwich Treatment Outcomes in RA (MENTOR) study. Glasgow, UK: British Soc Rheumatology (Oxford); 2012. P. 221.; Hazlewood G. Sucutaneous delivery of methotrexate is associated with improved treatment survival compared to oral administration of the initial treatment of patients with early rheumatoid arthritis. Arthritis Rheum. 2013;65(Suppl 10):627.; Liakos A, Batley M, Hammond T, et al. Subcutaneous methotrexate is more efficacious and better tolerated than oral methotrexate: the experience of a large group of patients in the Rheumatology department of a district general hospital. Ann Rheum Dis. 2012;71(Suppl 3):672. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-eular.593.; Mueller R, Schiff MH, Haile SR, von Kempis J. Effectiveness, tolerability, and safety of subcutaneous methotexate in early rheumatoid arthritis: clinical data from Dt. Gallen cohort. Ann Rheum Dis. 2014;73(Suppl 2). DOI:10.1136/annrheumdis-2014-eular.2031.; Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at dose ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51. DOI:10.1136/annrheumdis-2014-205228.; Fitzpatric R, Scott DG, Keary I. Cost-minimization analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who had have an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32:1605–12. DOI: http://dx.doi.org/10.1007/s10067-013-2318-z.; Van der Heijde DM, van Riel PL, Gribnau FW, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;333:1036–8. DOI: http://dx.doi.org/10.1016/S0140-6736(89)92442-2.; Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet. 1999;353:259–66. DOI: http://dx.doi.org/10.1016/S0140-6736(98)09403-3.; Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 2000;43:495–505. DOI: http://dx.doi.org/10.1002/1529- 0131(200003)43:3%3C495::AID-ANR4%3E3.0.CO;2-U.; Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med. 1999;159:2542–50. DOI: http://dx.doi.org/10.1001/archinte.159.21.2542.; Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomized, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–5. DOI: http://dx.doi.org/10.1136/ard.58.4.220.; Kavanaugh A, Wells AF. Benefits and risk of low-dose glucocorticoid treatment in the patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology/keu135.; Caporali R, Scire CA, Todoerti M, Montecucco C. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol. 2013;31(Suppl 78):S9–13.; Roubille C, Richer V, Starnino T. The effects of the TNF inhibitors, methotrexate, NSAIDS and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2014;73 (Suppl 2) [P0169].; Dernis E, Ruyssen-Wtrand A, Mouterde C, et al. Use of glucocorticoids in rheumatoid arthritis – practical modalities based on data from literature and expert opinion. Join Bone Spain. 2010;77:451–7. DOI:10.1016/j.jbspin.2009.12.010.; Ma MHY, Kingsley GH, Scott DL. A systemic comparison of combination DMARD therapy and tumor necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2010;49:91–8. DOI:10.1093/Rheumatology (Oxford)/kep331.; Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systemic review and meta-analysis of efficacy and safety. BMC Musculoskeletal Dis. 2008;9:52. DOI: http://dx.doi.org/10.1186/1471-2474-9-52.; Aaltonen KJ, Vikki LM, Malmiaara A, et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in the treatment of rheumatoid arthritis. PLoS ONE. 2012;7:e30275. DOI: http://dx.doi.org/10.1371/journal. pone.0030275.; Nixon RM, Bansback N, Brennan A. Using mixed treatment comparison and meta-regression to perform indirect comparisons to estimate efficacy of biologic treatment in rheumatoid arthritis. Stat Med. 2007;26:1237–54. DOI: http://dx.doi.org/10.1002/sim.2624.; Schmitz S, Adams R, Walsh CD, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrated differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225–30. DOI:10.1136/ard.2011.200228.; Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta-analysis. J Rheumatol. 2006;33(12):2398–407.; Kristensen LE, Christensen R, Biddal H, et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systemic literature review. Scand J Rheumatol. 2007;36:411–7. DOI: http://dx.doi.org/10.1080/03009740701607067.; Wiens A, Venson R, Pharm D, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339–53. DOI: http://dx.doi.org/10.1592/phco.30.4.339.; Schmitz S, Adams R, Walsh C, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71:225–30. DOI:http://dx.doi.org/10.1136/annrheumdis-2011-200228.; Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. DOI:10.1002/14651858.CD007848.pub2; Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological anti-rheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta-analysis. Ann Rheum Dis. 2011;70:266–71. DOI: http://dx.doi.org/10.1136/ard.2010.132134.; Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010;39:425–41. DOI: http://dx.doi.org/10.1016/j.semarthrit.2009.12.002.; Kristensen LE, Jakobsen AK, Bartels EM, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011;40:1–7. DOI:10.3109/03009742.2010.491834.; Devine EB, Alfonso-Cristanchp R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy. 2011;31:39–51. DOI: http://dx.doi.org/10.1592/phco.31.1.39.; Roy S, Cifaldi MA. Number needed to treat for biologic therapies in patients with active rheumatoid arthritis despite methotrexate: a mixed treatment comparison meta-analysis. Ann Rheum Dis. 2011;70(Suppl 3):432.; Gallego-Galisteo M, Villa-Rubio A, Alergre-del Rau E, et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012;37:301–7. DOI:10.1111/j.1365-2710.2011.01292.x.; Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther. 2011;13:R204. DOI: http://dx.doi.org/10.1186/ar3537.; Turksta E, Ng S-K, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011;27:1885–97. DOI: http://dx.doi.org/10.1185/03007995.2011.608655.; Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011;90:828–35. DOI: http://dx.doi.org/10.1038/clpt.2011.256.; Favalli EG, Pregnolato F, Biggioggero M, Meroni PL. The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskeletal Dis. 2012;4:213–23. DOI:10.1177/1759720X12449082.; Pierreisnard A, Issa N, Barnetche T, et al. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Join Bone Spain. 2013;80:386–93. DOI:10.1016/j.jbspin.2012.09.03.; Jones G, Darian-Smith E, Kwok M, Winzenberg T. Effect of biologic therapy on radiologic progression in rheumatoid arthritis: what does it add to methotrexate? Biologics. 2012;6:155–61.; Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65:28–38. DOI: http://dx.doi.org/10.1002/art.37711.; Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;17:2275–85. DOI: http://dx.doi.org/10.1001/jama.295.19.2275.; Leombruno JP, Einarson TR, Keystone EC. The safety of antitumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analysis of serious adverse events. Ann Rheum Dis. 2009;68:1136–45. DOI:10.1136/ard.2008.091025.; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. DOI:10.1002/14651858.CD008794.pub2.; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2012;3.; Fautrel B, Pham T, Mouterde G, et al. Recommendations of the French Society for Rheumatology (Oxford) regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine. 2007;74:627–37. DOI:http://dx.doi.org/10.1016/j.jbspin.2007.10.001.; Caporali R, Conti F, Aliverini S, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology (Oxford). I Efficacy. Clin Exp Rheumatol. 2011;29(Suppl 66):S7–14.; Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010;49:1197–9. DOI: http://dx.doi.org/10.1093/rheumatology/keq006a.; Goeb V, Ardizzone M, Arnaud L, et al.; Club Rhumatismes at Inflammations (CRI). Recommendations for using TNFα antagonists and French clinical practice guidelines endorsed by French National Authority for health. Join Bone Spain. 2013;80:574–81. DOI:10.1016/j.jspin.2013.09.001.; Smolen JS, Schoels MM, Nishimoto N, et al. Consensus state on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72:482–92. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-202469.; Malavia AP, Ledingham J, Bloxham J, et al.; BSR Clinical Affairs Committee and Standards, audit and Guidelines Working Group, the BHPR. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology/ker168.; Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of Rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–20. DOI:10.1136/annrheumdis.-2010-144998.; Bukhari M, Abernethy R, Deighton C, et al. BSR and BHPR guidelines on the use of Rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:2311–3. DOI:10.1093/Rheumatology/ker106a.; Bathon JM, Martin RW, Fleischmann RM, et al. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93. DOI: http://dx.doi.org/10.1056/NEJM200011303432201.; Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcome. Arthritis Rheum. 2002;46:1443–50. DOI: http://dx.doi.org/10.1002/art.10308.; Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomized CONCERTO trial. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-204769.; Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914–5. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201544.; Pope JE, Haraoui B, Thorne JT, et al. The Canadian Methotrexate and Etanercept Outcome Study: a randomized trial of discontinuation methotrexate after 6 months or etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-203684.; Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from JESMR study. J Rheumatol. 2011;38:1585–92. DOI:10.3899/jrheum.110014.; Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or anather diseasemodifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatolofy Biologics Register. Arthritis Rheum. 2006;54:1786–95. DOI: http://dx.doi.org/10.1002/art.21830.; Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to AR and EULAR criteria in patients with established RA: results from South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495–99. DOI:10.1093/Rheumatology (Oxford)/ken002.; Kristensen LE, Saxne T, Nilsson JA, Geborec P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from six-year observational study in South Sweden. Artritis Res Ther. 2006;8(6):R174; Hertland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveilance of clinical practice in the natiowide Danish DANBIO registry. Arthritis Rheum. 2010;62:22–32. DOI:10.1002/art.27227.; Iannone F, Gremese E, Atzeni F, et al. Long-term retention of tumor necrosis factor-alpha inhibitor therapy in large Italian cohort of patients with rheumatoid arthritis from GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179–84. DOI:10.3899/jrheum.111125.; Aga A-B, Lie E, Uhling T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-2013-204020.; Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the ersistence with anti- TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology (Oxford) Biologics Register. Ann Rheum Dis. 2011;70:583–9. DOI:10.1136/ard.2010.139774.; Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with adherence to biologics for rheumatoid arthritis: a systemic review. Clin Ther. 2011;33:901–3. DOI:10/1016/j.clinthera.2011.06.001.; Takeuchi T, Kaneko Y, Atsumi T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study). Ann Rheum Dis. 2013;72(Suppl 3):62.; Kojima T, Yabe Y, Kaneko A, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford). 2014. DOI:10.1093/Rheumatology (Oxford)/key/302.; Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010;69:88–96. DOI: http://dx.doi.org/10.1136/ard.2008.105197.; Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet. 2013;381:1541–50. DOI: http://dx.doi.org/10.1016/S0140-6736(13)60250-0.; Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43–50. DOI:10.1136/annrheumdis-2011-201282.; Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenetic effects after 1 year of tocilisumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803–9. DOI:10.1136/annrheumdis-2013-204761.; Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systemic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72:583–9. DOI:10.1136/annrheumdis- 012-202470.; Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patients reported outcome (PROs) in rheumatoid arthritis patients with an inadequate to conventional DMARDs – a systemic review and network meta-analysis. Health Quality Life Outcome. 2014;12:102. DOI: http://dx.doi.org/10.1186/1477-7525-12-102.; Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806. DOI: http://dx.doi.org/10.1002/art.22025.; Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23. DOI: http://dx.doi.org/10.1136/ard.2007.074773.; Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Ann Rheum Dis. 2008;67:547–54. DOI: http://dx.doi.org/10.1136/ard.2007.074773.; Emery P, Keystone E, Tony H-P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23. DOI: http://dx.doi.org/10.1136/ard.2008.092932.; Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors (GO-AFTER study): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210–21. DOI: http://dx.doi.org/10.1016/S0140-6736(09)60506-7.; Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum. 2007;57:448–53. DOI: http://dx.doi.org/10.1002/art.22617.; Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29. DOI: http://dx.doi.org/10.1186/ar1881.; Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34:353–8. DOI: http://dx.doi.org/10.1080/03009740510026887.; Gomez-Reino JJ, Maneiro JR, Ruiz J, et al. Comparative effectiveness of switching to alternative tumor necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71:1861–4. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201324.; Burmester GR, Kary S, Unnebrink K, et al. Treatment of rheumatoid arthritis with adalimumab is effective for patients ith and without history of other anti-TNF therapies.Rheumatology (Oxford). 2010;49(Suppl 1):i89–111.; Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis – a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30:1447–54. DOI: http://dx.doi.org/10.1007/s10067-011-1779-1.; Chatzidionysiou K, Askling J, Eriksson J, et al.; ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-204714.; Lloyd S, Bujkiewicz S, Wailoo AJ, et al. The effectiveness of anti-TNF-α therapies when used sequential in rheumatoid arthritis patients: a systemic review and meta-analysis. Rheumatology (Oxford). 2010;49:2313–21. DOI:10.1093/Rheumatology (Oxford) keq169.; Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis with inadequate response to tumor necrosis factoralpha inhibitors. Arthritis Res Ther. 2011;13:R25. DOI: http://dx.doi.org/10.1186/ar3249.; Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumor necrosis factor inhibitor failure in rheumatoid arthritis: systemic review and indirect pair wise meta-analysis. Ann Rheum Dis. 2012;71:1303–8. DOI:10.1136/annrheumdis-2011-200490.; Remy A, Avouac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96–103. 233. NICE. Rheumatoid arthritis – drugs for treatment after failure of a TNF inhibitor: final appraisal determination. Available from: http://guidance.nice.org.uk/TA/WaveR/61/FAD/FinalAppraisalDetermination/pdf/; Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after failure of a tumor necrosis factor inhibitor: a syreview and economic evaluation. Health Technol Assess. 2011;15(4):1–278.; Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: a systemic review. Rheumatology (Oxford). 2012;51:2252–61. DOI:10.1093/Rheumatology (Oxford)/kes217.; Finckh A, Ciurea A, Brulhart L, et al.; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417–23. DOI: http://dx.doi.org/10.1002/art.22520.; Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumor necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387–93. DOI: http://dx.doi.org/10.1136/ard.2008.105064.; Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology (Oxford) Biologics Register. Arthritis Care Res (Hoboken). 2012;64:1108–15.; Solau-Gervais E, Prudhomme C, Philippe P, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine. 2012;79:281–4. DOI; http://dx.doi.org/10.1016/j.jbspin.2011.05.002.; Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014. DOI:10.1136/annrheumdis-2013-203993.; Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. В кн: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2011. C. 55–93. [Nasonov EL. Application rituksimab at rheumatoid arthritis. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Nasonov EL, editor. Moscow: IMA-PRESS; 2011. P. 55–93.]; Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19. DOI: http://dx.doi.org/10.1056/NEJMoa1112072.; Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507. DOI: http://dx.doi.org/10.1056/NEJMoa1109071.; Van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-month data from a 24-month phase 3 randomized radiographic study. Arthritis Rheum. 2013;65:559–70. DOI: http://dx.doi.org/10.1002/art.37816.; Lee EB, Fleischmann RM, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New Engl J Med. 2014;370:2377–86. DOI: http://dx.doi.org/10.1056/NEJMoa1310476.; Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomized phase 3 trial. Lancet. 2013;381:451–60. DOI:10.1016/S0140- 6736(12)61424-X.; Kawalec P, Mikrut A, Wisniewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor. In the treatment of rheumatoid arthritis: a systemic review and meta-analysis. Clin Rheumatol. 2013;32:1414–24. DOI:10.1007/s10067-013- 2329-9.; Berhan A. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying antirheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC Musculoskeletal Disorders. 2103;14:332. DOI: http://dx.doi.org/10.1186/1471-2474-14-332.; Vieira MC, Wallenstein G, Bradley J, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors – a network meta-analysis. Ann Rheum Dis. 2014;72(Suppl 3):619. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.1841.; Bredermeier M, de Oliveira FK, Rocha CM. Low-versus highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228–35. DOI:10.1002/acr.22116.; Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: expletory analysis from the BeST study. Ann Rheum Dis. 2011;70:315–9. DOI: http://dx.doi.org/10.1136/ard.2010.136556.; Van der Maas A, Kievit W, van der Bemt BJF, et al. Downtitration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012:71:1849–54. DOI:10.1136/annrheumdis-2011-200945.; Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2013. DOI:10.1136/annrheumdis-3013- 204016.; Chatzidionysiou K, Turesson C, Teleman A, et al. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Arthritis Rheum. 2012;64(Suppl):S336.; Hariga M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 2012;22(6):814–22. DOI: http://dx.doi.org/10.3109/s10165- 011-0586-5.; Kavanaugh A, Emery P, Felischmann RM, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2012;51(Suppl 3):iii27.; Fautrel B, Gandjbakhch F, Foltz V, et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial). Ann Rheum Dis. 2013;2(Suppl 3):72. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.271.; Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet. 2013;381:918–29. DOI: 10/1016/S0140-6736(12)61811-X.; Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet. 2014;383:321–32. DOI:10.1016/S010-673(13)61751-1.; Horslev-Petersen K, Hertland ML, Junker P, et al. Very high rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab; year 2 clinical results of an investigator-initiated randomized, controlled clinical trial of early, rheumatoid arthritis (OPERA). Arthritis Rheum. 2013;65 (Suppl):S1148.; Emery P, Hamouden M, FitzGerald M, et al. Induction of remission in patients with up to 12 months of moderate-tosevere rheumatoid arthritis symptoms treated with etanercept plus methotrexate over 52 weeks. Arthritis Rheum. 2012;64 (Suppl):S1077.; Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study. Ann Rheum Dis. 2013;72(Suppl 3):399.; Nampei A, Nagayama Y. Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 3):877. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.2618.; Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1069–73. DOI:10.3899/jrheum.121427.; Durez P, Depresseux G, Nzeusseu Toukar A, et al. Rate or remission by tocilizumab or methotrexate induction therapy in early active rheumatoid arthritis: results of the TOMERS trial. Ann Rheum Dis. 2013;72(Suppl 3):623. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.1852.; Takeuchi T, Matsubara T, Ohta S, et al. Abatacept biologicfree remission study in established rheumatoid arthritis – ORION study. Ann Rheum Dis. 2013;72(Suppl 3):613. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-eular.1826.; Batticciotto A, Varisco V, Antivalle M, et al. Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis. 2013;72(Suppl l):877. DOI: http://dx.doi.org/10.1136/annrheumdis-2013- eular.2619.; O’Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2010;69:1823–6. DOI: http://dx.doi.org/10.1136/ard.2008.105577.; Ten Wolde S, Breedveld FC, Hermans J, et al. Randomized placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347–52. DOI: http://dx.doi.org/10.1016/S0140-6736(96)90535-8.; Ten Wolde S, Hermans J, Breedvald FC, Dijkmans BA. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis. 1997;56:235–9. DOI: http://dx.doi.org/10.1136/ard.56.4.235.; Van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012;51:1120–8. DOI: http://dx.doi.org/10.1093/rheumatology/ker516.; Gonzalez A, Maradit KH, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64–9. DOI: http://dx.doi.org/10.1136/ard.2006.059980.; Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701. DOI: http://dx.doi.org/10.1002/art.21675.; Попкова ТВ, Герасимова ЕВ, Новикова ДС, Насонов ЕЛ. Метотрексат и риск сердечно-сосудистых осложнений при ревматоидном артрите. Научно-практическая ревматология. 2012;50(6):70–9. [Popkova TV, Gerasimova EV, Novikova DS, Nasonov EL. Methotrexate and cardiovascular risk in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):70–9. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1297.; Wasco MCM, Dasgupta A, Hubert H, et al. Propensity-adjusted assoсiation of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334–42. DOI: http://dx.doi.org/10.1002/art.37723.; Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatologic register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from British Society for Rheumatology (Oxford) Biologics Register. Arthritis Rheum. 2007;56:2905–91. DOI: http://dx.doi.org/10.1002/art.22809.; Westlake SL, Colebatch AN, Baird J, et al. Tumоr necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518–31. DOI: http://dx.doi.org/10.1093/rheumatology/keq316.; Del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose trashholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2013. DOI 10.1002/art.38210.; Pereira IA, da Mota LMH, Cruz BA, et al. 2012 Brazilian Society of Rheumatology (Oxford) Consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol. 2012;52:474–95.; Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–31. DOI: http://dx.doi.org/10.1136/ard.2009.113696.; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26. [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014- 8-26.; Pincus T, Kathryn A, Gibson MD, Castrejon I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Joint Dis. 2013;71 (Suppl 1):S9–19.; McLean-Tooke A, Aldridge C, Waugh A, et al. Methotrexate, rheumatoid arthritis and infection risk – what is the evidence? Rheumatology (Oxford). 2009;48:867–71. DOI: http://dx.doi.org/10.1093/rheumatology/kep101.; Bourre-Tessier J, Haraou B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systemic review. J Rheumatology (Oxford). 2010;37:1416–21. DOI:10.3899/jrheum.090153.; Dougados MR, van der Heijde DM, Brault Y, et al. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: finding from a randomized study (COMET). J Rheumatol. 2014. DOI:10.3899/jrheum.131238.; Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. 2014. DOI:10.1002/acr.22383.; Alsaeedi S, Keystone EC. Oral or subcutaneous methotrexate for rheumatoid arthritis. Nat Rev Rheumatol. 2014. DOI:10.1038/nrreum.2014.129.; Strand V, Williams S, Miller PSJ, et al. Discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the Consortium of Rheumatology (Oxford) Researchers of North America (CORRONA) database. Ann Rheum Dis. 2013;72(Suppl 3):71.; Asai S, Kojima T, Oguchi T, et al. OP0069 Concomitant methotrexate affect the incidence of large joint replacement surgery in the rheumatoid arthritis patients treated with etanercept. Ann Rheum Dis. 2014;73:86–87. DOI:10.1136/annrheumdis-2014-eular.1502.; Rezaei H, Saevarsdottir S, Forslind K, et al. The early rheumatoid arthritis patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responder’s population in the SWEFOT trial. Ann Rheum Dis. 2012;71:186–91. DOI:10.1136/annrheumdis-2011-200038.; Gaujoux-Viala C, Mitrovic S, Barnetche T, et al. THU0116 Efficacy of glucocorticoids for early rheumatoid arthritis (RA): a meta-analysis of randomized controlled trials. Ann Rheum Dis. 2014;73:218. DOI:10.1136/annrheumdis-2014- eular.5840.; Verschueren P, de Cock D, Corluy L, et al. THU0137 Associated with a glucocorticoid bridging scheme, methotrexate is as effective alone as in combination with other DMARDs for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the CARERA trial. Ann Rheum Dis. 2014;73:226. DOI:10.1136/annrheumdis-2014-eular.2137.; Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно- практическая ревматология. 2014;52(2):209–21. [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):209–21. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-209-221.; European Medical Agency. Xeljanz. 2013; accessed 25 May, 2014) Available from: http://www.ema.europa.eu/ema/indexjsp?curl=pages/medicines/human/medicines/002542/smops/Negative/human_smop_000501jsp&mid=WC0b01ac058001d127; Committee for Medicinal Products for Human Use (CHMP). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). 22–25 July 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_a nd_events/news/2013/07/news_detail_001851.jsp&mid=WC0 b01ac058004d5c1.; Pfizer. Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ (tofacitinib citrate). 2013; accessed 25 May 2013. Available from: http://press.pfizer.com/pressrelease/ pfizer-receives-chmp-negative-opinion-regardingmarketing-authorization-europe-rheumat; Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systemic review and meta-analysis. Ann Rheum Dis. 2013, April 18. DOI:10.1136/annrheumdis-2012-203116.; Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–95. DOI: http://dx.doi.org/10.1001/jama.2013.1099.; https://rsp.mediar-press.net/rsp/article/view/1981

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1981
https://doi.org/10.14412/1995-4484-2014-477-494

المؤلفون: V Amirdzhanova N

المصدر: Rheumatology Science and Practice; Vol 51, No 4 (2013); 469-470 ; Научно-практическая ревматология; Vol 51, No 4 (2013); 469-470 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-4

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1573/1067; https://rsp.mediar-press.net/rsp/article/view/1573

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1573
https://doi.org/10.14412/1995-4484-2013-1263

المؤلفون: E Panasyuk Yu, V Amirdzhanova N, Anastasia Avdeyeva Sergeyevna, E Luchikhina L, E Aleksandrova N, A Novikov A, E Nasonov L, Е. Панасюк Ю., Е. Лучихина Л., Елена Александрова Николаевна, А. Новиков А., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 51, No 2 (2013); 104-110 ; Научно-практическая ревматология; Vol 51, No 2 (2013); 104-110 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-2

مصطلحات موضوعية: DAS28, SDAI, rheumatoid arthritis, tocilizumab, quality of life, remission, ревматоидный артрит, тоцилизумаб, качество жизни, ремиссия заболевания

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/773/466; Амирджанова В.Н. Популяционные показатели качества жизни. Науч-практич ревматол 2008;1:36-48. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер арх 2010;5:64-71. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538-42. Assier E., Boissier M., Dayer J. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010;77:532-6. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. Romano M., Polentarutti N., Fruscella P. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6;315—25. Lally F., Smith E., Filer A. et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthr Rheum 2005;52:3460-9. Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthr Res 2002;4(Suppl 3):81-90. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthr Res Ther 2007;9:203. Kudo O., Sabokbar A., Pocock A. et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7. Nakahara H., Song J., Sugimoto M. et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthr Rheum 2003;48:1521-9. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010;49:15-24. Bettelli E., Carrier Y., Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8. Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthr Res 2002;4(Suppl 3):233-42. Heinrich P.C., Behrmann I., Haan S. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374(Pt 1):1-20. Rose-John S., Scheller J., Elson G., Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36. Jones S.A., Richards PJ., Scheller J., Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-53. Houssiau F.A., Devogelaer J.P., van Damme J. et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthr Rheum 1988;31:784-8. Kotake S., Sato K., Kim K.J. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95. Sack U., Kinne R.W., Marx T. et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45-51. Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial. Lancet 2008;371:987-97. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Emery P., Keystone E., Tony H. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. Burmester G., Feis E., Kellner H. et al. Effectiveness and safety of Ше interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9. Sibilia J., Graninger W., Ostor A. et al. Comparison of tocilizumab as monotherapy or with add-on DMARDS in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 2011;70(Suppl 3):466. Patel A., Moreland L. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 2010;4:263-78. Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum 2003;49:214-24. Felson D., Anderson J., Lange M. et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthr Rheum 1998;41:1564-70. Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57. Aletaha D., Nell V., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther 2005;7:796-806. Choy E., Isenberg D.A., Garrood T. et al. Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin 6 receptor monoclonal antibody. Arthr Rheum 2002;46:3143-50. Nishimoto N., Yoshizaka K., Miaysaka N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthr Rheum 2004;50:1761-9. Kremer J., Blanco R., Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthr Rheum 2011;63:609-21. Leffers H., Ostergaard M., Glintborg B. Rheumatoid arthritis patients treated in routine care efficacy of abatacept and tocilizumab based on data from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70(Suppl 3):463. Yoshida K., Kishimoto M., Tokuda Y. Tocilizumab vs TNF inhibitors: difference in the quality of remission. Ann Rheum Dis 2011;70(Suppl 3):470. Yazici Y., Curtis J., Ince A. et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012;71:198-205. Iking-Konert C., Aringer M., Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011;70:1986-90. Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96. Maini P., Taylor P., Szechinski J. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr Rheum 2006;54:2817-29. Emery P., Keystone E., Tony H.-P. IL-6 Receptor inhibition with tocilizumab improves arthritis refractory to anti-TNF biologics: results treatment outcomes in patients with rheumatoid from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9. BykerkV., Ostor A., Alvaro-Gracia J. et al. Tocilizumab in patients with active rheumatoid arthritis and an inadequate response to DMARDs and/or the TNF inhibitor therapy: a large open-label study close to clinical precice. Ann Rheum Dis 2012;71:1950-4. Dougados M., Kissel K., Sheeran T. et al. Adding tocilizumab or switching to tociluzumab monotherapy in methotrexate inadequate responders: 24-week symtomatic and structural results od a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50. Weinblatt E., Kremer J.M., Cush J.J. et al. Tocilizumab monotherapy and tocilizumab plus disease-modifying antirheumatic drugs in a US rheumatoid arthritis population with inadequate response to anti-tumor necrosis factor agents. Arthr Rheum 2011;63(Suppl):162.; https://rsp.mediar-press.net/rsp/article/view/773

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/773
https://doi.org/10.14412/1995-4484-2013-635

المؤلفون: A. Potapova, A. Karateev, E. Pogozheva, E. Matianova, A. Bobkova, A. Semashko, E. Filatova, V. Amirdzhanova, E. Zotkin, A. Lila

المصدر: Annals of the Rheumatic Diseases. 81:1675.2-1675

مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::40b62f17faa47c125f8d2d5835e7a685
https://doi.org/10.1136/annrheumdis-2022-eular.2317

المؤلفون: A. Khramov, M. Makarov, S. Makarov, V. Amirdzhanova, S. Maglevaniy, I. Kushnareva, T. C. Phan

المصدر: Annals of the Rheumatic Diseases. 81:1330.3-1331

مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0e312c3cce433031e92a660ded0d26ba
https://doi.org/10.1136/annrheumdis-2022-eular.2687

المؤلفون: E. Polishchuk, A. Karateev, A. Potapova, V. Amirdzhanova

المصدر: Annals of the Rheumatic Diseases. 81:1623.1-1623

مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0b297c7c49e2fb3b92437ef405f3a791
https://doi.org/10.1136/annrheumdis-2022-eular.4637

المؤلفون: E. Polishchuk, A. Karateev, V. Amirdzhanova

المصدر: Annals of the Rheumatic Diseases. 81:895.3-896

مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e84eef371160580fbdf45da8852267e6
https://doi.org/10.1136/annrheumdis-2022-eular.4588

المؤلفون: Anna Starkova Sergeyevna, V Amirdzhanova N, A Avdeyeva S, E Panasyuk Yu, E Nasonov L, Е. Панасюк Ю., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 3 (2012); 33-37 ; Научно-практическая ревматология; Vol 50, No 3 (2012); 33-37 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-3

مصطلحات موضوعية: rheumatoid arthritis, tocilizumab, fatigue, visual analog scale, ревматоидный артрит, тоцилизумаб, усталость, визуальная аналоговая шкала

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/843/535; Tehlirian C.V., Bathon J.M. Rheumatoid arthritis: Clinical and laboratory manifestations. In: Klippel J.H., Stone J.H., Crofford L.J., White P.H. (eds). Primer on the Rheumatic diseases. 13th ed. NY: Springer, 2008;114-21. Pollard L.C., Choy E.H., Khoshaba B., Scott L. Fatigue in rheumatoid arthritis reflects pain not diseases activity. Rheumatology 2006;45:885-9. Kirwan J.R., Minnock P., Adebajo A. et al. Patient perspective: Fatigue as a recommended patient center outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-7. Belza B.L. Comparison of self reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995;2:639-43. Davis M.C., Zautra A.J., Younger J. et al. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immunol 2008;22:24-32. Wolfe F., Michaud K., Pincus T. Fatigue, rheumatoid arthritis and anti tumor necrosis factor theraphy: an investigation in 24.831 patients. J Rheunatol 2004;31:2115-20. Mathew A.J., Antony J., Eremenco S. et al. Health related quality of life in rheumatoid arthritis patients in South India. Singapore Med J 2007;50:800-3. Raj D.S.C. Role of Interleukin 6 in the anemia of chronic disease. Sem Arthr Rheum 2009;38(5):382-8. Галушко Е.А. Анемия хронического заболевания. Науч-практич ревматол 2009;3(Прил. 3):70-7. Han E., Rahman M.U., Doyle M.K. et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007;34:2177-82. Escobar M.E., Gerhardt C., Roesler E. et al. Anemia versus disease activity as cause of fatigue in rheumatoid arthritis. Acta Rumatol Port 2010;35:2-8. Smolen J.S., Breedveld Е.С., Eberal G. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthr Rheum 1995;38(1):38-43. Pincus T., Bergman M.J., Yazici Y. RAPID3 - An index of physical function, pain, and global status as «vital signs» to improve care for people with chronic rheumatic diseases. Bull of the NYU Hosp Joint Dis 2009;67(2):211-25. Aletaha D., Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheum 2005;23(Suppl. 39):100-8. Международные индексы оценки активности, функционального статуса и качества жизни больных ревматическими заболеваниями. М., 2007;13-6. Hyuser B.A., Parker J.C., Thoreson R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthr Rheum 1998;41:2230-7. Yoshida K., Tokuda Y., Oshikawa H et al. An observational study of tocilizumab and TNF-a inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology 2011;50:20932099 doi:10.1093/rheumatology/ker295 Takeuchi T., Tanaka Y., Amano K. et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION 52-week study. Rheumatology 2011;50(10):1908-15. Smolen J.S., Beaulieu A., Rubbert-Rot A. et al. Effect of interleukin-6 receptor inhibition with Tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled trial. Lancet 2008;371:987-97. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleikin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthr Rheum 2008;58:2968-80. Emery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2006;65:59. Nashimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in desease activity and serum vascular endothelial growth factor by Il-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9. Jones G., Sebba A., Gu J. et al. Comparison of Tocilizumab monotherapy versus metotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69(1):88-96. Yusuf Y., Curtis J.R., Ince A. et al. Efficacy and safety of tocilizumab in patients with moderate to severe active ra and a previous inadequate response to DMARDs: The ROSE Study. Arthr Rheum 2010;62(Suppl.):S754 [1808].; https://rsp.mediar-press.net/rsp/article/view/843

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/843
https://doi.org/10.14412/1995-4484-2012-706

المؤلفون: Elena Pogozheva Yuryevna, V Amirdzhanova N, S Makarov A, E Nasonov L, С. Макаров А., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 3 (2012); 43-48 ; Научно-практическая ревматология; Vol 50, No 3 (2012); 43-48 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-3

مصطلحات موضوعية: endoprosthetic knee and hip joint replacement, genetically engineered biological preparations_, эндопротезирование коленных и тазобедренных суставов, генно-инженерные биологические препараты, ревматические заболевания

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/845/537; Teeny S.M., York S.C., Mesko J.W., Rea R.E. Long-term follow-up care recommendations after total hip and knee arthroplasty: results of the American Association of Hip and Knee Surgeons’ member survey. J Arthroplasty 2003;18:954-62. Галушко Е.А., Эрдес Ш.Ф., Амирджанова В.Н. Особенности диагностики ревматоидного артрита в реальной клинической практике. Науч-практич ревматол 2011;1:21-7. Puolakka T.J., Pajamaki K.J., Halonen PJ. et al. The Finnish Arthroplasty Register Report of the hip register. Acta Orthop Scand 2001;72(5):433-41. Dixon T., Shaw M., Ebrahim S., Dieppe P. Trends in hip and knee joint replacement: socioeconomic inequalities and projections of need. Ann Rheum Dis 2004;63:825-30. Australian Orthopedic Association, National Joint Replacement Registry Annual Report 2009. Swedish Hip Arthroplasty Register Annual Report 2008. Ward M.M. Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthr Rheum 2004;50(4):1122-31. Weiss R.J., Stark A., "Wick M.C. et al. Orthopedic surgery of the lower limbs in 49 802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis 2006;65:335-41. Weiss R.J., Ehlin A., Montgomery S.M. et al. Decrease of RA-related orthopedic surgery of the upper limbs between 1998 and 2004: data from 54,579 Swedish RA inpatients. Rheumatology (Oxford) 2008;47:491-4. Fevang B.T., Lie S.A., Havelin L.I. et al. Reduction in orthopedic surgery among patients with chronic inflammatory joint disease in Norway, 1994-2004. Arthr Rheum 2007;57(3):529-32. Sokka T., Kautiainen H., Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis 2007;66(3):341-4. Kobelt G., Eberhardt K., Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10. Hetland M.L., Christensen I.J., Tarp U. et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthr Rheum 2010;62(1):22-32. Sarzi-Puttini P., Antivalle M., Marchesoni A. et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 2008;60(4):290-5. Vander Cruyssen B., Durez P., Westhovens R. et al. The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthr Res Ther 2010;12(5):R169. Dixon W.G., Hyrich K.L., Watson K.D. et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69(3):522-8. Амирджанова В.Н., Кайгородцева Е.Ю., Горячев Д.В. и др. Российский регистр Инфликсимаба. Влияние терапии на функциональное состояние больных ревматоидным артритом. Науч-практич ревматол 2010;6:23-31. Амирджанова В.Н., Горячев Д.В., Лукина Г.В. и др. Российский регистр ритуксимаба. Анализ эффективности терапии и функционального состояния больных ревматоидным артритом. Науч-практич ревматол 2010;4:31-40. Белов Б.С. Бактериальный (септический) артрит и инфекция протезированного сустава: современные аспекты. Совр ревматол 2010;3:10-7. NIH consensus conference: Total hip replacement. NIH Consensus Development Panel on Total Hip Replacement. JAMA 1995;273:1950-6. Sperling J.W., Kosak T.K., Hanssen A.D., Cofield R.H. Infection after shoulder arthroplasty. Clin Orthop 2001;382:206-16. Harris W.H., Sledge C.B. Total hip and total knee replacement. N Engl J Med 1990;323:801-7. Keane J., Gershon S., Wise R.P. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104. Tubach F., Salmon D., Ravaud P. et al. Research Axed on Tolerance of Biotherapies Group: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthr Rheum 2009;60:1884-94. Bongartz T., Sutton A.J., Sweeting M.J. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of antitumor necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45. Curtis J.R., Patkar N., Xie A. et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor a antagonists. Arthr Rheum 2007;56:1125-33. Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions. J Rheumatol 2007;34:653-5. Wendling D., Balblanc J.C., Brousse A. et al. Surgery in patients receiving anti-tumour necrosis factor a treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 2005;64:1378-9. Talwalkar S.C., Grennan D.M., Gray J. et al. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005;64:650-1. Bibbo C., Goldberg J.W. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-5. Giles J.T., Bartlett S.J., Gelber A.C. et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthr Rheum 2006;55:333-7. Momohara S., Kawakami K., Iwamoto T. et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011;21(5):469-75. Kawakami K., Ikari K., Kawamura K. et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-a blockers: perioperative interruption of tumour necrosis factor-a blockers decreases complications? Rheumatology 2010;49:341-7. den Broeder A.A., Creemers M.C., Fransen J. et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34(4):689-95. Prevoo M.L., van’t Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eigth-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995;38:44-8. Garrett S., Jenkinson T., Kennedy L.G. et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91. Gladman D., Helliwell P., Mease P. еt al. Assessment of patients with psoriatic arthritis. Arthr Rheum 2004;50(1):24-35. Fries J.F., Spitz P., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis. Arthr Rheum 1980;23:137-45. Rabin R., de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.; https://rsp.mediar-press.net/rsp/article/view/845

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/845
https://doi.org/10.14412/1995-4484-2012-708